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CHAPTER 1
INTRODUCTION
1.1 Abstract
DNA serve as an ideal target where drugs such as cisplatin (cisPt) bind and exert their
anticancer activities. CisPt is known to preferentially coordinate with DNA leading to formation of
cisPt-deoxyguanosine (dGuo) adducts. The adducts distort the DNA structure and contribute to
inhibition of DNA-mediated cellular functions and ultimately cancer cell death. Despite its
utilization as an anticancer drug, cisPt has a number of drawbacks, which include toxic side effects
and cellular resistance. Resistance occurs through processes such as repair of damaged DNA
and inactivation of cisPt present in the cell. To overcome these challenges, the aim of this thesis
work was to synthesize and investigate compounds that coordinate to different sites from those
targeted by cisPt, including sites found in RNA. In this highly collaborative dissertation project,
amino acid-linked platinum(II) compounds were synthesized and studied as alternatives to cisPt.
The reactivity preferences of these compounds towards DNA/RNA nucleosides and
oligonucleotides were determined through pseudo-first-order kinetics. The products formed by the
reactions of amino acid-linked platinum(II) compounds with DNA and RNA were studied by
electrospray ionization mass spectrometry (ESI-MS) to determine the type of adducts formed by
the compounds. NMR spectroscopy was used to determine the non-canonical adducts formed by
the compounds that include platination of the N1, N3, or N7 positions of RNA adenosine (Ado)
residues. Features of amino acid-linked platinum(II) compounds that impact the glycosidic bond
stability of Ado residues were explored by using tandem mass spectrometry in collaboration with
the Rodgers laboratory. Furthermore, cytotoxicity assays and inductively coupled plasma mass
spectrometry (ICP-MS) were used to determine the potency and accumulation of the compounds
in cancer cells. Altogether, the unique characteristics of the amino acid-linked compounds such
as altered reactivity preferences, formation of adducts at non-canonical residues, destabilization
of glycosidic bonds, selective potency, and higher accumulation in cancer cells are important
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features that could circumvent drug resistance faced by the currently available platinum-based
drugs.
1.2 Introduction to discovery, mechanism of action, and kinetics of cisPt
1.2.1

Discovery of cisPt and its application in cancer therapy
CisPt, cis-diamminedichloridoplatinum(II), is a widely used platinum-based antitumor drug

[1] that has come a long way since it was first synthesized in 1844 by an Italian chemist, Michele
Peyrone (Fig.1.1) [2]. Peyrone was interested in the synthesis and reactivity of various platinumbased compounds. He documented some of the physical and chemical properties of cisPt, which
at the time was called Peyrone’s salt [3]. Although Peyrone described some of the properties of
cisPt, the structure of the compound was not fully elucidated at that time [2]. In 1893, Alfred
Werner, a scientist interested in the coordination chemistry of inorganic compounds proposed
that the structure of cisPt consists of a square-planar geometry [4]. After Werner’s findings, cisPt
went into obscurity for many years until the 1960s when crystallographic studies of the compound
were done [5] . A crystal structure confirmed the cis configuration of cisPt, while also revealing
that transplatin (trans-diamminedichloridoplatinum(II), is an isomer of cisPt with the trans
configuration (Fig. 1.2).
The biological applications of cisPt were not realized until the 1960s when Barnett
Rosenberg serendipitously discovered its antitumor activity [6-7]. This discovery occurred while
Rosenberg and coworkers were investigating the effects of electrical fields on the growth of E.
coli. They observed inhibition of cell division, along with dramatic changes in the cell morphology,
when the bacteria were exposed to an electrical current with platinum electrodes in an ammonium
chloride buffer [6]. Further investigation revealed that these effects were not due to the electric
current, but rather because cisPt was being formed from a reaction between the buffer and the
platinum electrodes [6]. Using cisPt and related platinum-based compounds, Rosenberg,
VanCamp, and co-workers carried out antitumor testing with animal models [7]. They treated
tumor mice models using various concentrations of the compounds, and observed that the mice
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had remarkable tumor regression after low doses of cisPt. This work contributed to discovery of
the antitumor activity of cisPt in mammals, and led to the introduction of cisPt as a clinical
platinum-based antitumor candidate in 1969 [7-8]. After more clinical investigation was done, cisPt
was approved by the FDA in 1978 to be used for treatment of testicular and bladder cancer,
becoming the first platinum-based anticancer drug [9].

Figure 1.1. Timeline for discovery, development, and applications of cisPt. CisPt was first
synthesized more than 150 years ago, but its application in human cancer therapy did not take
place until the1970s [10].

cisplatin (cisPt)

transplatin

Figure 1.2. The structures of cisplatin (cisPt) and transplatin with their respective
configurations. Both of the isomeric compounds assume a square-planar geometry.
Since its approval by the FDA, cisPt has been used for treatment of several other forms
of cancer, including testicular, ovarian, colorectal, prostate, lung, breast, and head and neck
cancer [9, 11]. The response of the various forms of cancer to cisPt treatment varies from one
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tissue to another. Testicular cancer is the most responsive, with a cure rate of 90-100%, especially
when discovered and treated with cisPt early [11-12]. Other forms of cancer such as non-small
lung cancer are not as responsive, and cancer regression can be hampered by development of
cisPt resistance with each round of dosage given to the patient [13-14].
1.2.2

Structural components of cisPt
CisPt, [PtCl2(NH3)2], is a platinum-based complex with a square-planar cis geometry (Fig.

1.3). The platinum metal element has atomic number 78 and exists as various stable isotopes
with the most abundant being

195

Pt. Platinum has two valence states, (II) and (IV), which have

different numbers of coordinated ligands. CisPt has a Pt(II) center coordinated by two ammine
and two chlorido ligands. According to the hard-soft acid-base (HSAB) principle, the platinum is
a soft acid that prefers coordination to softer bases such as amines compared to chlorine [15].
Because coordination to the N-containing ligands is more thermodynamically stable, the two
ammines are referred to as ‘non-leaving groups’, whereas the two chlorido ligands are referred to
as the ‘leaving groups’ (Fig. 1.3). These two different ligand types determine the various chemical
properties of cisPt, ranging from the kinetic reactivities of the compound to the preferred biological
targets [16-17].

Figure 1.3. The structural components of cisPt. The two chlorido ligands are referred to as
leaving groups, because they can be replaced during reactions with the target. The two ammines
are thermodynamically stable and remain coordinated.
1.2.3

Mechanism of action, reaction kinetics, and adduct formation of cisPt
The mechanism of action of cisPt has been studied extensively over the past 50 years in

an effort to understand its clinical efficacy [16, 18]. CisPt is administered intravenously into the
bloodstream from where it can enter cells through various modes, including passive diffusion [1920]. Passive diffusion is driven by the different cisPt concentrations inside and outside of the cell
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(Fig. 1.4) [20-21]. Other modes of cisPt uptake are active and facilitated transport. For example,
copper transporters in cancer cells facilitate the regulation and intake of cisPt [22-24]. Presence
of such facilitated transport is crucial to the biological activity of cisPt, since upregulation of copper
transporters increases the sensitivity of cancer cells to cisPt [22]. Downregulation of facilitated
transporters and reliance on passive diffusion is one factor that may lead to cellular resistance to
cisPt treatment [22].
Blood serum has a high chloride concentration of approximately 100 mM, which inhibits
the loss of the chlorido ligands of cisPt and enables the compound to reach the cell membrane in
its intact neutral form, [PtCl2(NH3)2]0 [25]. However, aquation (replacement with an aqua ligand)
occurs once cisPt is inside the cell where the chloride concentration is much lower (2-30 mM) [25]
(Fig. 1.4). The aquated cisPt can include the monoaquated form, [PtCl(H2O)(NH3)2]+, or the bisaquated form, [Pt(H2O)2(NH3)2]2+, in which either one or both of the chlorido ligands are replaced
by aqua ligands, respectively [19]. The aquated forms of cisPt are positively charged and can
interact with negatively charged nucleic acids through electrostatic interactions before
coordination to the nucleobase occurs [19]. The aquated forms of cisPt preferentially coordinate
to neighboring dGuo residues of DNA [26-27]. Formation of these adducts alters the DNA
structure and inhibits biological processes such as replication and transcription [11]. The adducts
trigger other cellular responses, including cell cycle arrest, DNA repair, and apoptosis [1]. Aside
from DNA, cisPt can also coordinate with other cellular biomolecules including RNA, thiol
containing metabolites, and S-containing proteins (Fig. 1.4) [28-30]. These interactions play
different roles, from contributing to the potent activity of cisPt in the cell to cellular resistance
towards the same compound [28-31].
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Figure 1.4. Mode of action of cisPt. The mechanism of cisPt antitumor activity includes uptake,
aquation, formation of adducts with DNA, inhibition of cellular processes, apoptosis, and possible
resistance due to factors such as drug efflux, reactions with other cellular components, and DNA
repair. Inhibition of cellular processes such as replication, occurs when cisPt adduct block DNA
polymerase. Repair of damaged DNA occurs when the cell removes the platinum adducts using
an excision repair complex.
Reactions of the aquated cisPt species with DNA occur under kinetic control, leading to stable
adduct formation at the preferred dGuo sites [30, 32]. The coordination of cisPt with DNA involves
a number of steps that contribute to the overall reaction rates (Fig.1.5). The replacement of the
first chlorido ligand with an aqua ligand is the rate-determining step that leads to formation of
monoaquated species, [PtCl(H2O)NH3]+ [32]. The monoaquated cisPt coordinates with DNA at
the N7 position of dGuo residues to form a monofunctional adduct, [PtCl(N7-dGuo)NH3]+ [32]. The
monofunctional adduct is then hydrolyzed through replacement of the second chlorido to form
[Pt(H2O)(N7-dGuo)NH3]2+. This aquated monofunctional adduct then coordinates with a nitrogen
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(preferably at N7) of the second dGuo residue, leading to formation of a bifunctional adduct,
[Pt(N7-dGuo)2NH3]2+ (Fig. 1.5) [32].

Figure 1.5. Reaction kinetics of cisPt and DNA. CisPt loses the first chlorido ligand to form a
monoaquated species. The monoaquated species coordinates with DNA at the N7 position of a
dGuo residue. The second chlorido of cisPt is then replaced by another aqua ligand. This step is
followed by coordination of the complex to the adjacent dGuo residue at the N7 position. The rate
constants for each step are indicated [32]. The structures and numbering of dGuo and dAdo are
shown on the right.
All of the steps of cisPt coordination to DNA contribute to the kinetics of DNA platination and
are therefore important in the cellular activity of cisPt (and other platinum-based compounds as
well) [33-36]. For example, cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) (carboplatin)
is less potent than cisPt, which is partly attributed to its 100-fold slower adduct formation with
DNA (more discussion of cisPt analogues will be given in subsequent sections) [34].
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Figure 1.6. Potential DNA coordination sites for cisPt. The site preference is dictated by
nucleophilicity and accessibility, with the major groove being more accessible to the platinum
compounds. Atoms involved in hydrogen bonding between the nucleotide bases are less likely to
participate in platinum coordination.

There are several potential binding sites in the DNA for cisPt to coordinate with varying
degrees of preference (Fig. 1.6). The nitrogen atoms of nucleosides, especially dGuo and
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deoxyadenosine (dAdo), are soft bases that provide nucleophilic sites to which the platinum
center can coordinate. Coordination occurs preferentially at the N7 position of dGuo due to its
high nucleophilicity compared to the nitrogens of other nucleosides or positions of dGuo [10, 3738]. Furthermore, the N7 position of dGuo is found in the major groove of the DNA, which makes
it more accessible for adduct formation by cisPt compared to other sites such as N3 of the same
nucleoside [18, 39].
As mentioned above, cisPt can lose two chlorido ligands leading to formation of crosslinks. CisPt forms the DNA bifunctional adducts by coordinating to two adjacent dGuo residues at
their N7 positions [32, 37, 40]. Of the DNA adducts that are formed, 90–95% are intrastrand crosslinks (Fig. 1.7). Further analysis shows that 60–65% are 1,2-(dGuo-p-dGuo), 25% are 1,2-(dAdop-dGuo), and 5% are 1,3-(dGuo-p-Nuo-p-dGuo) intrastrand cross-links in which the coordination
occurs at neighboring nucleotides (1,2) on the same strand or with an intervening nucleotide
(1,Nuo,3) (p indicates the phosphate ester bond). The rest of the adducts are a small percentage
comprising interstrand cross-links (across two strands of DNA) and monofunctional adducts (Fig.
1.7) [37, 41].
Compared to cisPt, transplatin has a different DNA adduct profile owing to its trans
configuration and therefore large angle (180°) between available coordination sites. While a
majority of the adducts formed by cisPt (95%) are bifunctional adducts that are formed by cisPt
coordinating with two adjacent nucleosides [37], transplatin forms predominantly monofunctional
adducts [38, 42-43]. The cis configuration is more compatible with coordination to adjacent sites
[37-38, 42]. The angle imparted by the platinum metal center leads to DNA bending [11, 38]. Since
transplatin forms predominantly monofunctional adducts, the impact on DNA structure is different
[38, 42-43].
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Figure 1.7. Various types of DNA adducts that are formed by cisPt. CisPt coordinates with
purines at the N7 position and forms intrastrand and interstrand cross-links, and monofunctional
adducts with varying abundance [41].

The overall process of cisPt adduct formation such as aquation and DNA platination [34, 36]
is influenced by a number of factors associated with the non-leaving group ligand (typically an
ammine), including coordination type and hydrogen-bonding properties [35-36]. These factors
play roles in target preferences and the types of adducts that are formed. The adducts that are
formed when cisPt reacts with dGuo are kinetically inert [27, 35, 44]. The adducts form when the
aqua ligand of cisPt is substituted by a nucleobase atom (typically a nitrogen) via a trigonalbipyramidal transition state [45]. Hydrogen bonding is implicated in the kinetic control of platination
[36, 46] and can stabilize the transition state of the cisPt-dGuo reaction [27]. It was demonstrated
using computational analysis that during the transition state, cisPt forms a strong hydrogen bond
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between its ammine ligand and the oxo at the 6 position of dGuo (Fig. 1.8) [27]. As such, this
hydrogen-bonding interaction together with charge-charge interactions results in preferential
coordination of cisPt to dGuo residues of DNA [27]. In contrast, formation of the cisPt-dAdo adduct
is less favored because the dAdo has an amine at the 6 position, which cannot hydrogen bond
with the cisPt ammine ligand [27].

Figure 1.8. Structure of cisPt-nucleoside adducts. CisPt binds to the N7 position of dGuo and
forms a hydrogen bond between its ammine ligand and the 6-oxo of dGuo. A hydrogen bond
would not form in the cisPt-dAdo adduct.
The binding of cisPt in the DNA major groove results in distortion of the helical structure
[38]. The distortion of the helix induces the recruitment of proteins that recognize the damage of
the DNA structure. These proteins, which include the high-mobility-group (HMG) proteins,
recognize and bind to the bent DNA structures and further increase the bend angle [47-48]. The
binding of the HMG proteins leads to a cascade of downstream effects that are correlated with
cancer cell death and hence mediate the antitumor activity of cisPt [48]. The adducts that are
formed also disrupt normal DNA-protein recognition leading to inhibition of important cellular
processes, such as replication and transcription [1].
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1.3 Introduction to alternative biological targets of cisPt
1.3.1

RNA as a target of platinum-based compounds
Previous studies have shown that RNA is also a biomolecular target of cisPt [49-54]. While

the interaction of DNA and cisPt has been largely studied, investigation of the platination of RNA
by cisPt and its role in cellular toxicity has been minimal. In recent years there has been increased
interest in RNA-cisPt interactions [49-54]. RNA is an important biomolecule that plays crucial roles
in cellular functions ranging from translation to regulation of gene expression. Therefore, RNA
modifications or damage by small molecules could adversely affect the functions of RNA. By
extension, disruption of the RNA integrity and its functions could lead to a cascade of events that
ultimately lead to cell death [29, 55-56].
There are various reasons why cellular RNA is a plausible target for cisPt. Unlike DNA,
RNA abundance and localization in a cell are not limited to the nucleus, and rRNA, mRNA, and
other forms of regulatory RNA can be found in the cytoplasm. Since cisPt is activated to generate
its reactive monoaquated species in the cytoplasm, it could interact with cytoplasmic components,
including the readily available cytoplasmic RNAs [29, 50, 53-56]. One of the important features
that enables coordination of cisPt to DNA nucleotides is their nucleophilicity. RNA also has
nucleophilic sites such as the N7 position of guanosine (Guo) residues where cisPt could bind,
and therefore modify the RNA and trigger apoptosis [29, 51, 53, 56].
Investigation of the interaction of cisPt with various forms of RNA has been carried out
using various techniques. CisPt has been shown to bind to Guo residues of RNAs of varying
sizes, structures, and cellular locations, including the ribosome, mRNA, and tRNA [50, 53, 57-58].
Melnikov and coworkers reported a 2.6 Å-resolution X-ray crystal structure of cisPt bound to 70S
ribosomes. The structure revealed nine ribosomal target sites in which cisPt coordinated RNA,
including six in the 50S subunit (Fig. 1.9), two in the 30S subunit, and one on ribosomal L9 protein
[51]. One of the sites (A790 of 16S RNA) is in the mRNA channel; cisPt platinates a nucleotide
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that is in direct contact with the mRNA [51]. In inductively coupled plasma mass spectrometry
(ICP-MS) quantification of the abundance of cisPt bound to DNA vs. RNA after cellular treatment,
it was observed that there is more than four-fold higher accumulation of cisPt on RNA than DNA
[59]. The abundance of cisPt adducts on RNA also varies from one form of RNA to another. For
example, cells treated with cisPt have up to six-fold higher platinum accumulation on rRNA
compared to mRNA [59]. A comparison of the reactivity of small RNA and DNA hairpins with
platinum-based compounds indicated that RNA is the kinetically preferred target [49]. Platination
of tRNA has also been observed with cisPt coordination occurring at the Guo-Cyd (cytidine) rich
regions of the RNA [58]. The platination of long noncoding RNA (lncRNA) has also gained interest
due to the importance of lncRNAs in regulation of cellular functions. Previous studies have shown
that binding of cisPt to lncRNA plays a role in modulating cancer resistance [60].

Figure 1.9. Crystal structure of cisPt bound to 50S RNA (PDB ID: 5J4B) [51]. Residues
modified by cisPt in the 50S subunit of the ribosome are shown by red spheres. The 50S subunit
has six cisPt adducts and one adduct on the L9 ribosomal protein (where cisPt binds with a
methionine residue). The sequence numbers of the platinated residues are indicated.
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Since clinical use of cisPt has become challenging due to cellular resistance through
processes such as DNA repair, targeting RNA may provide another avenue for triggering
apoptosis while averting resistance. Similar to the target preferences in DNA, aquated cisPt
coordinates to accessible Guo residues of RNA [49-54]. Analogues of cisPt that exhibit altered
mechanisms of action, such as targeting RNA over DNA, modifying alternative nucleosides rather
than dGuo/Guo or altering RNA levels through induced decay pathways, may play a role in
circumventing cellular resistance [29, 55-56].
1.3.2

Proteins as targets of platinum-based compounds
There is evidence that cisPt interacts and forms adducts with proteins, especially at

locations with sulfur-, nitrogen-, and oxygen-containing amino acids such as cysteine, methionine,
and histidine [61]. The coordination of cisPt to cellular proteins plays a role in cisPt uptake, side
effects, and resistance [30, 61-62]. As noted earlier in Section 1.2.3, proteins such as copper
transporters are crucial for the uptake of cisPt, and their role in facilitating transport causes the
cell to be more sensitive towards cisPt treatment [22-24]. Besides facilitating transport, some
cellular proteins are biomolecular targets of cisPt and other platinum-based compounds [30, 6162]. Considering hard-soft acid-base (HSAB) principle, platinum is a soft acid and has a high
affinity for soft bases such as sulfur and nitrogen, and therefore readily coordinates to sulfur- and
nitrogen-containing biomolecules [15]. Various proteins are rich in sulfur-containing residues such
as methionine and cysteine. Therefore, cisPt can coordinate to proteins through such residues.
For example, it has been reported that cisPt binds to human superoxide dismutase (hSOD)
protein through a cysteine residue (Cys111) (Fig.1.10) [61, 63].
Various biochemical and analytical tools have been used to characterize possible
platination sites of proteins by cisPt and other platinum-based compounds, and to understand the
downstream effects of such platination events [62]. The reactivity of cisPt with proteins such as
cytochrome c, superoxide dismutase, lysozyme, myoglobin and ubiquitin have been investigated
[62]. These studies were carried out using NMR, mass spectrometry, inductively coupled plasma
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optical emission spectroscopy (ICP-OES), and X-ray crystallography [61, 64-67]. These studies
have shown that cisPt coordinates with the proteins through their cysteine, histidine, and proline
residues [61-63, 68].

Figure 1.10. Crystal structure cisPt bound to a protein. Crystal structure of human superoxide
dismutase (hSOD) subunit with cisPt coordinated to its cysteine residue (PDB code 3RE0) [63].
The cisPt coordinates with hSOD through the sulfur atom of Cys111. Cysteine is represented in
yellow sticks, whereas Pt and ligands are represented with colored spheres.

1.4 Cellular resistance and toxicity of cisPt; development of cisPt analogues
1.4.1

Toxicity and low selectivity of platinum-based cancer agents
Despite cisPt being used to treat a variety of cancer types, its clinical use may be limited

by adverse side effects [69-71]. One of the major side effects of cisPt is nephrotoxicity, which
results from cisPt being toxic to cells in several parts of the kidney [69]. CisPt nephrotoxicity
includes serious acute kidney injury (AKI), which affects 20–30% of patients [72]. Nephrotoxicity
affects cells in the distal convoluted tubules and collecting ducts. CisPt accumulates in the kidney
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and causes injury to normal renal epithelial cells, leading to unwanted cell death [72]. Since the
effectiveness of cisPt is dose dependent, it is desirable to maximize its dosage for maximal
efficacy. However, the effect of nephrotoxicity is also dependent on the dosage and the frequency
at which the compound is administered to the patient [72]. Therefore, due to this risk of toxicity,
the dosage has to be limited in order to avoid causing renal cell injury [70].
CisPt causes cell death either through apoptosis or necrosis. Apoptosis is programmed
cell death, which is induced by cytotoxic drugs such as cisPt [73, 70]. Necrosis is cell death that
is caused by damage or injury to the cells [74]. It has been observed that low concentrations (10–
100 μM) of cisPt induce apoptosis [70], whereas higher concentrations of cisPt (200–800 μM)
lead to necrosis [70, 72, 75]. Nephrotoxins, including cisPt at high concentrations, cause injuries
to renal tabular cells, which is characterized by swelling and rupturing [76]. This injury ultimately
leads to cell death and activation of an inflammatory response [70, 72, 75-76]. To reduce the
nephrotoxic effects of cisPt, the drug is sometimes administered clinically followed by thiolcontaining compounds shortly after to react and inactivate excess cisPt in the cells [70, 77]. Such
sulfur-containing compounds include methimazole, which reduces nephrotoxicity without
reducing the efficacy of cisPt [70, 78].
CisPt can cause other forms of toxicity that are associated a high cellular concentration of
the drug. Ototoxicity, which is a form of toxicity that leads to hearing loss, is a side effect of many
drugs [10, 79]. High dosages of cisPt induce formation of reactive oxygen species (ROS) in the
cochlea cells [10, 79]. The ROS further cause inflammation of the cochlea cells, which ultimately
leads to ototoxicity. CisPt has also been implicated in hepatoxicity, which is an effect on the liver
[80]. Through a process enhanced by cytochrome P450 2E1, cisPt induces increased levels of
ROS and oxidative stress, leading to hepatoxicity [80]. Other forms of cisPt toxicities and side
effects that have been noted include nausea, vomiting, hair loss, diarrhea, and cardiotoxicity,
among others [10].
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1.4.2

Cellular resistance to cisPt
The use of cisPt as a clinical anticancer drug is also limited by cellular resistance [69-71].

Resistance occurs when cancer cells do not undergo apoptosis with the clinically relevant drug
dose [71]. There are several factors that lead to cellular resistance, including reduced drug
accumulation, inactivation of the drug, and increased DNA repair by the cell [71].
Cancer cells with reduced drug accumulation of cisPt by 20–72% have significant
resistance to the compound [81]. There are two main causes of reduced cisPt concentrations in
the cell: (1) increased drug efflux from the cell, and (2) inhibition or reduced drug uptake [71]. One
or both mechanisms may contribute to resistance [71]. Reduced drug uptake may occur due to a
defect in the cell’s permeability during passive diffusion or due to aberrant proteins that regulate
facilitated transport of cisPt [71]. Development of cisPt resistance due to increased drug efflux is
mostly caused by exporter proteins. Multidrug resistance-associated proteins (MRP), found on
cellular membranes, have been shown to be upregulated in cancer cells, and have been
associated with cellular efflux of various drugs [82]. A member of this protein family called MRP2
is highly abundant in resistant tumor cells, with its upregulation being linked to cisPt resistance
[83]. Other proteins that have been linked to cisPt efflux include two copper-transporting Ptype
ATPases, ATP7A and ATP7B, which are upregulated in cisPt resistant cancer cells [84-85].
Transfection of ATP7B into tumor cells induces a nine-fold cisPt resistance due to increased drug
efflux [85].
CisPt is inactivated when it reacts with certain cytoplasmic nucleophilic metabolites [71],
which are usually sulfur-containing. The metabolites that primarily inactivate cisPt include
glutathione (GSH) and the cysteine-rich metallothionein [71]. Aquated cisPt is highly reactive
towards these metabolites, which then renders it unreactive with DNA. GSH is highly elevated in
cancer cells that have chronic exposure to cisPt [71], and therefore can induce resistance by
decreasing cisPt levels available for interaction with DNA. Increased levels of GSH in cisPtresistant cancer cells also upregulates the repair of DNA damaged by cisPt [81]. Metallothionein,
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which has sulfur-rich sites for cisPt coordination, has also been demonstrated to have a five-fold
higher abundance in cisPt-resistant human tumor cells [86].
Formation and sustaining cisPt-DNA adducts is important for inducing apoptosis.
However, the cell can also circumvent cisPt-induced apoptosis by triggering repair of the
damaged DNA [71]. Increased rates of removal of the adducts have been shown to attenuate
cisPt-induced cytotoxicity [71]. The cell can remove the platinum adducts and repair the damaged
DNA through a process known as nucleotide excision repair (NER) [87]. The NER pathway is
activated when DNA residues are modified by helix-distorting adducts (Fig. 1.11) [87]. First, the
adducts are recognized by a sensor complex that includes the XPE protein, followed by
recruitment of the excision repair complex [87]. The complex then excises a patch of nucleotides
from the region overlapping with the adduct in the damaged DNA (Fig. 1.11) [87]. This excision
removes approximately 24 nucleotides on the 5′ end of the adduct and three nucleotides on the
3′ side. The remaining complementary single strand is then used as a template for new DNA
synthesis (Fig. 1.11). After polymerization occurs, the new oligonucleotide is ligated to the rest of
the DNA to complete the repair [87]. Studies have shown that aberrant NER proteins or repair
pathways lead to sensitivity of a cell to cisPt treatment and that by re-establishing NER, the
sensitivity to cisPt returns to original levels [88-89]. Furthermore upregulation of proteins involved
in the NER complex lead to an increase in the repair of DNA and cellular resistance to cisPt [89].
Besides NER, a resistant cell can employ other mechanisms to tolerate platinum damage. These
include enhancing the DNA replication machinery to replicate past the platinum adducts and
allowing the cells to survive high levels of cisPt-mediated DNA modifications [71, 88].
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Figure 1.11. Nucleotide repair mechanism to remove cisPt adducts. The NER pathway is
activated when the DNA helical structure is distorted by adducts (represented by x). Excision of
nucleotides removes approximately 24 nucleotides from the 5′ and 3′ ends of the adduct. DNA
polymerization then occurs using the complementary single strand as a template. This step is
followed by ligation to complete the DNA repair.
1.4.3 Development of cisPt analogues for anticancer therapeutics
Chemoresistance of cancer cells to cisPt and toxic effects to normal cells have led to the
development of new platinum-based compounds [90]. Numerous cisPt analogues have been
developed to combat the limitations of the parent compound. These analogues exhibit structureactivity relationships that enable them to retain biological activity in cells. More specifically, the
active Pt(II) or Pt(IV) complexes are typically coordinated to their ligands in a cis geometry and
have the general formula cis-[PtX2Z2] or cis-[PtX2Y2Z2], in which X is the leaving group ligand, Z
is a non-leaving group with at least one N-H moiety, and Y is the axial ligand [91]. Despite these
consensus structures, exceptions do exist that violate this structure-activity relationship, and
those compounds have been developed using a different approach than for cisPt. Even though
thousands of cisPt analogues have been synthesized, only a small number have gone into clinical
trials [91]. Carboplatin, oxaliplatin, and nedaplatin are a few examples that have been approved
for clinical use worldwide [91].
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Figure 1.12. Antitumor platinum-based compounds. Aside from cisPt, these platinum(II)based compounds have been clinically used for antitumor targeting either worldwide or in a few
regions of the world.

Carboplatin (cis-diammine-1,1-cyclobutanedicarboxylate platinum(II)) (Fig. 1.12) is a
second-generation platinum-based drug with reduced toxic side effects compared to cisPt [3336]. However, in cancer cells, carboplatin is not as potent as cisPt at similar concentrations [3336]. The structure of carboplatin consists of a chelating cyclobutanedicarboxylate ligand instead
of the two chlorido ligands (in the case of cisPt). The cyclobutanedicarboxylate ligand plays a
number of roles such as modulating the rate of aquation and adduct formation, and increasing
the solubility of carboplatin, which is important for cell penetration [91]. The chelate ring in the
cyclobutanedicarboxylate stabilizes the ligand and slows the reaction rate for ligand exchange
with H2O by two orders of magnitude compared to cisPt [91-92]. The rate of adduct formation with
DNA is also 100-fold slower for carboplatin than for cisPt, due to the slower aquation rate [34].
The chemical characteristics of carboplatin have given the compound certain advantages over
cisPt such that it can circumvent the toxicity usually caused by high dosage [91]. However, due
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to a lower abundance of adducts, carboplatin has a reduced efficacy compared to cisPt, meaning
that a much higher dose is required in order to achieve the same effect [16]. Clinically, it has been
noted that up to four times as much carboplatin is needed to acquire the same effect as cisPt [16].

Figure 1.13. Platinum drugs bound to dGuo residues in the major groove of DNA. Oxaliplatin
has a large DACH ligand that protrudes into the major grove and interferes with DNA replication
and transcription machinery (PDB code 1PG9). Compared to oxaliplatin, cisPt forms a smaller
adduct that does not efficiently block replication and transcription machinery (PDB code 2NPW).

Oxaliplatin was approved worldwide due to its persistent activity in cisPt-resistant cancers
and absence of nephrotoxicity [93]. The non-leaving group ligand of oxaliplatin is a chelated 1,2diamminocylohexane (DACH) ligand (Fig. 1.12). This ligand gives the complex a unique structureactivity relationship that is crucial in averting cellular resistance that challenges utilization of cisPt
[91]. As mentioned before, one form of cellular resistance occurs when a cell tolerates the adducts
and enables the replication machinery to bypass and read through the platinum adducts [94-95].
Oxaliplatin has been observed to circumvent such resistance, likely because its DACH ligand
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protrudes into the major groove of DNA and is more effective at preventing the replication
machinery from bypassing the adducts [96, 94] (Fig. 1.13). Although oxaliplatin does not exhibit
nephrotoxicity, it causes other side effects including neurological toxicity [95]. Oxaliplatin is also
not fully effective by itself and normally requires combination therapy with other anticancer agents
such as 5-fluorouracil and cisPt [95].
There are several second-generation platinum-based drugs that have received approval
in various regions of the world (Table 1.1) [93]. Nedaplatin, diammine[hydroxyacetato(2-)-O,Ó]
platinum(II), was approved in Japan in 1995 for treatment of lung, oesophageal, and head and
neck cancers [93]. It has an added advantage of being more soluble than cisPt as well as having
lower nephrotoxicity [97]. Heptaplatin is an approved platinum-based drug used in Korea for
treatment of gastric cancer [93]. It also has higher solubility in water and a lower toxicity profile.
Lobaplatin, which is used to target chronic myeloid leukemia, has received regional approval in
China [93]. Lobaplatin is also in clinical trials in other parts of the world, including the US, South
Africa, EU, and Australia, for treatment of breast, ovarian, chronic myeloid leukemia, and lung
cancer [93]. The advantage of lobaplatin over cisPt is that its mode of action involves altering the
expression of genes that modulate apoptosis, oncogenesis, and cell proliferation [98]. Picoplatin,
which entered clinical trials in 1997, has an interesting structural feature that enables aversion of
resistance [91]. It has a 2-methylpyridine ring that can tilt by about 102.7°, which results in
positioning of the methyl group over the square plane [19, 91] This structural positioning causes
steric hindrance to thiol-containing deactivating agents such as glutathione. The tilt can therefore
block these metabolites from effectively reacting with the complex. The blocking of the thiolcontaining agents is important for circumventing inactivation, so that the platinum complex can
form adducts with DNA [19, 91].
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Table 1.1. Clinically approved cancer platinum-based drugs [93]
year of
country
drug
approval approved
types of cancer treated
carboplatin 1989
worldwide ovarian, brain, head, neck, cervical, testicular, breast
nedaplatin

1995

Japan

oesophageal, head, neck, lung

oxaliplatin

1996

worldwide

colon

heptaplatin 1999

Korea

advanced gastric

lobaplatin

China

small cell lung, breast, chronic myeloid leukemia

1.4.4

2010

Platinum(IV)-based compounds as antitumor agents
In addition to Pt(II)-based complexes, there are also Pt(IV)-based compounds that exhibit

anticancer activity [99]. The Pt(IV) complexes are generally inert and only act as prodrugs that
can exert their therapeutic activity after reduction to the reactive Pt(II) complex form [19, 99].
These complexes have the ability to be administered orally in their inactive form, and are
converted into the reactive form once in the cell, with potentially high potent activity and low
toxicity [99].
As shown in Fig. 1.14, Pt(IV) complexes have an octahedral geometry with two cis nonleaving ligands (usually ammine ligands), two cis leaving groups, and two axial ligands [10, 19].
The Pt(IV) complex can be converted to Pt(II), which by extension leads to the loss of the axial
ligands [19]. There are a number of Pt(IV) complexes that have gone into clinical trials for
antitumor therapy. Iproplatin has a structure with ligands (including two axial OH groups) that play
a role in its high solubility, broad range of activity, and lower toxicity in animal studies (Fig. 1.15)
[100]. However, iproplatin was dropped in clinical trials after it did not show clear advantages over
carboplatin [100]. Tetraplatin (Fig. 1.15) is another Pt(IV)-based compound that exhibits
advantages over cisPt in animal studies in that it is less nephrotoxic and circumvents cellular
resistance. However, it was also abandoned in clinical trials due to severe neurotoxicity in humans
[100]. Satraplatin (Fig. 1.15) has seen more success in phase 3 clinical trials for hormone-
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refractory prostate cancer due to its reduced nephrotoxicity and neurotoxicity [19]. Satraplatin was
designed to be an inactive prodrug that can be administered orally, giving it an advantage over
the intravenously administered cisPt [19]. Its stability as a prodrug enables it to be distributed in
blood plasma in the inactive form before being converted into the active form once inside the cells.
It was observed that with oral administration of satraplatin, its cellular potency was comparable to
intravenously administered cisPt and carboplatin [100].

Figure 1.14. Ligands of Pt(IV)-based complexes and their roles. Pt(IV)-based antitumor
agents have three types of ligands, including leaving group, non-leaving group, and axial ligands.
These ligands play different roles in the activity of the compounds towards tumor cells as
indicated.

Figure 1.15. Structures of Pt(IV)-based anticancer agents. Iproplatin, tetraplatin, and
satraplatin are some of the Pt(IV)-based compounds that are or have been used in clinical trials.
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In summary, the currently approved antitumor platinum-based drugs have shown
significant success in cancer therapies and some analogues have advantages over cisPt in terms
of reduced toxic side effects and the ability to circumvent resistance. However, there are still
challenges with cancer therapies involving platinum compounds, ranging from DNA repair and
off-target inactivation to various forms of toxicity. The reduced toxicity of the second-generation
platinum-based drugs is overshadowed by their reduced effectiveness in cells. It is therefore
important to develop new cisPt analogues that have alternative biomolecular targets, altered
reactivity preferences, and a balance between high efficacy and reduced toxicity.
1.5 Thesis objectives
CisPt exerts its anticancer activity by preferentially coordinating to dGuo residues within
DNA [38]. The dGuo adducts that are formed alter the DNA structure and contribute to inhibition
of functions such as replication and transcription that ultimately lead to cancer cell death [1, 11].
Nevertheless, cisPt has a number of drawbacks such as cellular resistance that reduce its efficacy
[71]. Analogues of cisPt that exhibit altered reactivity with other cellular targets such as RNA or
form non-canonical adducts with alternative DNA residues could be useful in circumventing
resistance by causing irreparable damage and triggering apoptosis [29, 55].
Aim 1: Synthesize and characterize amino acid-linked platinum(II) compounds
In this thesis work, platinum-based compounds with diversified structures, ligand sizes,
and charge distributions were synthesized by coordinating amino acids with platinum. The thesis
hypothesis is that modification of cisPt with amino acid ligands of varying sizes and charges will
alter the reaction kinetics and nucleoside binding preferences. The amino acids linked to
platinum(II) provide an array of compounds (AAPt) with diverse ligands and chemical
characteristics. The platinum(II) compounds generated with their corresponding amino acid
ligands are AlaPt (alanine), OrnPt (ornithine), and ArgPt (arginine). The amino acid-linked
compounds that were successfully synthesized and used for further studies are shown in Fig.
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1.16. The compounds were characterized by using NMR spectroscopy (1H,

13

C,

195

Pt), mass

spectrometry, and X-ray crystallography.

Figure 1.16. The structures of cisPt and amino acid-linked platinum(II) compounds, AlaPt, OrnPt,
and ArgPt, are shown.

Aim 2: Characterize non-canonical adducts formed by amino acid-linked platinum(II)
compounds with DNA and RNA residues
When cisPt coordinates with DNA, it predominantly platinates the N7 position of dGuo
[101-102]. Platinum-based compounds may form intrastrand or interstrand adducts, depending
on whether they coordinate to the same strand or two strands, respectively [18, 41]. Adducts can
also be defined as monofunctional, bifunctional, or doubly platinated, depending on the
platinum:nucleoside ratio (i.e., 1:1, 1:2, or 2:1, respectively). The adduct types also vary,
depending on the site of platination on the nucleobase (e.g., N1, N3, or N7). We sought to
determine the binding site preferences and to characterize the types of adducts formed by amino
acid-linked platinum(II) compounds in DNA and RNA residues. The structures and corresponding
chemical properties of various amino acid-linked platinum(II) compounds may alter the preferred
sites of reactivity versus those targeted by cisPt. In this work, mass spectrometry was used to
determine the composition and type (e.g., mono- or bifunctional) of adducts formed by the
platinum-based compounds, and 1H-NMR spectroscopy was used for characterization of the
platination sites on the nucleoside. In collaboration with Dr. M. T. Rodgers’ laboratory, we also
sought to evaluate the effect of platination on the relative glycosidic bond strengths of these noncanonical adducts using tandem mass spectrometry.
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Aim 3: Determine reaction kinetics of amino acid-linked platinum(II) compounds with
DNA/RNA nucleosides and oligonucleotides
The nucleophilicity and accessibly of the N7 position in dGuo residues of DNA is thought
to be favorable for cisPt adduct formation [102]. Less is known about reactivity of other positions
such as N7, N3, or N1 of dAdo. The reaction kinetics of three amino acid-linked platinum
compounds (AlaPt, OrnPt, and ArgPt) were examined. The rate constants obtained were used to
determine how the chemical structures and physical properties of the functional groups of the
amino acid ligands relate to reactivity the platinum-based complexes with DNA/RNA nucleosides
and oligonucleotides. The DNA/RNA nucleosides or oligonucleotides were reacted with a 50-fold
excess of AAPt compound for pseudo-first-order reaction conditions. An HPLC equipped with a
C-18 column was utilized to quantify levels of reacted nucleoside/oligonucleotide and the data
were analyzed to give the pseudo-first-order kinetics of the platinum compounds. The peak area
of unreacted nucleoside/oligonucleotide was monitored over time and the diminishing ratio to the
product peaks was determined. The data were fit using an exponential equation assuming
pseudo-first-order kinetics. The reaction rate constants obtained from reactions in the nucleoside
and oligonucleotide levels were compared in order to understand the reactivity preferences and
selectivities of the compounds.
Aim 4: Determine potency of amino acid-linked platinum(II) compounds and quantify their
accumulation in cancer and normal cells
At the cellular level, it is important to develop analogues that are more selective than cisPt
and can strike a balance between selective potency in cancer cells and reduced toxicity in normal
cells. An understanding of the cellular activity of amino acid-linked platinum(II) compounds is
important for determining which structural features of the compounds are critical for achieving
selective potency and accumulation in cancer cells. The potency of AAPt in human cancer and
normal

cell

lines

was

determined

using

the

MTT

(3-(4,5-dimethylthiaxol-2-yl)-2,5-

diphenyltetrazolium bromide) assay. In this assay, IC50 values were obtained following treatment
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of cell lines with varying concentrations of AAPt compounds (and cisPt for comparison). To
determine the cellular abundance of platinum-based compounds, the cell lines were treated with
AAPt compounds and cisPt followed by chemical digestion. The abundance of platinum in each
sample was then quantified by using ICP-MS. This research will drive the development of new
compounds that are not only effective in cancer cells, but can discriminate against normal cells.
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CHAPTER 2
AMINO ACID-LINKED PLATINUM(II) COMPOUNDS: SYNTHESIS, CHARACTERIZATION,
AND METHODS TO INVESTIGATE THEIR KINETICS, ADDUCTS, AND CELLULAR
ACTIVITIESǂ
ǂ

Adapted from Kimutai B, He CC, Roberts A, Jones ML, Bao X, Jiang J, Yang Z, Rodgers MT,

Chow CS (2019) J Biol Inorg Chem 24:985-997.
2.1 Abstract
The work in this thesis focuses on synthesis, characterization, adduct formation, kinetics,
and biological activity of cisplatin (cisPt) analogues. CisPt analogues can be generated with
simple ligand modifications. Small modifications may alter the reactivity preferences of the
analogues towards residues that are not preferentially targeted by cisPt. In this work, amino acids
are used as ligands and coordinated to a platinum metal center to generate amino acid-linked
platinum(II) (AAPt) compounds. The amino acids provide a range of ligands with varied sizes and
charge distributions. The AAPt compounds generated may in turn have diversified reactivity
profiles compared to cisPt. AAPt compounds that are derivatives of alanine, ornithine, and
arginine were synthesized. These compounds are referred to as AlaPt, OrnPt, and ArgPt,
respectively. The compounds were characterized using different methods, including 1H-, 13C-, and
195

Pt-NMR spectroscopy, mass spectrometry, and X-ray crystallography. A variety of techniques

described in this chapter were also used to determine the kinetics of adduct formation, adduct
structures, and biological activities of the synthesized compounds. Non-canonical adducts formed
by AAPt compounds with nucleosides/oligonucleotides were characterized using mass
spectrometry and NMR spectroscopy. The reaction kinetics were determined using HPLC
analysis. The influence of AAPt compounds on glycosidic bond stability were investigated using
tandem mass spectrometry and survival yield analysis (in collaboration with Dr. M. T. Rodgers’
lab). The potency of the compounds in human cell lines was determined using MTT (3-(4,5-
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dimethylthiaxol-2-yl)-2,5-diphenyltetrazolium bromide) assays, and their cellular accumulation
was quantified using inductively coupled plasma mass spectrometry (ICP-MS).
2.2 Introduction
2.2.1 Application of amino acids as ligands of cisplatin analogues
Despite the application of cisPt in treatment of a variety of cancer types, its clinical use is
limited by cellular resistance and adverse side effects emanating from toxicity to normal cells [6971]. Furthermore, DNA repair and reduced accumulation of cisPt allow cancer cells to continue
propagating despite drug treatment [71]. There has been research and development of numerous
cisPt analogues aimed at circumventing the limitations of cisPt. However, with thousands of cisPt
analogues having been synthesized, only a small number have made it to clinical trials. The few
analogues that have been approved for clinical use worldwide include carboplatin, oxaliplatin, and
nedaplatin [91]. Therefore, there is still need to develop platinum-based compounds that not only
have a balance between potency in cancer cells and toxicity in normal cells, but also have
alternative biological targets from those targeted by cisPt.
Amino acids are a great source of ligands with diversified sizes and charge distributions.
Based on the chemical and physical properties of their side chains, naturally occurring amino
acids can be categorized into groups such as basic, acidic, hydrophobic, and polar. Amino acids
with basic side chains include lysine and arginine, whereas the acidic group includes aspartate
and glutamate. The nonpolar group includes alanine, leucine, isoleucine, valine, and
phenylalanine. Amino acids with polar side chains include serine and cysteine. These amino
acids can be linked with a platinum metal center to generate amino acid-linked platinum(II) (AAPt)
compounds [103-106]. The diversity of the side chain functional groups together with the
contribution of backbone atom metal coordination means that the AAPt compounds can
potentially have a wider range of reactivity and targets, which could give them advantages over
cisPt. The amino acids are also inexpensive and readily available starting materials, which not
only reduces the cost of synthesis but also the number of steps in the synthetic protocols.
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There have been a number of previous reports on the synthesis and characterization of
AAPt compounds, either with naturally occurring or modified amino acid derivatives [103-104,
107-112]. In these studies, platinum-based derivatives of histidine, serine, methionine, arginine,
lysine, and ornithine were synthesized and characterized [103-104, 107-112]. The techniques
used for characterization of these platinum-based compounds include

195

Pt-NMR spectroscopy,

X-ray crystallography, and mass spectrometry. Previous reports focused mainly on the synthesis
and characterization of the compounds, but not on the biological applications [107-108, 110, 113].
The platinum(II) metal center was observed to coordinate with the soft bases (nitrogen and sulfur
atoms) as well as hard bases (oxygen atoms) of the amino acids [103-104, 107, 110-111]. The
general structures of the Pt(II) complexes consist of one chelating amino acid and two chlorine
atoms coordinating with the metal center [103-104, 107, 110-111]. Chelation of the amino acid
through the backbone nitrogen and oxygen atoms with the Pt(II) center leads to a five-membered
ring (N,O binding mode) (Fig. 2.1) [103-104, 107, 110-111]. The platinum metal center may also
coordinate with the side chain, especially if there is a soft base such as a sulfur atom to form (N,S)
type of binding (Fig. 2.1) [109]. The presence of an amine in the side chain (e.g., lysine and
ornithine) may lead to formation of (N,N) type structures, in which the platinum center coordinates
to the nitrogen atoms in the backbone and side chain (Fig. 2.1). Even though the (N,N) type
structures have not been observed in crystal structures of ornithine and lysine derivatives, they
cannot be ruled out. Crystallization conditions may favor only the (N,O) type structures [107].
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Figure 2.1. Possible structures of AAPt compounds. The platinum(II) metal center can chelate
with the amino acid through the backbone or side-chain atoms.
There have been a few applications of AAPt compounds in biological studies. Cellular
activity and toxicity of lysine, ornithine, histidine, and methionine derivatives in cancer cell lines
were found to be generally lower than that of cisPt [104, 109, 103, 111-112]. Biological
applications of the compounds have been minimal and only focused on a few different cell lines
and DNA as the biological target [104, 109, 112]. Further studies on the interactions of AAPt
compounds with alternative biological targets, as well as comprehensive cellular studies with
cisPt-resistant cell lines, are necessary. Previous studies in our lab showed that several AAPt
compounds (ornithine and arginine derivatives) interact and form adducts with RNA [106]. There
is still a need to understand how the chemical structures and physical properties of the functional
groups of the AAPt complexes relate to their reactivity and target preference. Understanding the
role of the ligands in target preferences will be important for the rational development of novel
compounds that have improved cellular activities and effectiveness.
In this chapter, the synthesis and characterization of several AAPt compounds is
described. The derivatives of alanine, ornithine, and arginine (AlaPt, OrnPt, and ArgPt) were
successfully synthesized and characterized. These compounds were used in subsequent work to
study their reactivities with nucleic acids and also to screen their cellular potency in cancer cells.
The synthesized compounds were characterized using 1H-,13C-, and

195

Pt-NMR spectroscopy,

mass spectrometry, and X-ray crystallography. It was hypothesized that the structures of the
synthesized AAPt compounds would have the (N,O) type of binding structures, in which the
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platinum(II) center coordinates with the backbone nitrogen and oxygen atoms of the amino acid
(Fig. 2.2).

Figure 2.2. The structures of amino acid-linked platinum(II) compounds. The AAPt
compounds consist of a platinum(II) metal center coordinated to a chelating amino acid and two
chlorido ligands.
2.2.2 Formation and characterization of non-canonical AAPt-nucleic acids adducts
The AAPt compounds form adducts by coordinating with dAdo/Ado residues of DNA and
RNA [105-106]. In this thesis work, the adducts formed by AlaPt, OrnPt, and ArgPt with
nucleosides and oligonucleotides were characterized to determine the adduct types and sites of
platination. AAPt (or cisPt) compounds were first activated to form monoaquated species, which
were then reacted with target nucleosides/oligonucleotides. The reactions could result in
formation of different types of products that vary in composition, platination sites (N1, N3, or N7),
and geometry. The reactions and products formed were monitored using HPLC. The fractions
corresponding to adducts were isolated and characterized by using mass spectrometry and NMR
spectroscopy.
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2.2.3 Kinetics of AAPt with DNA/RNA nucleosides and oligonucleotides
Modifications to cisPt may alter its reactivity and direct the compound towards alternative
biological targets. Different behaviors of the platinum-based compounds can be achieved by
modifying the ligands to favor different interactions such as hydrogen bonding, charge-charge
interactions, and steric hindrance, among others. For example, an analogue of cisPt with a
heteroaromatic ligand, 4,4′-dipyrazolylmethane, shows a reactivity preference for the dAdo/dThdrich regions of DNA rather than the dGuo-rich regions [114]. In this thesis work, the reaction
kinetics of three AAPt compounds (AlaPt, OrnPt, and ArgPt) were examined to determine how
the chemical structures and physical properties of the functional groups of the amino acids relate
to reactivity and nucleoside preferences. The hypothesis is that modification of cisPt with amino
acid ligands of varying sizes and charges will alter the reaction kinetics and nucleic acid target
preferences. Influence of the oligonucleotide local environment was also investigated since the
nucleotides surrounding the target nucleotide may modulate the binding kinetics of cisPt and AAPt
and lead to different platination rates and profiles. Timecourse reactions of the AAPt compounds
with nucleosides/oligonucleosides were monitored by using HPLC equipped with a C18 column.
Pseudo-first-order kinetics were used to compare the preferences of three AAPt compounds (and
cisPt) with purine nucleosides and also to understand the impact of local nucleic acid environment
on their reactivity with oligonucleotides.
2.2.4 Impact of AAPt compounds on glycosidic bond stability of adducts
Platination of nucleic acids may have unique influences on the chemical properties of the
nucleosides such as bond strengths. For example, modifications such as alkylation or protonation
of DNA residues have previously been observed to weaken the glycosidic bond and accelerate
the process of depurination [115-118]. Thus, hydrolytic instability of purine glycosidic bonds may
impact nucleoside integrity, particularly under varying pH and ionic strength conditions and
modification states [116, 119-121]. Stability of the glycosidic bond may also be influenced
differentially by platination at varying sites on the nucleobase. In this thesis work, the impact of
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AlaPt and OrnPt adducts on relative glycosidic bond strengths of adducts is investigated by
employing energy-resolved collision-induced dissociation (ER-CID) tandem mass spectrometry
and survival yield analysis [116, 122-125].
2.2.5 Potency and accumulation of AAPt compounds in human cancer and normal cells
Application of cisPt in cancer therapy has had major drawbacks due to resistance and
adverse side effects, including nephrotoxicity [69-71]. Clinical analogues of cisPt such as
carboplatin have low potency, meaning that a higher dose is required to achieve the same
effectiveness as cisplatin [16]. Development of new platinum-based compounds will focus on not
only maintaining the efficacy of cisPt, but also having reduced side effects and selectivity for
cancer cells. Based on Lipinski rules [126], the AAPt compounds could provide another class of
metal-based compounds with oral drug-like features. The anticancer potency of AAPt compounds
can be evaluated by determining the IC50 values in several human cancer cell lines using the 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [127]. This assay utilizes
viable cells to convert MTT into a purple-colored formazan. The NAD(P)H-dependent cellular
oxidoreductase enzymes in viable cells convert MTT into insoluble purple formazan. The
formazan is dissolved by solvents such as DMSO and the optical density (OD) measurements of
the resulting solutions are taken using a uv-visible spectrophotometer. The OD measurements
are used to determine the percentage of viable cells present following exposure to a given
concentration of the cytotoxic compound.
Accumulation of platinum-based compounds inside cells drives the pharmacological
impact of the anticancer compound. Low accumulation of cisplatin in cells leads to reduced DNA
damage and could potentially stimulate resistance rather than apoptosis [71]. The cellular
accumulation of AAPt compounds in comparison to cisplatin in both cancer and normal prostate
cells was investigated in this work. Cells were treated with either AAPt compounds or cisPt
followed by quantitative measurements of cellular platinum concentrations with inductively
coupled plasma mass spectrometry (ICP-MS).
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2.3 Materials
2.3.1 Chemicals
Potassium tetrachloroplatinate(II), L-alanine, trimethylsilyl propionate (TSP), 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 3-hydroxypicolinic acid (3-HPA),
and HCl were purchased from Sigma-Aldrich (St. Louis, MO). L-Ornithine, L-arginine, and cisdiamminedichloridoplatinum(II) were from Alfa Aesar (Haverhill, MA). Deuterium oxide (D2O),
chloroform-D, and acetonitrile-D3 were from Cambridge Isotope Laboratories (Tewksbury, MA).
Silver nitrate, acetonitrile, ammonium acetate, ethanol, methanol, dimethylsulfoxide, and nitric
acid (trace metal grade) were obtained from Fisher Chemical (Hampton, NH). Poly(Ado) RNA
was from Pharmacia LKB Biotechnology (Uppsala, Sweden). Sodium phosphate, monobasic and
dibasic, were obtained from EMD Millipore (Kankakee, IL). All amino acid-linked platinum(II)
compounds were synthesized in the lab (described in Section 2.4).
All nucleosides (deoxyguanosine (dGuo), guanosine (Guo), deoxyadenosine (dAdo), and
adenosine (Ado)) were purchased from Sigma-Aldrich (St. Louis, MO). Oligonucleotide strands,
5′-d(TTATT)-3′ and 5′-UUAUU-3′, were purchased from Integrated DNA Technologies (Coralville,
IA).
2.3.2 Human cell lines and cell culture supplies
The cancer cell lines HeLa (cervical), H1299 (non-small cell lung), MDA-MB-231 (breast),
and MDA-MB-453 (breast) [128-132] were obtained from Dr. Young-Hoon Ahn’s lab, Wayne State
University. DU145 (prostate cancer) [133] was received from Dr. K. V. Honn’s lab, Wayne State
University. RWPE-1 (normal prostate cell line) [134] was acquired from Dr. Zhihui Qin’s lab,
Wayne State University. Dulbecco's modified eagle medium (DMEM), keratinocyte serum free
medium (K-SFM), human recombinant epidermal growth factor 1-53 (EGF 1-53), bovine pituitary
extract (BPE), phosphate buffered saline (PBS), and trypsin-EDTA (0.25%) were purchased from
Gibco-ThermoFisher Scientific (Waltham, MA). Transparent flat-bottom 96-well plates were
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acquired from USA Scientific (Ocala, FL). Cell culture dishes (60 x 15 mm and 100 x 20 mm) were
purchased from Sigma Aldrich (St. Louis, MO).
2.3.3 Instrumentation
Proton and

13

C-NMR spectra of the AAPt compounds were recorded on an Agilent MR-

400 MHz spectrometer in the Wayne State University Lumigen Instrument Center
(LIC). The 195Pt-NMR spectrum of the AlaPt compound was recorded on a Varian VNMRS-500
MHz spectrometer in the LIC. Absorption of nucleosides and oligonucleosides were measured
on Beckman Coulter DU730 UV/Vis spectrophotometer (Brea, CA). The 1H and 13C NMR spectra
of the AAPt-nucleoside adducts, and two-dimensional heteronuclear single quantum coherence
(HSQC) spectroscopy of OrnPt-nucleoside adducts were recorded on a Bruker Avance 700 MHz
spectrometer equipped with a TXI cryoprobe in the LIC. The MS analyses were performed by Dr.
C. C. He on a 7T Fourier transform ion cyclotron mass spectrometer (FT-ICR MS, solariX,
Bruker Daltonics, Billerica, MA) in Dr. M. T. Rodgers’ laboratory. X-ray crystallography was
performed by Dr. P. Martin on an X-ray single-crystal diffractometer (Bruker X8 APEX) in the LIC.
MALDI-MS characterization was performed on a Bruker UltrafleXtreme MALDI-TOF/TOF mass
spectrometer (Billerica, MA) in the LIC. HPLC analysis was carried out on a Waters 600 LC with
a 717plus autosampler (Milford, MA) fitted with a Sigma-Aldrich Supelco Discovery C18 column
(5 μm particle diameter; 4.6 mm × 250 mm, St. Louis, MO) and UV detector set at 254 nm.
Platinum-195 quantification was performed on an Agilent 7700X ICP-MS equipped with an ASX500 series autosampler and Agilent MassHunter software (Santa Clara, CA) (LIC). Orbitrap-MS
spectra were obtained on a ThermoScientific LTQ Orbitrap XL (Waltham, MA) (LIC). LC-MS
characterization was performed on a Shimadzu 8040 triple quadrupole (Columbia, MD) equipped
with ESI (LIC) and a Waters C18 Acquity HSS T3 100 mm column (Milford, MA). Energy-resolved
collision-induced dissociation (ER-CID) and survival yield experiments were performed by Dr. C.
C. He on a Bruker Daltonics amaZon ETD quadrupole ion trap mass spectrometer (Billerica, MA)
in Dr. M. T. Rodgers’ laboratory. ER-CID data processing was done by C. C. He using Bruker
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Daltonics DataAnalysis 4.0 (Billerica, MA). Survival yield data analysis was performed by Dr. C.
C. He using Systat Software SigmaPlot 10.0 (San Jose, CA) and custom software developed in
Dr. M. T. Rodgers’ laboratory. Optical density measurements for cytotoxicity experiments were
performed using a BioTek synergy H1 hybrid reader (Winooski, VT) in Dr. Y. H. Ahn’s laboratory.
2.4 Methods
2.4.1 Synthesis and characterization of AlaPt
Synthesis of AlaPt was carried out following a previously described procedure, but with
some modifications to improve yield and minimize undesired side reactions [104]. First, 0.17
mmoles (70 mg) of K2PtCl4 and five equivalents of L-alanine (75 mg) were dissolved in 2 mL of
double-distilled water (ddH2O) and heated at 50 °C overnight on a Fisher thermoshaker at 950
rpm. The crude product was filtered and vacuum dried for approximately 12 h. Next, 3.0 mL of ice
cold ddH2O was added to the resulting solid, and the solution was mixed by vortexing for one
minute, followed by centrifugation at 14,000 rpm for 10 min. The supernatant was removed and
discarded. To the pellet was added 3.0 mL of cold 95% ethanol, followed by vortexing and
centrifugation at 14,000 rpm for 8 min and removal of the supernatant; this procedure was
repeated three times. The solid precipitate was then dried under vacuum overnight. To the dried
sample was added 250 µL of 100 mM NaOH, followed by vortexing and filtering under
centrifugation (Millipore 10 kDa centrifugal filter) at 14,000 rpm for 10 min to remove high
molecular weight aggregates. The filtrate was collected and vacuum dried to obtain a light-yellow
product. The final product, obtained in 47% yield (28 mg), was characterized by 1H-NMR
spectroscopy,

13

C-NMR,

195

Pt-NMR, and high-resolution mass spectrometry. Melting point, 249-

251 °C; δ/ppm (1H-NMR, D2O, 400 MHz), 3.50 (1 H, q, J=7.1 Hz, =CHCH3), 1.28 (3 H, d, J=7.0
Hz, -CH3); δ/ppm (13C-NMR, D2O, 400 MHz) 193 ((-COO)CH=), 57 (=CHCH3), 20 (=CHCH3);
δ/ppm (195Pt-NMR, D2O, 500 MHz, -1639); m/z (electrospray ionization mass spectrometry (ESIMS)) 352.943 Da/e [M]¯; calculated exact mass 352.942 Da [M]¯; chemical formula PtC3H6Cl2NO2
([M]¯, at neutral pH).
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The synthesized AlaPt was characterized by using 1H-, 13C-, and 195Pt-NMR spectroscopy.
The 1H-NMR spectrum of AlaPt was analyzed in comparison to the 1H-NMR spectrum of L-alanine
(Fig. 2.7). The Hα proton peak of alanine has a chemical shift of 3.61 ppm, whereas the
corresponding Hα peak for AlaPt is shifted upfield by 0.11 ppm (δ 3.50 ppm). The Hβ proton peak
of L-alanine has a chemical shift of 1.31 ppm, whereas the corresponding Hβ peak for AlaPt is
shifted slightly upfield by 0.03 ppm (δ 1.28 ppm). The changes in chemical shifts are consistent
with coordination of the amino acid to the platinum center.

Figure 2.7. The 1H-NMR spectra of L-alanine (top) and AlaPt (bottom). For L-alanine; δ/ppm
(1H-NMR, D2O, 400 MHz), 3.61 (1 H, q, J=7.7 Hz, =CHCH3), 1.31 (3 H, d, J=7.6 Hz, -CH3). For
AlaPt; δ/ppm (1H-NMR, D2O, 400 MHz), 3.50 (1 H, q, J=7.1 Hz, =CHCH3), 1.28 (3 H, d, J=7.0 Hz,
-CH3).
In the 13C-NMR spectrum, the carboxylate carbon peak for alanine has a chemical shift of
176 ppm, whereas the corresponding peak for AlaPt is at 193 ppm (Fig. 2.8). The Cα and Cβ are
shifted less (from 50 to 57 ppm and 16 to 20 ppm, respectively) because they are further away
from the platinum center. The 13C-NMR spectrum of AlaPt also has extra peaks that are possibly
from the aquated AlaPt species. AlaPt is relatively soluble and as much as 100 mg can be
dissolved in 1 mL of D2O. Due to its high solubility, the aquation (replacement of chlorido with
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aqua) can occur rapidly. It was observed that when an equivalent ratio of AgNO 3 is added to an
AlaPt solution, a white precipitate (AgCl) is rapidly formed, possibly due to the fast aquation. To
further monitor the presence of aquated species in solution by NMR spectroscopy, AlaPt was
mixed with an equivalent ratio of AgNO3 for varying time points of 1, 2, 6, and 24 h. After each
time point, the sample was centrifuged to precipitate the AgCl. The supernatant was then
characterized with

13

C-NMR spectroscopy. It was observed that with increasing time, the peak

pattern changed to reflect the diminishing non-aquated AlaPt and the formation of mono- and bisaquated species (Fig. 2.9).

Figure 2.8. The 13C-NMR spectra of L-alanine (top) and AlaPt (bottom). For L-alanine; δ/ppm
(13C-NMR, D2O, 400 MHz) 176 ((-COO)CH=), 50 (=CHCH3), 16 (=CHCH3); For AlaPt; δ/ppm (13CNMR, D2O, 400 MHz) 193 ((-COO)CH=), 57 (=CHCH3), 20 (=CHCH3). The minor peaks are due
to possible aquation of AlaPt which occurs in a H2O or D2O environment as described in the
introduction (Section 1.2.3).
In the

195

Pt-NMR spectrum, the chemical shift of the platinum(II) center of AlaPt is

compared to that of potassium tetrachloroplatinate(II), which is the starting material for AlaPt
synthesis (Fig. 2.10). The

195

Pt-NMR spectrum shows a

195

Pt peak at -1607 ppm for potassium

tetrachloroplatinate(II) that shifts to -1639 ppm for the AlaPt product.
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Figure 2.9. The 13C-NMR time course of AlaPt aquation. The spectrum of aquated AlaPt
changes over time with different species diminishing or forming at varying proportions. The nonaquated species (black asterisks) are diminished with time. The monoaquated species (red
circles) also diminish over time while the bis-aquated species (green triangles) become dominant
at longer time periods.

AlaPt was also characterized by using ESI mass spectrometry. The mass analysis gives
an observed m/z of 352.9 Da/e. This result agrees with the calculated exact mass of 352.9 Da for
a singly charged (negative) AlaPt product with a chemical formula PtC3H6Cl2NO2 (Fig. 2.11). The
mass data are consistent with one amino acid and two chlorido ligands coordinated to a platinum
center, with AlaPt having (N,O) type of binding (platinum coordination to the N and O atoms of
alanine).
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Figure 2.10. The 195Pt-NMR spectrum of potassium tetrachloroplatinate(II) and AlaPt. For
potassium tetrachloroplatinate(II) (top), δ/ppm (195Pt-NMR, D2O, 400 MHz) is -1607 (PtCl4); for
AlaPt (bottom), δ/ppm (195Pt-NMR, D2O, 400 MHz) is -1639 (PtCl2(NH2)O). The 195Pt chemical
shift for AlaPt is in the same region where peaks for other comparable platinum-based compounds
are found [110, 135]. Assistance to obtain these spectra was provided by Dr. Dennis Anderson in
the Wayne State University Lumigen Instrument Center.

Figure 2.11. ESI mass spectrum of AlaPt. m/z (ESI-MS) 352.9 Da/e [AlaPt]¯; calculated exact
mass 352.9 Da [AlaPt]¯; chemical formula PtC3H6Cl2NO2 ([AlaPt]¯, at neutral pH). The spectrum
was obtained by Dr. C. C. He in Dr. M. T. Rodgers’ lab.
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2.4.2 Synthesis and characterization of OrnPt
Synthesis of OrnPt was carried out as described previously [104]. First, 0.17 mmoles of
K2PtCl4 and two equivalents of L-ornithine (44 mg) were dissolved in 2 mL of ddH2O. The mixture
was heated at 50 °C overnight on a thermoshaker and afterwards dried under vacuum. The crude
product was washed with ice-cold ddH2O and vacuum dried again. The product, obtained in 40%
yield (27 mg), was characterized by 1H-NMR spectroscopy,

13

C-NMR spectroscopy and high-

resolution mass spectrometry. A sample of OrnPt product was also crystallized to be used for
solving its crystal structure through X-ray crystallography. The crystals were first grown through
the slow evaporation method. A 10 mM concentration of OrnPt dissolved in ddH2O was placed in
a capped glass tube fitted with a needle-sized hole at the top. The tube was kept in the dark for 3
weeks at room temperature with minimal disturbance. Shiny yellow rod-like crystals were
obtained. The biggest crystal was selected, and the structure was solved using a Bruker D8
diffractometer. δ/ppm (1H-NMR, D2O, 400 MHz), 3.54 (1 H, t, J=6.3 Hz, -CH(NH2)CH2-), 2.89 (2
H, t, J=7.9 Hz, -CH2NH3), 1.84–1.69 (4H, m, -CH(NH2)CH2CH2-); m/z (ESI-MS) 395.986 Da/e [M–
H]¯; calculated exact mass 395.984 Da [M–H]¯; chemical formula PtC5H11Cl2N2O2 ([M–H]¯, at
neutral pH). The crystal structure shows that the Pt center is coordinated with nitrogen and oxygen
of the amino acid.
The OrnPt was characterized by using

1

H- and

13

C-NMR spectroscopy, mass

spectrometry, and X-ray crystallography. The 1H-NMR spectrum of OrnPt was compared to that
of L-ornithine (Fig. 2.12). The chemical shift of the L-ornithine Hα proton peak is 3.60 ppm. The
close proximity of the metal center shifts the corresponding Hα proton for OrnPt upfield to 3.50
ppm. The platinum-induced chemical shift is subtle for the Hβ and Hγ protons, likely because they
are further away from the metal center.
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Figure 2.12. The 1H-NMR spectra of L-ornithine (upper) and OrnPt (lower). For L-ornithine,
δ/ppm (1H-NMR, D2O, 400 MHz) is 3.63 (1 H, t, J=6.3 Hz, -CH(NH3)CH2-), 2.90 (2 H, t, J=8.0 Hz,
-CH2NH3), 1.82 – 1.52 (4H, m, -CH(NH3)CH2CH2-). For OrnPt; δ/ppm (1H-NMR, D2O, 400 MHz),
3.54 (1 H, t, J=6.3 Hz, -CH(NH2)CH2-), 2.89 (2 H, t, J=7.9 Hz, -CH2NH3), and 1.84 – 1.69 (4H, m,
-CH(NH2)CH2CH2-). The chemical shifts are consistent with a previously described
characterization of OrnPt [104].
In the 13C-NMR spectrum, the peaks from L-ornithine were compared to those for OrnPt.
The Cα, Cβ, Cγ, and Cδ peaks for L-ornithine are more upfield in comparison to OrnPt (54 to 58
ppm, 37 to 38 ppm, 27 to 29 ppm, and 22 to 23 ppm, respectively) (Fig. 2.13). The carboxylate
carbon peak for L-ornithine has a chemical shift of 174 ppm. The corresponding peak for OrnPt
was not fully resolved likely due to the low solubility of OrnPt in D2O. OrnPt has moderate solubility
in D2O and gets saturated at approximately 5 mg/mL.
Other solvents that were used to dissolve OrnPt for possible

13

C-NMR spectroscopic

analysis at higher concentrations include deuterated-acetonitrile, CDCl3, and DMSO. However,
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while the solubility of OrnPt is also very low in deuterated-acetonitrile and CDCl3, the DMSO
solvent likely reacts with the compound due to the presence of the sulfur, which has been
observed to occur when DMSO is mixed with cisPt [136]. The reactivity of OrnPt with DMSO was
confirmed by 1H-NMR spectroscopy in which a change in the NMR spectrum is observed (Fig.
2.14). For future 13C-NMR analysis, perhaps the carboxylate carbon could be resolved by running
the analysis for a longer time period (approx. 24 h in D2O) or with other solvents such as
deuterated-methanol, which can dissolve the compound at higher concentrations.

Figure 2.13. The 13C-NMR spectra of L-ornithine and OrnPt. The 13C chemical shifts change
between L-ornithine and OrnPt due to coordination of the amino acid with the platinum(II) center.
The Cα, Cβ ,Cγ, and Cδ are shifted from 54 to 58 ppm, 37 to 38 ppm, 27 to 29 ppm, and 22 to 23
ppm, respectively. The carboxylate carbon peak for OrnPt is not observed due to the relatively
low solubility of the compound in D2O compared to L-ornithine.
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Figure 2.14. The 1H-NMR spectra of OrnPt in D2O and DMSO. DMSO reacts with OrnPt,
resulting in an altered 1H-NMR spectrum (bottom) compared to that of OrnPt dissolved in D2O
(top).

Analysis of OrnPt using ESI mass spectrometry gave an observed m/z of 395.986 Da/e
(Fig. 2.15), which is consistent with the calculated exact mass of 395.984 Da for the OrnPt product
with the chemical formula PtC5H11Cl2N2O2. A dimer, [2(OrnPt)-H]¯, is also observed at 794.975
Da/e. The mass data for OrnPt support a structure with one ornithine and two chlorido ligands
coordinated to the platinum center.
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Figure 2.15. ESI mass spectrum of OrnPt. m/z (ESI-MS) 395.986 Da/e [M-H]¯; calculated exact
mass 395.984 Da [M-H]¯; chemical formula PtC5H11Cl2N2O2 ([OrnPt-H]¯; at neutral pH); a dimer
[2(OrnPt)-H]¯ is observed at 794.975 Da/e. This spectrum was obtained by Dr. C. C. He in Dr
M.T. Rodgers’ lab.
While the above data are consistent with the coordination of one amino acid to a metal
center, the spectra do not reveal whether the structure is (N,O) or (N,N) type. In the (N,N) type
structure, the propylamine side chain of ornithine could coordinate to the metal center through its
nitrogen atom. The structure of OrnPt was therefore analyzed by using X-ray crystallography (Fig.
2.16), which shows that the platinum(II) maintains a square-planar geometry and is part of a fivemembered ring with (N,O) coordination, consistent with a previous report [104]. The crystallization
conditions for OrnPt may favor the (N,O) type, but the presence of (N,N) type structures in solution
cannot be ruled out [107].
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Figure 2.16. Crystal structure of OrnPt. The structure is consistent with a previously described
(Nb,Ob) binding structure [104], in which the platinum maintains its square-planar geometry in a
five-membered chelation ring. The structure was obtained by Dr. Phil Martin in the Wayne State
University Lumigen Instrument Center.

2.4.3 Synthesis and characterization of ArgPt
Synthesis of ArgPt was carried out using L-arginine and K2PtCl4 as the starting materials
and following the OrnPt synthesis protocol above with several modifications to optimize purity.
First, 0.17 mmol of K2PtCl4 and one equivalent of L-arginine (29 mg) were mixed in 2 mL ddH2O.
An equivalent amount of KCl (13 mg) was also added to the mixture to inhibit disproportionation
of K2PtCl4 [112]. The mixture was heated at 50 °C overnight on a thermoshaker at 950 rpm,
followed by vacuum drying. The crude product was washed with 1 mL ice-cold ddH2O three times
and vacuum dried again to obtain a light greenish product. The product was obtained in a 23%
yield (17 mg) and characterized by 1H-NMR spectroscopy,

13

C-NMR, and mass spectrometry.

δ/ppm (1H-NMR, D2O, 400 MHz), 3.49 (1 H, t, J=6.7 Hz, -CH(NH2)CH2-), 3.14 (2 H, t, J=6.8 Hz, CH2NH-), 1.90 – 1.48 (4H, m, -CH(NH)CH2CH2-). m/z (ESI-MS) 439.007 Da/e [M+H]+; calculated
exact mass 439.014 Da [M+H]+; chemical formula PtC6H13Cl2N4O2 ([M-H]—, at neutral pH).
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Figure 2.17. The 1H-NMR spectra of L-arginine and ArgPt. For L-arginine (upper); δ/ppm (1HNMR, D2O, 400 MHz), 3.10 (1 H, t, J=5.5 Hz, -CH(NH3)CH2-), 3.04 (2 H, t, J=6.3 Hz, -CH2NH-),
1.53 – 1.40 (4 H, m, -CH(NH)CH2CH2-). For ArgPt (lower); δ/ppm (1H-NMR, D2O, 400 MHz), 3.49
(1 H, t, J=6.7 Hz, -CH(NH2)CH2-), 3.14 (2 H, t, J=6.8 Hz, -CH2NH-), 1.90 – 1.48 (4 H, m, CH(NH)CH2CH2-).
The ArgPt was characterized by using 1H- and

13

C-NMR spectroscopy, and mass

spectrometry. The 1H-NMR spectrum of ArgPt was analyzed in comparison to that of L-arginine
(Fig. 2.17). The chemical shift of the L-arginine Hα proton peak is at 3.10 ppm, whereas the
corresponding Hα proton for ArgPt is shifted downfield to 3.49 ppm due to the close proximity of
the metal center. Since the Hβ and Hγ protons are further away from the metal center, their
platinum-induced chemical shift is relatively smaller. In the 13C-NMR spectrum, the peaks from Larginine were compared to those for ArgPt. The Cα, Cβ, Cγ, and Cδ peaks for L-arginine are shifted
in comparison to ArgPt (55.5 to 57.8 ppm, 40.8 to 40.5 ppm, 31.5 to 29.3 ppm, and 24.3 to 23.7
ppm, respectively) (Fig. 2.18). The Cε and Ci (carboxylate carbon) peaks of L-arginine have
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chemical shifts of 156.8 and 183.2 ppm, respectively. Similar to OrnPt, the corresponding peaks
for ArgPt were not fully resolved likely due to the low solubility of ArgPt in D2O (ArgPt is saturated
at approximately 5 mg/mL).

Figure 2.18. The 13C-NMR spectra of L-arginine and ArgPt. The chemical shifts for carbons
change between L-arginine and ArgPt due to coordination of the amino acid with the platinum
center. The Cα, Cβ, Cγ, and Cδ of L-arginine and ArgPt change from 55.5 to 57.8 ppm, 40.8 to 40.5
ppm, 31.5 to 29.3 ppm, and 24.3 to 23.7 ppm, respectively. The Cε and Ci (carboxylate carbon)
peaks for ArgPt are not observed likely due to low solubility of the compound in D2O compared to
L-arginine.
Analysis of ArgPt using ESI mass spectrometry gave an observed m/z of 439.007 Da/e
(Fig. 2.19), which is consistent with the calculated exact mass of 439.015 Da for ArgPt with a
chemical formula PtC6H14Cl2N4O2. The mass data suggest that the complex consists on one
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arginine and two chlorido ligands coordinated to the platinum(II) center. A dimer, [2(ArgPt)+Cl]+,
is observed at 914.993 Da/e. A species, [(ArgPt)+Cl]+, with 474.982 Da/e is also observed.

Figure 2.19. Mass analysis of ArgPt using FT-ICR MS. m/z (ESI-MS) 439.007 Da/e [M+H]+;
calculated exact mass 439.014 Da [M+H]+; chemical formula PtC6H14Cl2N4O2 ([M+H]+, at neutral
pH); Other species include a dimer, [2(ArgPt)+HCl]+ , observed at 914.993 Da/e and [(ArgPt)+Cl]+
observed at 474.982 Da/e. This spectrum was obtained by Dr. C. C. He at Dr. M.T. Rodgers’ lab.

2.4.4 Preparation of aquated AAPt compounds
For in vitro studies, cisPt or AAPt analogues converted into monoaquated species
prior to reactions with nucleosides or oligonucleotides. Aquation of AlaPt, OrnPt, and
ArgPt to generate the corresponding monoaquated AAPt species, involves replacement
of one chlorido with an aqua ligand (Scheme 2.1). The AAPt compound (1.8 µmoles) and
AgNO3 (1.3 µmoles, ratio of 1:0.7) were dissolved in 300 µL double deionized water
(ddH2O) and agitated (using a vortex shaker) in the dark at room temperature for 15 h.
The resulting white precipitate (AgCl) was removed through two centrifugation steps at
14,000 rpm for 10 min each. The supernatant contained the corresponding monoaquated
AlaPt, OrnPt, or ArgPt. CisPt was converted to monoaquated cisPt using the same
procedure.
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Scheme 2.1. Aquation of platinum compounds

2.4.5 Preparation of nucleosides and oligonucleotides
To prepare stock solutions, individual nucleosides were dissolved in ddH2O and filtered
through centrifugation. Supernatants were collected and concentrations of the nucleosides were
determined by measuring absorption on a DU730 UV/Vis spectrophotometer (Beckman Coulter)
at the maximum wavelength and using molar extinction coefficient of the respective nucleoside.
The extinction coefficients and wavelengths used were 14,900 M-1 cm-1 at 260 nm for Ado, 13,600
M-1 cm-1 at 253 nm for Guo, 15,700 M -1 cm-1 at 260 nm for dAdo, and 13,000 M-1 cm-1 at 254 nm
for dGuo [137].
HPLC analysis and matrix assisted laser desorption ionization mass spectrometry
(MALDI-MS) characterization of 5′-d(TTATT)-3′ (Figs. 2.20 and 2.21) and 5′-UUAUU-3′ (Figs.
2.22 and 2.23) show that the oligonucleotides were pure and had the expected calculated
masses. Concentrations of each strand were determined by measuring absorbance at 260 nm.
At this wavelength, the extinction coefficients are 47,000 M-1 cm-1 for 5′-d(TTATT)-3′ and 52,600
M-1 cm-1 for 5′-UUAUU-3′.
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Figure 2.20. HPLC analysis of 5′-d(TTATT)-3′. A single peak for 5′-d(TTATT)-3′ is observed with
only minor impurities (C18 column).

Figure 2.21. MALDI-MS mass spectrum of 5′-d(TTATT)-3′. MALDI analysis (positive mode) of
5′-d(TTATT)-3′ gave an observed m/z of 1548.6 Da/e (calculated exact mass of [d(TTATT)+H]+ is
1548.3 Da). A peak corresponding to the oligonucleotide associated with a sodium ion is observed
at m/z 1571.8 Da/e. Other minor peaks associated with multiple sodium ions are observed as
well.
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Figure 2.22. HPLC analysis of 5′-UUAUU-3′. A single peak for 5′-UUAUU-3′ is observed with
only minor impurities (C18 column).

Figure 2.23. MALDI-MS mass spectrum of the 5′-UUAUU-3′. MALDI analysis (positive mode)
of 5′- UUAUU-3′ gave an observed m/z of 1571.7 Da/e (calculated exact mass of [UUAUU+H]+ is
1572.1 Da). A peak corresponding to the oligonucleotide associated with one sodium ion is
observed at m/z 1594.1 Da/e while an oligonucleotide associated with two sodium ions is
observed at m/z 1616.0 Da/e.
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2.4.6 Pseudo-first-order reaction kinetics
The monoaquated AAPt compounds (or monoaquated cisPt) were used in 50-fold excess
to produce pseudo-first-order reaction conditions. A 0.1 mM solution of the relevant nucleoside
(Ado, Guo, dAdo, dGuo) or oligonucleotide was incubated with 5 mM of the aquated platinum
complex in 25 mM Na2HPO4/NaH2PO4 buffer (pH 7) at 37 °C. For nucleoside reactions, six
aliquots were collected from the sample at different time points (0, 0.5, 1, 2, 3, 4, and 6 h). For
oligonucleotide reactions, six aliquots were collected from the sample at different time points (0,
5, 15, 30, 60, 90, and 120 min). Each aliquot was quenched with NaCl (0.12 M final concentration)
and then frozen at -80 °C until HPLC analysis. The HPLC was fitted with the Supelco Discovery
C18 column (see instrumentation Section 2.4.5). For nucleoside elution, buffers A (40 mM
NH4OAc, pH 6.5) and B (40% acetonitrile, 60% ddH2O) were employed using isocratic conditions
with 5% B for 5 min followed by a linear gradient in which B was increased to 35% over 25 min.
For oligonucleotide elution, the same buffers were employed using isocratic conditions with 10%
B for 5 min followed by a linear gradient in which B was increased to 20% over 10 min, and further
increased to 50% over the next 15 min. The peak area of unreacted nucleoside/oligonucleotide
was monitored over the six time points and their diminishing ratio to the product peaks was
determined [138]. The unreacted nucleoside/oligonucleotide was monitored because its peak was
dominant in area and could also be distinguished from other multiple product peaks based on the
retention time of the control. The HPLC calibration curves show a linear relationship between the
nucleoside concentration and normalized peak area (Fig. 2.24). Therefore, the peak area of the
nucleoside at each time point can be integrated quantitatively.
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Figure 2.24. HPLC calibration curves for Ado and Guo. There is a linear
relationship between the amount of a nucleoside injected and the area under
curve.

2.4.7 Fitting data into a kinetic equation
The data were fit using an exponential equation assuming pseudo-first-order kinetics
(Eqs. 2.1-2.5). The pseudo-first order kinetics equation is derived as follows, in which AAPtaq is
the monoaquated compound and Nuo is the nucleoside or oligonucleotide [139]:
Nuo + AAPtaq

AAPt-Nuo adduct + H2O (Eq. 2.1)

Depending on the platinum-based compound, various charged species such as monoaquated
or bisaquated species can be present in the solution and take part in the reaction [140]. The rate
of reaction (V) is given by,
V = kapp [AAPtaq] [Nuo] (Eq. 2.2)
in which, kapp is the apparent bimolecular rate constant. Under pseudo-first-order conditions,
[AAPtaq] >> [Nuo] (50-fold excess of AAPtaq over Nuo) and remains approximately constant. Under
these conditions, the rate constant, k, equals kapp[AAPtaq] and the rate (V) is given by,
-d[Nuo]/dt = k [Nuo] (Eq. 2.3)
By integration and rearrangement,
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ln[Nuo]t = -kt + ln[Nuo]0 (Eq. 2.4)
By rewriting the above equation in exponential form,
[Nuo]t = e-kt + [Nuo]0 (Eq. 2.5)
in which [Nuo]t is the concentration of unreacted nucleoside or oligonucleotide at time t, and [Nuo]0
is the initial concentration of unreacted nucleoside or oligonucleotide. When [Nuo]t is plotted
against t, the decay factor is k. The equation was input into KaleidaGraph software and used to
fit the data. Experiments were performed in triplicate. The standard error was calculated by
dividing the standard of the mean deviation by the square root of the number of replicates.
2.4.8 Mass analysis of HPLC isolated AAPt-nucleoside adducts
The HPLC fractions containing the AAPt-nucleoside adducts were collected and vacuum
dried. The samples were redissolved in 50:50 MeOH:ddH2O (v/v) and ions were generated with
an ESI source. The MS analyses were performed using a 7T Fourier transform ion cyclotron mass
spectrometer (FT-ICR MS, solariX, Bruker Daltonics). Major ions were identified for each fraction.
The dominant AAPt-nucleoside adduct in each fraction was isolated and subjected to CID-tandem
mass spectrometry analysis. Fragments were observed and assigned based on their measured
m/z values.

2.4.9 NMR spectroscopy of AAPt-nucleoside adducts
The 1H and

13

C NMR (700 MHz) spectra of the AAPt-nucleoside adducts were recorded

on a Bruker Avance 700 MHz spectrometer equipped with a TXI cryoprobe. The H2 and H8
signals in Ado were assigned by identifying the C2 and C8 chemical shifts in

13

C NMR [141]

followed by two-dimensional heteronuclear single quantum coherence (HSQC) spectroscopy to
correlate C2-H2 and C8-H8. To each sample, 10 μM trimethylsilyl propionate (TSP) was added
as an internal standard. The 1H chemical shifts were referenced to the residual HDO (semi-heavy
water) signal, which was calibrated against TSP. D2O (with no buffer) was also chosen as the
solvent for the 1H and 13C NMR (700 MHz) spectra of the adducts.
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2.4.10 Mass analysis of HPLC isolated AAPt-oligonucleotide adducts
The HPLC fractions containing the AAPt-oligonucleotide adducts were collected and
vacuum dried. For MALDI analyses, the dried samples were first redissolved in 10 µL ddH2O. A
1.5 µL of each sample was mixed with 1.5 µL of saturated 3-HPA and spotted on a MALDI plate.
The analyses were carried out on the Bruker UltrafleXtreme MALDI-TOF/TOF. For Orbitrap-ms
analyses, the dried HPLC fractions containing the AAPt-nucleoside adducts were redissolved in
100 µL ddH2O with 0.03% triethylamine. Ions were generated with an ESI source and spectra
obtained on the ThermoScientific LTQ Orbitrap XL.
2.4.11 Reactions of AAPt with poly(Ado) RNA, ethanol precipitation, and LC-MS
characterization of adducts
For platination reactions with poly(Ado) RNA, monoaquated AAPt was used in 4-fold
excess to the RNA molecule. The sample was incubated in 25 mM Na2HPO4/NaH2PO4 buffer (pH
7) at 37 °C overnight. Afterwards, the RNA was desalted using ethanol precipitation. To carry out
ethanol precipitation, the platinum nucleic acid solution (of volume V) was mixed with 2.5 V of
100% ethanol and 0.1 V of 3 M NH4OAc. The sample mixture was placed on dry ice for 45 min
and then centrifuged at 14,000 rpm for 30 min at 4 °C. The supernatant was removed and 100 µL
of 70% ethanol was added to the remaining pellet. The sample was centrifuged again at 14,000
rpm for 30 min at 4 °C. The supernatant was removed followed by vacuum drying of the remaining
pellet. The dried pellet was redissolved in 50 µL ddH2O and digested with P1 nuclease (1 unit) for
5 h at 37 °C. This step was followed by calf intestine phosphatase (CIP, 2 units) treatment for
another 5 h at 37 °C. The sample was then filtered with centrifugation (Millipore 10 kDa centrifugal
filter) at 10,000 rpm for 30 min. The collected sample was vacuum-dried and redissolved in 50:50
MeOH:ddH2O (v/v).
LC-MS (Shimadzu 8040 triple quadrupole) was used to separate and identify the platinum
adducts and corresponding unplatinated material. The LC-MS was equipped with ESI and fitted
with a C18 Acquity HSS T3 100mm column. For elution, buffer A (10 mM NH4OAc, pH 6.5) and
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buffer B (9% acetonitrile with 10 mM NH4OAc in ddH2O) were employed under isocratic conditions
with 0% B for 5 min followed by a linear gradient in which B was increased from 0 to 33% over 20
min.
2.4.12 Energy-resolved collision-induced dissociation (ER-CID) experiments and survival
yield analyses
ER-CID experiments of the HPLC fractions containing the AlaPt-Ado, OrnPt-Ado, and
ArgPt-Ado adducts were performed on a quadrupole ion trap mass spectrometer (QIT MS,
amaZon ETD, Bruker Daltonics). The method has been described in detail in previous work [116,
124-125]. Briefly, HPLC fractions were vacuum dried and then redissolved in a MeOH:ddH2O
(50:50 v/v) mixture. Each HPLC fraction (10 μM) was introduced to the ESI source to generate
ions, which were then guided into the ion trap. In the trap, ions were accumulated and mass
selected for tandem ER-CID experiments. Helium (1 mtorr) served as both the buffer and collision
gas to provide efficient trapping and cooling of the ions as well as to achieve fragmentation of the
precursor AAPt-nucleoside complex. The qz value was set to 0.25 for the ER-CID experiments,
which leads to low mass cutoff of 27% of the precursor ion m/z. The rf excitation amplitude was
increased from 0 V to the rf excitation amplitude required to produce complete dissociation of the
precursor ion at a stepsize of 0.01 V. Experiments were performed in triplicate to assess
reproducibility. All data were processed using Data Analysis 4.0 (Bruker Daltonics).
The glycosidic bond cleavage (GBC) survival yield was calculated from the intensities of
the precursor and fragment ions, and the ratio of the precursor ion intensity to the total ion intensity
was determined using Eq. 2.6 [142],
Survival Yield (GBC) = (∑𝑛−𝑥
𝐼𝑓𝑖 + 𝐼𝑝 )⁄( ∑𝑖 𝐼𝑓𝑖 + 𝐼𝑝 )
𝑥

(2.6)

in which 𝐼𝑓𝑖 and 𝐼𝑝 are the ion intensities of the fragment and precursor ions, respectively; x
represents fragments in which the glycosidic bond remains intact. Data analyses were performed
using SigmaPlot 10.0 (Systat Software, Inc., San Jose, CA) and custom software developed in
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the Rodgers laboratory and reported previously [116, 122-125]. The GBC survival yield was
plotted as a function of the rf excitation amplitude. The rf excitation amplitude required to produce
50% glycosidic bond cleavage (GBC50%) was extracted by fitting of the survival yield curve using
the four-parameter logistic dynamic equation (Eq. 2.7) [116, 124-125].
Survival Yield (GBC50%) = min + (max − min)⁄[1 + (rfEA /GBC50% ]GBCslope

(2.7)

In this equation, max and min are defined as the maximum (1) and minimum (0) values of the
survival yield, rfEA is the rf excitation amplitude applied to induce fragmentation, and GBCslope is
the slope of the declining region of the survival yield curve.
2.4.13 MTT cytotoxicity assays in human cell lines
The number of cells was first determined using a hemocytometer. The cells (and media)
were seeded in a transparent flat-bottom, 96-well plate with each well having 10,000 cells. The
seeded plate was placed in an incubator (37 °C, 5% CO2) for 24 h to allow the cells to attach to
the wells. Afterwards, the media was removed and fresh media with varying concentrations of the
AAPt compound (or cisPt) added to the wells. In each plate, two types of controls were included.
The first, referred to as the growth control, contained cells and media but no platinum compounds.
The second, referred to as the blank control, had media only. The plates were incubated for 72 h
after which 10 µL of MTT stock (5 mg/mL) was added to each of the wells. The plates were
incubated for another 4 h during which time insoluble formazan is produced by viable cells. DMSO
(100 µL) was added to the wells and incubated for 10 min to dissolve the formazan. The optical
density (OD) of each well was measured at 520 nm using a microplate reader, BioTek synergy
H1 hybrid reader in Dr. Y. H. Ahn’s lab. The percentage of viable cells for each concentration of
platinum compound was determined using Eq. 2.8.
% of viable cells =

OD for platinum compound concentration−OD for blank control
OD for growth control−OD for blank control

(2.8)
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The IC50 plots were generated using GraphPad PRISM®, which fits the concentration of
platinum compound (X) and normalized response (percentage of viable cells, Y) into a model
equation, Eq. 2.9.
Y=100/(1+(XhillSlope)/(IC50hillSlope)), in which hillslope is -1.

(2.9)

The protocol for cell culture and maintenance of human cell lines is described in Appendix
A.
2.4.14 Quantification of cellular accumulation of platinum compounds
The human prostate cancer cell line, DU145, and normal prostate cell line, RWPE-1, were
grown in 100 x 20 mm tissue culture dishes until confluency. The cells were then detached from
bottom of dishes by treating with trypsin. The suspension was homogenized and the cell number
was determined using a hemocytometer. From the stock suspension, 460,000 cells were seeded
on 60 x 15 mm culture dishes each and grown in an incubator (37 °C, 5% CO2) for 18 h. The
media was removed and the dishes were washed with 3 mL PBS. In each dish, 3 mL of
keratinocyte media with 50 µM of platinum compound was added. The dishes were incubated for
another 2 h to allow uptake of the compounds by the attached cells. The media was removed and
dishes washed again with 3 mL of PBS. The cells on the dishes were resuspended using 500 µL
of trypsin and collected into centrifuge tubes. The cell number in each tube was counted using a
hemocytometer. The cells were chemically digested using 300 µL of concentrated HNO 3. The
samples were left to further digest at room temperature for 16 h after which they were diluted by
adding 2.7 mL of 2% HNO3 and 0.5% HCl (in ddH2O) solution prior to ICP-MS quantification.
For ICP-MS calibration, a platinum standard series with 0.5, 1, 5, 10, 25, 50, 100, 200 ppb
concentrations was prepared in 2% HNO3 and 0.5% HCl (in ddH2O). Aside from the standards
and the digested cell samples, solvent blanks and blanks without platinum compounds were also
included in the analysis. Quantification was carried out using an Agilent Technologies 7700 series
ICP-MS instrument (plasma gas flow 15 L/min, nebulizer pump speed 0.3 rps, spectrum
acquisition mode, 100 sweeps per sample, 3 replicates per sample, general purpose plasma
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mode). A 10 ppb concentration of 209Bi solution was used as the instrument internal standard. The
195

Pt isotope was used for detection since has minimal polyatomic interference [143]. Data were

collected under high energy He tune mode in which the internal standard signal was stable and
the R value for the calibration curve was closest to 1. For quality control, a 10 ppm standard was
run after the samples.
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CHAPTER 3
CHARACTERIZATION OF NON-CANONICAL ADDUCTS FORMED BY AMINO ACIDLINKED PLATINUM(II) COMPOUNDSǂ
ǂ

Nucleoside level studies are adapted from Kimutai B, He CC, Roberts A, Jones ML, Bao X,

Jiang J, Yang Z, Rodgers MT, Chow CS (2019) J Biol Inorg Chem 24:985-997.
3.1 Abstract
Cisplatin (cisPt) is an antitumor drug that preferentially coordinates and forms adducts
with deoxyguanosine (dGuo) residues within DNA. These adducts inhibit important cellular
functions and ultimately cause cancer cell death. Despite its success as an anticancer drug, cisPt
has a number of drawbacks that reduce its efficacy, including repair of adducts and drug
resistance. To overcome these problems, other approaches such as development of compounds
that form non-canonical adducts by coordinating to other purine nucleobases, including those
found in RNA can be pursued. The synthesized amino acid-linked platinum(II) (AAPt) compounds
of alanine, ornithine, and arginine (AlaPt, OrnPt, and ArgPt, respectively) have unique reactivities
that result in formation of non-canonical adducts with adenosine or deoxyadenosine (Ado or
dAdo) residues. In this chapter, the non-canonical adducts formed by the AAPt compounds with
nucleosides/oligonucleotides were characterized. Nucleoside-level adducts were separated by
HPLC on C18, then characterized by NMR spectroscopy and mass spectrometry (in collaboration
with Dr. M. T. Rodgers’ lab). The chosen AAPt compounds form predominantly monofunctional
adducts by reacting at the N1/N3, or N7 positions of purine nucleobases. The AAPt adducts with
oligonucleotides were also isolated by HPLC and characterized by matrix-assisted laser
desorption ionization mass spectrometry (MALDI-MS) and liquid chromatography mass
spectrometry (LC-MS). The AAPt compounds were observed to form a variety of adduct types
with oligonucleotides, including monofunctional, doubly platinated, and bifunctional adducts.
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3.2 Introduction
The antitumor drug cisPt platinates neighboring deoxyguanosine (dGuo) residues of DNA
by coordinating at their N7 positions and forming bifunctional adducts [18, 37-38]. These adducts
alter the DNA helical structure and inhibit important biological processes such as replication and
transcription [11]. The adducts trigger a number of cellular responses, including cell cycle arrest,
DNA repair, and apoptosis [1]. Despite its success, the application of cisPt as an anticancer drug
is limited by cellular resistance and adverse side effects such as nephrotoxicity [69-71].
Resistance, which is caused by factors such as DNA repair and reduced accumulation of drug,
enables cancer cells to survive cisPt treatment [71]. Resistance and adverse toxicity can be
circumvented by developing other platinum-based compounds that have altered reaction profiles.
Platinum analogues may coordinate with DNA sites that are not platinated by cisPt or target other
biomolecules such as RNA. These analogues may therefore exhibit unique mechanisms of action
that avert resistance, especially when the adducts cause irreparable damage [55-56, 29].
Therefore, the types of adducts formed by platinum-based compounds are important in their
cytotoxic mechanism, as exhibited by cisPt-DNA bifunctional adducts that bend the DNA helix
and trigger a cascade of events leading to apoptosis [37]. The adducts formed by cisPt or its
analogues can be analyzed by using various chemical and analytical methods.
As introduced previously in Chapter 1, there are several potential sites in the DNA where
cisPt can platinate with varying degrees of preference (Fig. 3.1). At these nucleoside residues,
cisPt coordinates with nitrogen atoms. The preferred site for cisPt coordination is the N7 position
of dGuo [37-38, 10]. This site is situated in the major groove of the DNA, which is highly accessible
compared to sites in the minor groove such as N3 [18, 39]. CisPt may form intrastrand or
interstrand adducts, depending on whether coordination occurs on the same strand or separate
strands, respectively [18, 41]. Adducts can also be defined as monofunctional, bifunctional, or
doubly platinated, depending on the platinum:nucleoside ratio (i.e., 1:1, 1:2, or 2:1, respectively).
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It has been reported that 90–95% of cisPt-DNA adducts are intrastrand cross-links. whereas the
rest are a combination of interstrand cross-links and monofunctional adducts [37, 41].

Figure 3.1. Possible coordination sites for cisPt in DNA. The preferred coordination site is
dictated by accessibility and nucleophilicity. Arrows point at potential atoms that coordinate with
cisPt. The N7 atom of dGuo is preferred since it is in the major groove and more nucleophilic than
other DNA sites.

Formation of cisPt adducts with DNA/RNA is influenced by a number of factors (e.g.,
coordination type and hydrogen-bonding properties) associated with the non-leaving group ligand
[35-36]. These factors influence the target preferences and the types of platinum adducts formed
with DNA or RNA. For example, hydrogen-bonding interactions are implicated in the preferential
coordination of cisPt to dGuo [27]. This preference is because during the transition state, cisPt
forms a strong hydrogen bond between its ammine ligand and the oxo at the 6 position of dGuo
[27]. In contrast, formation of the cisPt-Ado adduct is less favored because Ado has an amine at
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the 6 position, which cannot hydrogen bond with cisPt [27]. The type of ligands associated with
cisPt (or other platinum-based compounds) may also affect several factors associated with the
adduct structures due to unique interactions with the nucleobase functional groups. These factors
include nucleoside platination sites (such as N1, N3, or N7) and geometric or constitutional
isomers [105].

Figure 3.2. The structures of cisPt and amino acid-linked platinum(II) (AAPt) compounds.
The structures of AAPt compounds consist of a chelated amino acid and two chlorido ligands
coordinated to the platinum center.
Previous studies in our lab showed that AAPt compounds such as OrnPt and ArgPt form
adducts at Ado residues in RNA [106]. In this chapter, the non-canonical adducts formed by AlaPt,
OrnPt, and ArgPt (Fig. 3.2) with nucleosides and oligonucleotides were characterized to
determine their adduct types and sites of platination. AAPt (or cisPt) compounds were first
activated

to

form

the

monoaquated

species,

and

then

reacted

with

target

nucleosides/oligonucleotides (Scheme 3.1). The reactions could in formation of different types of
products that potentially vary in composition, platination site (N1, N3, or N7), and geometry. These
reactions and products formed were monitored using HPLC. The HPLC fractions corresponding
to adducts were isolated and characterized using mass spectrometry and NMR spectroscopy.
These characterizations are crucial for understanding how functional groups of the amino acid
ligands of AAPt compounds and their chemical features relate to their reactivities and biological
target preferences.

67

Scheme 3.1. Aquation of platinum compounds and subsequent platination of purine residues.
Possible coordination sites are highlighted in blue (N7) and red (N1 and N3).

3.3 Results and discussion
3.3.1 Characterization of AAPt-nucleoside adducts
When cisPt coordinates with DNA, it predominantly platinates the N7 position of dGuo
[101-102]. In this thesis work, we sought to characterize the non-canonical adducts formed by
AAPt compounds and determine their binding site preferences. The structures and corresponding
chemical properties of various AAPt compounds may alter the preferred sites of reactivity versus
those targeted by cisPt. Mass spectrometry was used to determine the composition and type
(e.g., monofunctional, bifunctional, or doubly platinated) of adducts formed by the platinum-based
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compounds, and 1H-NMR spectroscopy was used for characterization of the platination sites (e.g.,
N1, N3, or N7) on the nucleoside.
The reactions of nucleosides with the monoaquated AAPt compounds result in the
formation of one or more adducts with longer (AlaPt and ArgPt adducts) or shorter (OrnPt adducts)
retention times on a C18 column relative to the unreacted nucleosides (Fig. 3.3A). Only one AAPtGuo adduct was expected based on the known preference for coordination of the aquated cisPt
at the dGuo N7 position [101, 144]. Previously in our lab, Dr. Xun Bao characterized the products
formed by platination of the Guo nucleoside [145]. HPLC and mass spectrometric analysis
showed that platination (by cisPt or OrnPt) led to formation of one major product. NMR
spectroscopy was used to determine that platination occurs at the N7 position of Guo [145].
The reactions of Ado with the monoaquated AAPt compounds result in the formation of
one or more adducts with longer (AlaPt and ArgPt adducts) or shorter (OrnPt adducts) retention
times on a C18 column relative to the unreacted nucleosides (Fig. 3.3B). Monoaquated AlaPt
reacts with Ado to form two main products (distinct HPLC peaks), referred to as AlaPt-AdoN1/N3
and AlaPt-AdoN7 (Fig. 3.3B). These adducts have longer retention times compared to Ado due to
decreased polarity associated with the alanine ligand. Monoaquated OrnPt reacts with Ado to
form two major products, OrnPt-AdoN1/N3 and OrnPt-AdoN7, which have shorter retention times
than Ado on C18. Monoaquated ArgPt also reacts with Ado to form three major products, ArgPtAdoN1/N3, ArgPt-AdoN7, and ArgPt-Adomix, which have longer retention times than Ado. Although
L-ornithine and L-arginine amino acids both have polar side chains (amine and guanidinium,
respectively), the adducts formed by their respective AAPt derivatives have different behaviors
on the C18 column. The adducts of OrnPt have shorter retention times compared to the adducts
of ArgPt. This observation suggests that OrnPt and ArgPt may have different types of structures
(N,O vs. N,N) as discussed in Section 2.4.2. Furthermore, the two compounds may form adducts
that adopt different structural conformations that position their functional groups for favorable
interactions or to avoid steric clash. Mass analysis of the fractions obtained from HPLC C18
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separation of the AlaPt-Ado, OrnPt-Ado, and ArgPt-Ado adducts was carried out in collaboration
with the Rodgers’ laboratory using FT-ICR MS equipped with an ESI source.

Figure 3.3. HPLC analysis (C18) of platination products. The AAPt-Guo (A) or AAPt-Ado (B)
adduct profiles following reactions with monoaquated AlaPt, OrnPt, or ArgPt are shown. The
peaks are labeled as follows; black asterisks for the free nucleosides, blue circles for N7
platination adducts, and red triangles for N1/N3 platination adducts. The controls (unreacted Guo
or Ado) are shown as the top traces in (A) and (B).
Mass analysis of the compounds in the two fractions obtained from HPLC C18 separation
of the AlaPt adducts (Fig. 3.3B), referred to as AlaPt-AdoN1/N3 and AlaPt-AdoN7, reveals that they
have the same mass, charge, and isotopic distribution, corresponding to a monofunctional adduct,
[Pt(Ado)(Ala)(Cl)+H]+ (Fig. 3.4). Because they have the same mass, the two adducts are
constitutional isomers that may vary at the site of platination (N1, N3, or N7). For the geometric
isomers, we expect that the structures shown in Scheme 3.1 are preferred because of the trans
effect [146], but these structures still need to be confirmed experimentally. In addition, it would be
of interest to understand how the binding types of platinum-based compounds (i.e., (N,N) vs.
(N,O)) impact the adduct identities. Other species formed by the loss and addition of neutral
molecules

are

observed

(Fig.

3.5).

These

species

include

[Pt(Ado)(Ala)(NH3)]+,
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[Pt(Ado)(Ala)(CH3CO2H)]+, and [Pt(Ado)(Ala)(CH3CN)(NH3)]+, which form as a result of the
monofunctional adduct losing HCl and generating a complex with NH3, CH3CO2H, or CH3CN from
the HPLC buffer, respectively. Due to the soft ionization conditions offered by ESI, it is not
surprising to observe adduction of NH3 [147].

Figure 3.4. Mass spectra of the AlaPt-AdoN1/N3 and AlaPt-AdoN7 fractions. For both fractions,
the monofunctional adduct species [Pt(Ado)(Ala)(Cl)+H]+ is observed with the predicted isotopic
distribution. The spectra were obtained by Dr. C. C. He in Dr. M. T. Rodgers’ lab.
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Figure 3.5. Wide range mass spectra of the AlaPt-Ado fractions. Both of the mass spectra for
AlaPt-AdoN1/N3 (red) and AlaPt-AdoN7 (blue) contain the monofunctional adduct species,
[Pt(Ado)(Ala)(Cl)+H]+. Other adducts are formed by the loss or addition of neutral molecules to
the monofunctional adduct. The spectra were obtained by Dr. C. C. He in Dr. M. T. Rodgers’ lab.
Similar to that found for the reactions of AlaPt with Ado, compounds in the OrnPt-Ado
HPLC fractions (Fig. 3.3), referred to as OrnPt-AdoN1/N3 and OrnPt-AdoN7, have the same mass,
charge, and isotopic distribution corresponding to a monofunctional adduct [Pt(Ado)(Orn)(Cl)] +
(Fig. 3.6), i.e., the two adducts are constitutional isomers with variation at the site of coordination
(e.g., N1, N3, or N7) or varying geometries as discussed for AlaPt. Species assigned as
[Pt(Ado)(Orn)(NH3)–H]+ and [Pt(Ado)(Orn)(CH3CN)(NH3)–H]+ are also observed, suggesting that
ligand substitution of one of the chlorido ligands is facile in solution (Fig. 3.7).
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Figure 3.6. Mass spectra of the OrnPt-AdoN1/N3 and OrnPt-AdoN7 fractions. For both fractions,
the monofunctional adduct species [Pt(Ado)(Orn)(Cl)]+ is observed with the predicted isotopic
distribution. The spectra were obtained by Dr. C. C. He in Dr. M. T. Rodgers’ lab.

Figure 3.7. Wide range mass spectra of the OrnPt-Ado fractions. Both of the mass spectra
for OrnPt-AdoN1/N3 (red) and OrnPt-AdoN7 (blue) contain the monofunctional adduct species,
[Pt(Ado)(Orn)(Cl)]+. Other adducts are formed by the loss or addition of neutral molecules to the
monofunctional adduct. The spectra were obtained by Dr. C. C. He in Dr. M. T. Rodgers’ lab.
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The ArgPt reaction with Ado results in three product HPLC fractions (Fig. 3.3). The first
two product fractions, referred to as ArgPt-AdoN1/N3 and ArgPt-AdoN7, have the same mass,
charge, and isotopic distribution corresponding to a monofunctional adduct [Pt(Ado)(Arg)(Cl)] +
(Fig. 3.8), i.e., the two adducts are constitutional isomers with variation at the site of coordination
(e.g., N1, N3, or N7) or varying geometries as discussed for the AlaPt-Ado and OrnPt-Ado
adducts. Species assigned as [Pt(Ado)(Arg)(H2O)–H]+ are also observed, suggesting that ligand
substitution of one of the chlorido ligands with H2O is facile in solution (Fig. 3.9). The third fraction,
referred to as ArgPt-Adomix, is a mixture of bifunctional ([Pt(Ado)2(Arg)]2+) and doubly platinated
([Ado(Pt(Arg)Cl)2]2+) adducts (Fig. 3.10).

Figure 3.8. Mass spectra of the ArgPt-AdoN1/N3 and ArgPt-AdoN7 fractions. For both fractions,
the monofunctional adduct species [Pt(Ado)(Arg)(Cl)+H]+ is observed with the predicted isotopic
distribution. The spectra were obtained by Dr. C. C. He in Dr. M. T. Rodgers’ lab.
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Figure 3.9. Wide range mass spectra of the ArgPt-Ado fractions. Both of the mass spectra
for ArgPt-AdoN1/N3 (red) and ArgPt-AdoN7 (blue) contain the monofunctional adduct species,
[Pt(Ado)(Arg)(Cl)+H]+. An adduct, [Pt(Ado)(Arg)(H2O)-H]+, is also formed through ligand
substitution of one of the chlorido ligands with H2O. The spectra were obtained by Dr. C. C. He in
Dr. M. T. Rodgers’ lab.

Figure 3.10. Mass spectrum of ArgPt-Adomix fraction. ArgPt-Adomix consists of a mixture of
bifunctional ([Pt(Ado)2(Arg)]2+) and doubly platinated ([Ado(Pt(Arg)Cl)2]2+) adducts. A fragment of
the bifunctional adduct ([Pt(Ado)2(Arg)-ribose]2+) is also observed, and formed due to the loss of
one ribose sugar. All of the adducts are multiply charged and observed in the 2+ states. The
spectrum was obtained by Dr. C. C. He in Dr. M. T. Rodgers’ lab.
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Figure 3.11. The 2D heteronuclear single quantum correlation (HSQC) of OrnPt-AdoN7 (top)
and OrnPt-AdoN1/N3 (bottom). In reference to the signal for Ado C2-H2 (top) [141], the major
signal for OrnPt-AdoN1/N3 exhibits platination at the N1 (or N3) position. On the other hand, in
reference to the Ado C8-H8 (bottom) [141], the major peak for OrnPt-AdoN7 exhibits platination at
the N7 position. The minor signals observed are for doubly platinated or bifunctional adducts that
elute with the major peaks during HPLC separation of the adducts (experiment performed by Dr.
Jun Jiang and Dr. Xun Bao).
NMR analysis was used to assign the platination sites of the adducts [138]. Twodimensional (2D) heteronuclear single quantum correlation (HSQC) spectroscopy was employed
to assign the peaks for the H8 and H2 protons of OrnPt-AdoN1/N3 and OrnPt-AdoN7 (Fig. 3.11). 1HNMR spectroscopy was then employed to determine the specific platination sites of the AlaPtAdo, OrnPt-Ado, and ArgPt-Ado adducts by comparison of the chemical shifts of the H2 and H8
protons of Ado (Figs. 3.12, 3.13, and 3.14). Compared to the chemical shifts of the H2 and H8
protons of Ado, the corresponding peaks for the species assigned as AlaPt-AdoN1/N3 are shifted
downfield by 0.4 and 0.1 ppm, respectively (Table 3.1). The greater change in chemical shift of
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H2 compared to H8 suggests platination at the N1 position in AlaPt-AdoN1/N3 because of its
proximity to H2 [144, 148]. However, platination at N3 of Ado cannot be ruled out because that
adduct would also cause a downfield shift of H2. 1H-NMR analysis of AlaPt-AdoN7 shows the
peaks assigned as H2 and H8 shifting downfield by 0.1 and 0.5 ppm, respectively (Table 3.1),
suggesting that platination occurs at the N7 position for this adduct.

Figure 3.12. Aromatic region of 1H-NMR spectra of AlaPt-Ado HPLC fractions. Ado (top),
AlaPt-AdoN1/N3 (middle) and AlaPt-AdoN7 (bottom); proton signals assigned as H8 and H2 are
noted with triangles and circles, respectively. The open circles and triangles are assigned as
protons likely from bisaquated AlaPt-Ado species. The extent of proton signal shift is dependent
on proximity of the platination site. The data were collected with assistance from Evan Jones in
the Lumigen Instrument Center.
Table 3.1. Downfield shifts of protons (in ppm) of AlaPt-Ado adducts relative to Ado protons
H2
H8
AlaPt-AdoN1/N3a

0.4

0.1

AlaPt-AdoN7b

0.1

0.5

a

monofunctional [Pt(Ado)(Ala)(Cl)] with N1/N3 platination

b

monofunctional [Pt(Ado)(Ala)(Cl)] with N7 platination
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Figure 3.13. Aromatic region of 1H-NMR spectra of OrnPt-Ado HPLC fractions. Ado (top),
OrnPt-AdoN1/N3 (middle) and OrnPt-AdoN7 (bottom); proton signals for H8 and H2 are noted with
triangles and circles, respectively. The open circles and triangles are assigned as protons from
doubly platinated and bifuctional species that have also been confirmed by mass spectrometry.
The extent of proton signal shift is dependent on proximity to the platination site (experiment
performed by Dr. Jun Jiang and Dr. Xun Bao).

Table 3.2. Downfield shifts of protons (in ppm) of OrnPt-Ado adducts relative to Ado protons
H2
H8
OrnPt-AdoN1/N3a

0.5

0.1

OrnPt-AdoN7b

0.1

0.5

a

monofunctional [Pt(Ado)(Orn)(Cl)] with N1/N3 platination

b

monofunctional [Pt(Ado)(Orn)(Cl)] with N7 platination

The analysis of platination sites on the monoaquated OrnPt adducts is similar to that of
the AlaPt adducts (Fig. 3.13). In the 1H-NMR spectrum of OrnPt-AdoN1/N3, the major peak
corresponding to H8 (closed triangle) shows a small chemical shift change (0.1 ppm), whereas
the other major peak corresponding to H2 (closed circle) exhibits a 0.5 ppm downfield shift (Table
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3.2), which suggests that the metal center is most likely coordinated to the N1 (or N3) position of
Ado [149]. For OrnPt-AdoN7, both peaks for H8 (triangles, open and closed for major products)
are shifted downfield by approximately 0.5 ppm, while the corresponding changes in the H2
chemical shifts are only 0.1 ppm (Fig. 3.13 and Table 3.2). The stronger downfield shift observed
for the two H8 signals suggests that platination occurs on the neighboring N7 for both products.
Therefore, the larger chemical shift change of the H2 peak is consistent with N1/N3 platination of
the HPLC fraction assigned as OrnPt-AdoN1/N3, whereas OrnPt-AdoN7 is assigned as having N7
platination due to the larger chemical shift change of the H8 peak.

Figure 3.14. Aromatic region of 1H-NMR spectra of ArgPt-Ado HPLC fractions. Ado (top),
ArgPt-AdoN1/N3 (middle) and ArgPt-AdoN7 (bottom); proton signals assigned as H8 and H2 are
noted with triangles and circles, respectively. The extent of proton signal shift is dependent on
proximity to the platination site.
Table 3.3. Downfield shifts of protons (in ppm) of ArgPt-Ado adducts relative to Ado protons
H2
H8
ArgPt-AdoN1/N3a

0.5

0.1

ArgPt-AdoN7b

0.2

0.6

a

monofunctional [Pt(Ado)(Arg)(Cl)] with N1/N3 platination

b

monofunctional [Pt(Ado)(Arg)(Cl)] with N7 platination
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The platination sites on the first two adducts of monoaquated ArgPt are also similar to that
of the AlaPt and OrnPt adducts (Fig. 3.14). Compared to the chemical shifts of H2 and H8 protons
of Ado, the corresponding peaks for the species assigned as ArgPt-AdoN1/N3 are shifted downfield
by 0.5 and 0.1 ppm, respectively (Table 3.3). The greater change in chemical shift of H2
compared to H8 suggests that platination occurs at the N1 or N3 position in ArgPt-AdoN1/N3
because of its proximity to H2. The 1H-NMR spectrum of ArgPt-AdoN7 shows that the peaks
assigned as H2 and H8 are shifted downfield by 0.2 and 0.6 ppm, respectively (Table 3.3). This
change in chemical shift suggests that for the ArgPt-AdoN7 product, platination occurs at the N7
position.

3.3.2 Characterization of AAPt-RNA adducts
The local environment of an oligonucleotide may affect the coordination of a platinumbased compound. Elucidation of nucleoside-level adducts provides information about
coordination sites, adduct types, and influence of ligands in binding kinetics. However, the
nucleotides surrounding the target nucleotide within the context of RNA or DNA oligonucleotides
may also modulate the coordination and lead to different platination profiles. The interaction of
AAPt compounds with non-canonical targets of cisPt was investigated using the oligonucleotide
sequence 5′-UUAUU-3′. This sequence was selected because cisPt and AAPt compounds have
low reactivity with Thd (dT) and Urd (U) residues [106, 138]. Therefore, the presence of only one
preferred residue (Ado (A)) directs the platination to a single site.
MALDI-MS and ESI-MS were used to determine the composition and type (e.g., mono-,
bifunctional, or doubly platinated) of non-canonical adducts formed by AAPt compounds with the
5′-UUAUU-3′ oligonucleotide. The purity of 5′-UUAUU-3′ was first determined by HPLC (C18) as
shown in Chapter 2 (Fig. 2.22), where the oligonucleotide was observed with only minor impurity
peaks. The oligonucleotide was also further characterized by using MALDI mass spectrometry
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(Chapter 2, Fig. 2.23). A peak was observed at m/z of 1571.7 Da/e, consistent with a calculated
mass of 1571.2 Da for 5′-UUAUU-3′.
Reactions of monoaquated AAPt compounds with 5′-UUAUU-3′ result in formation of
adducts with longer retention times on a C18 column relative to the unreacted oligonucleotide.
Several reactions were carried out followed by HPLC isolation of the fractions to obtain enough
of the products for mass analysis. The fractions obtained were characterized using MALDI-MS or
ESI-MS. For the AlaPt reaction, a product peak (AlaPt-UUAUU-1) with a longer retention time
than the unreacted 5′-UUAUU-3′ oligonucleotide was formed (Fig. 3.15). The HPLC isolated
fraction was analyzed by MALDI-MS. However, platinum associated peaks were not observed in
the spectrum, likely because of low sample concentration. The sample was reanalyzed an
Orbitrap-MS equipped with an ESI source. A triply charged species with the predicted platinum
isotopic distribution was observed at 594.073 Da/e (Fig. 3.16). This species is assigned as a
monofunctional adduct in which one of the uridines is fragmented (base loss) during ionization
(calculated exact mass is 1782.150 Da or 594.050 Da/e for the triply charged state). The
calculated exact mass of triply charged adduct with all the bases is 1892.161 Da. Since platinum
compounds have low reactivity with Urd residues, it is most likely that this adduct involves RNA
platination at the Ado residue (Fig. 3.17).

Figure 3.15. HPLC analysis (C18) of AlaPt-UUAUU platination products. The AlaPt-UUAUU
adduct profile following reaction with monoaquated OrnPt is shown. A product, AlaPt-UUAUU-1,
elutes with a retention time of 21.5 min. The unreacted 5′-UUAUU-3′ has a retention time of 20.5
min.
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Figure 3.16. ESI mass spectrum of isolated AlaPt-UUAUU-1 product. A triply charged
species, [(M-uracil)+Pt(Ala)Cl+3H]3+, with the predicted platinum isotopic distribution observed at
594.073 Da/e is assigned as a monofunctional adduct, with a loss of one uracil base. The
calculated exact mass of the fragmented adduct is 1782.150 Da (594.050 Da/e for triply charged
state), while the unfragmented adduct is 1892.161 Da.

Figure 3.17. Adducts formed by AAPt compounds with 5′-UUAUU-3′ RNA. (A) A
monofunctional adduct in which one AAPt molecule coordinates with the oligonucleotide at the
Ado residue is shown. (B) A doubly platinated adduct in which two AAPt molecules coordinate
with the oligonucleotide at the Ado residue is shown. Nitrogen atoms are color coded with red at
possible sites of coordination.
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The reaction of OrnPt with 5′-UUAUU-3′ results in formation of three distinct HPLC product
peaks (OrnPt-UUAUU-1, OrnPt-UUAUU-2, and OrnPt-UUAUU-3) that have longer retention times
(21.1, 23.0, and 24.0 min, respectively) than the unreacted 5′-UUAUU-3′ oligonucleotide (Fig.
3.18). HPLC fractions of the adducts were concentrated and mass analysis was carried out using
MALDI-MS. The OrnPt-UUAUU-1 fraction has an observed m/z of 1933.8 Da/e, which is assigned
as a monofunctional adduct (calculated exact mass is 1933.2 Da) (Fig. 3.19). An unplatinated 5′UUAUU-3′ is also observed in the mass spectrum and could be formed if fragmentation of the
adduct during ionization occurs. Unreacted 5′-UUAUU-3′ could also be present in the sample if
there is incomplete HPLC peak separation (especially near the baseline) and residual unreacted
5′-UUAUU-3′ is collected together with the OrnPt-UUAUU-1 fraction.

Figure 3.18. HPLC analysis (C18) of OrnPt-UUAUU platination products. The OrnPt-UUAUU
adduct profile following reaction of 5′-UUAUU-3′ with monoaquated OrnPt is shown. Three
products, OrnPt-UUAUU-1, OrnPt-UUAUU-2, and OrnPt-UUAUU-3, are formed with retention
times of 21.1, 23.0, and 24.0 min, respectively. The unreacted 5′-UUAUU-3′ is shown as the top
trace.
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Figure 3.19. MALDI mass spectrum of HPLC isolated OrnPt-UUAUU-1 product. Analysis of
HPLC isolated OrnPt-UUAUU-1 indicates an m/z of 1933.8 Da/e, consistent with a
monofunctional adduct (calculated exact mass is 1933.2 Da). The unplatinated oligonucleotide
(m/z 1572.4 Da/e) is also observed in the spectrum. Adducts of unplatinated oligonucleotide with
Na+ (m/z 1595.9 Da/e), Na++ NH3 (m/z 1610.3 Da/e), and Na++ K+(m/z 1633.7 Da/e) are observed
as well.
HPLC fractions for OrnPt-UUAUU-2 and OrnPt-UUAUU-3 peaks were combined during
mass analysis due to incomplete separation of the two fractions in some of the HPLC isolations.
MALDI-MS data show that the two fractions consist of multiple adducts including a monofunctional
adduct observed at m/z 1933.4 Da/e (calculated mass is 1933.2 Da) and a doubly platinated
adduct observed at m/z 2295.7 Da/e (calculated exact mass is 2295.2 Da) (Fig. 3.20). This result
reveals that either the fraction of OrnPt-UUAUU-2 or OrnPt-UUAUU-3 contains a monofunctional
adduct while the other contains the doubly platinated adduct. For the doubly platinated adduct
structure, it is likely that both OrnPt molecules coordinate to different sites (N1, N3, or N7) of the
Ado residue of the oligonucleotide (Fig. 3.17). Other minor peaks corresponding to a bisaquated
adduct species (m/z 1916.4 Da/e), loss of chlorido ligands (m/z 1898.9 and 2260.1 Da/e), and
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association with sodium ions (m/z 1956.6 and 1992.2 Da/e) are observed in the MALDI spectrum
as well.

Figure 3.20. MALDI mass spectrum of isolated OrnPt-UUAUU-2 and OrnPt-UUAUU-3 HPLC
fractions. Analysis of isolated OrnPt-UUAUU-2, and OrnPt-UUAUU-3 indicate presence of a
monofunctional adduct (m/z of 1933.4 Da/e) and doubly platinated adduct (m/z 2295.7 Da). Minor
peaks observed (m/z 1898.9, 1916.4, 1956.6, 1992.2, and 2260.1 Da/e) are assigned on
bisaquated OrnPt, loss of Cl-, and association with sodium ions.
The reaction of ArgPt with 5′-UUAUU-3′ was analyzed and three HPLC product peaks
(ArgPt-UUAUU-1, ArgPt-UUAUU-2, and ArgPt-UUAUU-3) were observed, which all have longer
retention times (22.5, 23.8, and 25.5 min, respectively) than the unreacted 5′-UUAUU-3′
oligonucleotide (Fig. 3.21). Fractions were collected and analyzed by MALDI-MS. However, no
peaks associated with ArgPt or RNA were observed, likely due to low sample concentration. The
MALDI-MS characterization was repeated on a ArgPt-UUAUU reaction mixture that was first
desalted through ethanol precipitation. Multiple platinum adducts were observed (Fig. 3.22).
These include a monofunctional adduct observed at m/z 1979.4 Da/e (calculated mass is 1979.5
Da), a doubly platinated adduct observed at m/z 2405.3 Da/e (calculated exact mass is 2405.5
Da), and an aquated doubly platinated adduct observed at m/z 2366.1 Da/e (calculated exact
mass is 2366.5 Da). A species observed at m/z 2511.4 Da/e is likely a complex of doubly

85
platinated adduct associated with CH3COOH (from desalting buffers) (calculated exact mass is
2510.7 Da).

Figure 3.21. HPLC analysis (C18) of ArgPt-UUAUU platination products. The ArgPt-UUAUU
adduct profile following reaction of 5′-UUAUU-3′ with monoaquated ArgPt is shown. Three
products, ArgPt-UUAUU-1, ArgPt-UUAUU-2, and ArgPt-UUAUU-3, are observed with retention
times of 22.5, 23.8, and 25.5 min, respectively. The control (unreacted 5′-UUAUU-3′) is shown as
the top trace.

Figure 3.22. MALDI mass spectrum of isolated ArgPt-UUAUU reaction mixtures.
Characterization indicates presence of a monofunctional adduct (m/z 1979.4 Da/e), doubly
platinated adduct (m/z 2405.3 Da/e), and doubly platinated adduct with bisaquated ArgPt (m/z
2366.1 Da/e). An adduct formed by addition of neutral molecules of CH3COOH is also observed
at 2511.4 Da/e.
In a separate experiment to investigate the formation of ArgPt adducts with RNA, a
reaction of poly(Ado) RNA with ArgPt followed by P1 digestion was carried out and analyzed using
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LC-MS as described in Section 2.4.11. ArgPt reacts with poly(Ado) RNA and forms three product
peaks that were resolved on the liquid chromatograph (LC) (Fig. 3.23). The three product peaks
(ArgPt-poly-1, ArgPt-poly-2, and ArgPt-poly-3) were subjected to mass analysis (Fig. 3.24). The
first product peak (ArgPt-poly-1) has an observed m/z 482 Da/e, which is assigned as a
bifunctional adduct. This adduct is doubly charged (2+) and consistent with ArgPt coordinated
with two adjacent residues (Ado-p-Ado) (calculated mass is 964 Da). The second product peak
(ArgPt-poly-2) has an observed m/z 672 Da/e, which is assigned as a singly charged (+)
monofunctional adduct. This adduct consists of one ArgPt coordinated to a single Ado residue
(calculated mass is 671 Da). The third product peak (ArgPt-poly-3) has an observed m/z 647
Da/e. This is another doubly charged (2+) bifunctional adduct, which is consistent with three Ado
residues (Ado-p-Ado-p-Ado) coordinated with one ArgPt molecule (calculated exact mass is 1294
Da). The third Ado residue that is part of this adduct may be present because of incomplete
digestion by P1 nuclease.

Figure 3.23. LC spectrum of ArgPt-poly(Ado) reaction products. Three peaks referred to as
ArgPt-poly-1, ArgPt-poly-2, and ArgPt-poly-3 are formed following a reaction of ArgPt with
poly(Ado) RNA.
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Figure 3.24. LC-MS spectra of ArgPt-poly(Ado) reaction products. Mass spectra (positive
mode) of the LC product peaks of ArgPt-poly-1, ArgPt-poly-2, and ArgPt-poly-3 are shown. ArgPtpoly-1 contains a species assigned as a doubly charged bifunctional adduct (m/z 482 Da/e).
ArgPt-poly-2 contains a species assigned as the singly charged monofunctional adduct (m/z 672
Da/e), and ArgPt-poly-3 is assigned as a doubly charged bifuntional adduct with an additional Ado
residue (m/z 647 Da/e). Representative structures of the adducts are given (p indicates the

phosphate ester bond).
3.3.2 Structural isomers of AAPt adducts
In addition to the NMR data, the kinetic trans effect and previously reported theoretical
calculations were used to propose the structures of the adducts [150]. The adducts likely have
several structural orientations that allow maximum stability. We propose that AlaPt-Ado, OrnPtAdo, and ArgPt-Ado adducts have the trans orientation in which the α-NH2 is trans to the Ado
platination site (N1, N3, or N7) (Fig. 3.25). In the trans geometry, the AAPt compounds coordinate
to the nucleoside such that the α-amino group and the platinated nitrogen on the nucleoside are
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trans to each other. These structures can be used to explain the nucleoside preferences of the
platinum-based compounds. The selectivity of cisPt for dGuo has been attributed predominantly
to a strong hydrogen bond between the cisPt ammine ligand and the 6-oxo group of dGuo [27].
In contrast, the selectivity of AlaPt, OrnPt, and ArgPt for Ado/dAdo can be explained by a
hydrogen-bonding interaction unique to the AAPt compounds. The trans adduct structures (e.g.,
trans-Ado-N1 or trans-Ado-N7 in Fig. 3.26) would position the 6-amine of Ado/dAdo to form a
hydrogen bond with the carboxylate ligand of the AAPt compound. Such interactions would
stabilize the Ado/dAdo adduct, but are not available for Guo/dGuo, and possibly lead to higher
reactivities of Ado/dAdo with the three AAPt compounds studied here. Formation of N3 platination
products are less likely due to lack of a stabilizing hydrogen bond with the position 6 functional
group of the purine (Fig. 3.26).

Figure 3.25. Representative geometric and constitutional isomers of AAPt-Ado adducts.
Platination occurs at the N1 or N7 positions (N3 platination is also possible). The platinating
moiety may have different orientations to position the ligands for favorable interactions with the
nucleoside such as hydrogen bonding or to avoid steric clash.
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Figure 3.26. Possible adduct structures formed by AAPt with purines. AAPt compounds
could coordinate at different sites of purine nucleosides forming various isomers and orientations
of the platinum moieties.
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3.4 Conclusions
Platination by cisPt occurs predominantly at the N7 position of dGuo residues and results
in formation of bifunctional and monofunctional adducts. In contrast, the AAPt compounds (AlaPt,
OrnPt, and ArgPt) were observed to form non-canonical adducts by coordinating to multiple sites
on Ado/dAdo residues, specifically the N1/N3 and N7 positions of the nucleobases. Various
techniques were employed to identify and characterize these adducts. HPLC was used to identify
the products formed following the reaction of AAPt compounds with nucleosides or
oligonucleotides. The products have different retention times on a C18 column compared to free
nucleoside/oligonucleosides and could be isolated for further analysis. ESI-MS characterization
was used to identify the composition (i.e., Ado vs. Guo) and types of adducts formed. Each of the
AAPt compounds reacts with Ado residues and predominantly forms isomeric monofunctional
adducts with the same m/z and platinum isotopic distribution pattern. Additionally, bifunctional
and doubly platinated adducts are observed. MALDI-MS and ESI-MS were used to identify the
types of adducts formed when AAPt compounds platinate short oligonucleotides with single Ado
residues. Monofunctional and doubly platinated adducts are formed by AAPt compounds with
these oligonucleotides. NMR spectroscopy was employed in differentiating the isomeric adducts
formed by AAPt with Ado nucleosides. These isomers vary at their platination sites and could be
identified based on the chemical shifts of neighboring protons.
The three compounds coordinate at N1/N3 and N7 positions of Ado residues and the
resultant adducts adopt several structural orientations. Although methods such as mass
spectrometry and 1D-NMR spectroscopy were used for identifying the types of adducts formed,
they give limited information on the structural orientations of the adducts. These orientations can
be modulated by factors such as steric hindrance and hydrogen-bonding properties.
Differentiating between N1 and N3 platination was also challenging because these sites have
similar proximity to H2 proton. However, future studies could employ X-ray crystallography to
differentiate between N1 and N3 platination by AAPt compounds.
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CHAPTER 4
REACTION KINETICS OF AMINO ACID-LINKED PLATINUM(II) COMPOUNDS WITH
DNA/RNA NUCLEOSIDESǂ AND OLIGONUCLEOTIDES
ǂ

Nucleoside level kinetic studies are adapted from Kimutai B, He CC, Roberts A, Jones ML, Bao

X, Jiang J, Yang Z, Rodgers MT, Chow CS (2019) J Biol Inorg Chem 24:985-997.
Abstract
The diversity of the side chain functional groups together with the contribution of backbone
atoms of amino acid-linked platinum(II) (AAPt) compounds can modulate their reactivities and
targets. In this thesis work, the reaction kinetics of alanine-, ornithine-, and arginine-linked
platinum(II) compounds (AlaPt, OrnPt, and ArgPt, respectively) were determined. Their reactivity
preferences for DNA/RNA nucleosides and oligonucleotides were examined using pseudo-firstorder kinetics and HPLC analysis. The rate constants reflect the role of chemical structures and
physical properties of the amino acid functional groups in target residue preferences. The
oligonucleotide local environment also has an effect on the reactivity of the AAPt compounds.
4.2 Introduction
Platination kinetics have been shown to correlate with cellular activity of cisPt and secondgeneration analogues [33-36]. For example, cis-diammine-1,1-cyclobutane dicarboxylate
platinum(II) (carboplatin) is less potent and toxic than cisPt, which is partly attributed to its 100fold slower adduct formation with DNA [34]. As noted in Section 1.2.3, the coordination of
platinum-based compounds with DNA involves a number of steps that contribute to the overall
reaction rates. Before cisPt reacts with DNA in a cellular setting, it is first aquated to generate cis[PtCl(NH3)2(H2O)]+, whereby a chlorido is replaced with H2O [32, 151]. Reactions of the aquated
cisPt species with DNA then occur under kinetic control, leading to stable adduct formation at the
preferred dGuo sites [32, 40]. Therefore, kinetic studies can be used to compare the reactivities
of aquated cisPt and AAPt compounds (Fig. 4.1). For in vitro studies, cisPt or AAPt analogues
are reacted with AgNO3 in order to generate the monoaquated species prior to reactions with
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nucleosides or nucleic acids (Scheme 4.1) [32]. A number of AAPt-nucleoside adducts form by
coordination at the N7 of dGuo/Guo or N1, N3, or N7 positions of dAdo/Ado. By comparing the
kinetic rate constants (k values) for disappearance of the nucleoside/oligonucleotide over time,
the target preferences of aquated cisPt and AAPt (i.e., AlaPt, OrnPt, or ArgPt, Fig. 4.1) can be
determined [152-153, 58].

Figure 4.1. The structures of cisPt (cisPt) and amino acid-linked platinum(II) compounds,
AlaPt, OrnPt, and ArgPt.

Scheme 4.1. Aquation of platinum compounds and subsequent platination of
nucleosides/oligonucleotides. Possible coordination sites are highlighted in blue (N7) and red (N1
and N3).
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The overall process of cisPt adduct formation such as aquation and DNA platination [34,
36] is influenced by a number of factors associated with the non-leaving group ligand (typically an
amine), including coordination type and hydrogen-bonding properties [35-36]. These factors play
roles in target preferences and the types of adducts that are formed. CisPt reacts with dGuo of
single- and double-stranded DNA leading to formation of kinetically inert adducts [35, 27, 44]. The
adduct forms when the aqua ligand is substituted by a nucleobase atom via a trigonal-bipyramidal
transition state [45] (Scheme. 4.2). Hydrogen bonding is implicated in the kinetic control of
platination [36, 46] and can stabilize the transition state of the aquated cisPt-dGuo reaction [27].
More specifically, computational analysis showed that in the transition state, cisPt forms a strong
hydrogen bond between its ammine ligand and the oxo at the 6 position of dGuo [27]. As such,
this hydrogen-bonding interaction together with charge-charge interactions results in preferential
coordination of cisPt to dGuo [27]. In contrast, formation of the cisPt-Ado adduct is less favored
because Ado has an amine at the 6 position, which cannot hydrogen bond with cisPt [27].

Scheme 4.2. Associative substitution mechanism of cisPt coordination with dGuo.
Hydrogen bonding between ammine and oxo groups stabilizes the trigonal bipyramidal transition
state.

In this thesis work, the reaction kinetics of three AAPt compounds were examined to
determine how the chemical structures and physical properties of the functional groups of the
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amino acid relate to reactivity and nucleoside preference. Pseudo-first-order kinetics were used
to compare the reactivity of the three AAPt compounds with purine nucleosides. The hypothesis
is that modification of cisPt with amino acid ligands of varying sizes and charges would alter the
reaction kinetics and nucleic acid target preferences. Influence of the oligonucleotide local
environment was also investigated since the nucleotides surrounding the target nucleotide may
modulate the binding kinetics of cisPt and AAPt and lead to different platination rates and profiles.
The impact of this local environment was determined by comparing the reactivities and
preferences of AAPt compounds with oligonucleotides and nucleosides. The oligonucleotide
sequences chosen were 5′-UUAUU-3′ for RNA and 5′-d(TTATT)-3′ for DNA. These sequences
were selected because cisPt and AAPt compounds have low reactivity with Thd (dT) or Urd (U)
residues [106, 138]. Therefore, the presence of only one preferred residue (Ado (A) or dAdo (dA))
directs the platination to a single site. By excluding competing reactivity with the flanking residues,
the influence of the oligonucleotide local environment on platination at the preferred residue can
be analyzed. Understanding reactivity and selectivity of platinum-based compounds at both the
nucleoside and oligonucleotide level is needed to drive the development of new compounds that
target alternative biological residues or molecules such as RNA [55, 29, 154]. This approach could
potentially be important in achieving improved cellular activities and effectiveness.

4.3 Results and discussion
4.3.1 Kinetics of platination reactions with DNA/RNA purine nucleosides
The reactions of (deoxy)nucleosides with the monoaquated AAPt compounds result in the
formation of one or more adducts with longer (AlaPt and ArgPt adducts) or shorter (OrnPt adducts)
retention times on a C18 column relative to the unreacted (deoxy)nucleosides (Fig. 3.3, Section
3.3.1). The adduct characterization was described in previous chapter (Section 3.3.1). In
summary, monoaquated AlaPt, OrnPt, and ArgPt each reacts with Guo to form one major product
(distinct HPLC peak), referred to as AlaPt-GuoN7, OrnPt-GuoN7, and ArgPt-GuoN7, respectively. In
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contrast, platination of Ado leads to formation of multiple adducts. Monoaquated AlaPt reacts with
Ado to form two main products, AlaPt-AdoN1/N3 and AlaPt-AdoN7. Monoaquated OrnPt also reacts
with Ado to form two major products, OrnPt-AdoN1/N3 and OrnPt-AdoN7. Monoaquated ArgPt reacts
with Ado to form three major products, ArgPt-AdoN1/N3, ArgPt-AdoN7, and ArgPt-Adomix, which have
longer retention times than Ado. The subscripts refer to coordination sites at the adducts. The
rate of formation of products varies depending on the identity of the AAPt compound and the
target nucleoside. By monitoring the rates of formation of products, the rate constants (k values)
and reactivity preference of each platinum compound can be determined.
Kinetic rate constants (k values) were used to reveal the preferred target nucleoside of
each AAPt compound relative to cisPt. Under pseudo-first-order reaction conditions for the
monoaquated AAPt (or cisPt) and purine nucleosides, the peak areas of the unreacted
nucleosides were monitored by HPLC and observed to decrease with time (Fig. 4.2). The rate of
decrease of the peak area corresponding to the unreacted nucleoside (Ado, Guo, dAdo, or dGuo)
varies, depending on the identity of the platinum compound (monoaquated AlaPt, OrnPt, or
ArgPt). As described in Section 2.4.7, the peak area of the nucleoside at each time point can be
integrated quantitatively, plotted, and fitted to an exponential decay equation (Eq. 4.1) to extract
the pseudo-first-order rate constant (k).
[Nuo]t = e-kt + [Nuo]0 (Eq. 4.1)
From Eq. 4.1, [Nuo]t is the concentration of unreacted nucleoside or oligonucleotide at time t, and
[Nuo]0 is the initial concentration of unreacted nucleoside or oligonucleotide. When [Nuo] t is
plotted against t, the decay factor is k. The k values for each AAPt analogue with DNA/RNA
nucleosides were obtained (summarized in Table 4.1 and shown graphically in Fig. 4.3).
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Figure 4.2. Reaction rates of monoaquated AlaPt, OrnPt, and ArgPt with purine
nucleosides. Representative kinetic traces of reactions of monoaquated AlaPt, OrnPt, or ArgPt
with the purine nucleosides showing the fraction of the unreacted nucleoside diminishing over
time. Measurements were done in triplicate.
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Table 4.1. Pseudo-first-order rate constants, k (μs-1)a

cisPt

dGuo

Guo

dAdo

Ado

49±1

25±2

6±1

6±2

19±7

9±4

176±9

9±4

b

20±1

24±1

125±1

100±1

b

23±2

25±1

115±15

108±1

b

AlaPt

b

OrnPt
ArgPt
a
b

triplicate runs in 25 mM Na2HPO4/NaH2PO4 buffer (pH 7) at 37 °C;
monoaquated compounds

Figure 4.3. Comparisons of rate constants (k) for reaction of monoaquated cisPt (grey) and AAPt
compounds (monoaquated AlaPt, green; monoaquated OrnPt, orange; monoaquated ArgPt,
violet) with DNA/RNA purine nucleosides (dGuo, Guo, dAdo, and Ado) are shown.

CisPt is known to preferentially target dGuo over other residues of DNA [38, 33, 101, 41].
This selectivity was confirmed here with the nucleoside-level kinetic studies, in which the highest
reaction rate constant (k) of aquated cisPt is with dGuo (49 × 10-6 s-1) (Table 4.1). The reactivity
of monoaquated cisPt with Guo, dAdo, and Ado is lower than dGuo by two- to eight-fold. The
AAPt compounds display a wide range of reactivities as shown in Fig. 4.3. The highest reactivity
of monoaquated AlaPt is with dAdo (176 × 10-6 s-1), which is nine to twenty-fold higher than that
of reactions with Guo and dGuo, and demonstrates that monoaquated AlaPt prefers dAdo. The
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reactivity of monoaquated AlaPt is strongly influenced by both the identity of the purine base as
well the functional group at the 2′ position (e.g., H or OH), with a preference for dAdo over Ado.
The highest reaction rates for OrnPt are with dAdo and Ado (125 × 10-6 s-1 and 100 × 10-6 s-1,
respectively). These rates of reactions for monoaquated OrnPt with Ado/dAdo are four- to six-fold
higher than reactions with Guo/dGuo (Table 4.1 and Fig. 4.3), demonstrating its preference for
the adenine moiety. The highest reactivity of monoaquated ArgPt is with dAdo and Ado (115 ×
10-6 s-1 and 108 × 10-6 s-1), which is four- to five-fold higher than its reactivity with Guo/dGuo, and
demonstrates that monoaquated ArgPt also has a preference for the adenine moiety (Table 4.1
and Fig. 4.3).

4.3.2 Kinetics of platination reactions with DNA/RNA oligonucleotides
CisPt reacts with DNA and RNA constructs by preferentially targeting the Guo/dGuo
residues. The reactivity of cisPt is modulated by the local conditions such as salt concentrations
and pH [155-156, 49]. Previous literature reports and work from our lab focused on the reaction
kinetics of cisPt with various DNA and RNA constructs. Representative k values are shown in
Table 4.2. These values vary depending on the type of DNA/RNA construct and the conditions
(i.e., salt concentration, buffer type, etc.) of the experiments. Kinetic experiments with cisPt often
employ sequences with dGuo/Guo residues due to its preference for such residues. In this thesis
work, the reaction of cisPt (and AAPt compounds) with DNA/RNA constructs that do not have
dGuo/Guo residues, but instead have dAdo/Ado as the target sites were investigated.
The monoaquated cisPt or AAPt compounds react with DNA and RNA oligonucleotides
(5′-d(TTATT)-3′ and 5′-UUAUU-3′, respectively), resulting in formation of multiple product peaks
with longer retention times on a C18 column relative to the unreacted oligonucleotides (Fig. 4.4).
Multiple peaks result from formation of different types of adducts (e.g., monofunctional and doubly
platinated). Monoaquated cisPt reacts with the RNA oligonucleotide to form one major product,
which has longer retention times than the free RNA on C18 (Fig. 4.4A) Monoaquated AlaPt reacts
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with the RNA oligonucleotide to form two major products, that have longer retention times than
the free RNA on C18 (Fig. 4.4B). These AlaPt-UUAUU products likely have decreased polarity
due to the associated alanine ligand, leading to longer retention times compared to those of
unreacted oligonucleotide. Monoaquated OrnPt reacts with 5′-UUAUU-3′ to form three products,
which also have longer retention times on a C18 column relative to the unreacted oligonucleotides
(Fig. 4.4C). Similarly, monoaquated ArgPt reacts with the RNA oligo to form three products that
also have longer retention times on a C18 column relative to the free oligonucleotides (Fig. 4.4D).
Factors that could increase the retention time of platinated oligonucleotides relative to the free
oligonucleotides include neutralization of the oligonucleotide local charge by platinum
compounds, structural changes, and increased size of the oligonucleotide after platination.

Table 4.2. Rate constants of cisPt reactions with various DNA/RNA constructs

RNA

DNA

RNA
DNA

RNA
RNA
RNA

sequence
5′-CGCGUUGUUCGCG-3′
5′- (T)10-GG-(T)10-3′
5′- (U)10-GG-(U)10-3′
5′- (T)10-GG-(T)10-3′
5′- (U)10-GG-(U)10-3′
5′-GGCCGΨAACΨAΨAACGGUC-3′
5′-GCAGGAUUAGAUACCCUGC-3′

k values
(x10-4 s-1) [ref]
4.4 ± 0.4 [49]

conditions
35 mM Na+, pH 6.0, 37 °C

7.4 ± 0.8 [156]

10 mM K+, 5 mM Na+,
pH 6.2, 37 °C

3.3 ± 0.7 [156]

10 mM K+, 5 mM Na+,
pH 6.2, 37 °C

24 ± 5 [156]

10 mM K+, 20 mM Na+,
pH 6.2, 37 °C

33 ± 10 [156]

10 mM K+, 20 mM Na+,
pH 6.2, 37 °C

13.3 ± 0.9 [155]

10 mM K+, 20 mM Na+,
pH 6.2, 37 °C

16.2 ± 1.1 [155]

10 mM K+, 20 mM Na+,
pH 6.2, 37 °C
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Figure 4.4. HPLC analysis (C18) of platinated RNA products. The adduct profiles following
reactions of 5′-UUAUU-3′ with monoaquated cisPt (A), AlaPt (B), OrnPt (C), and ArgPt (D) are
given. Multilple product peaks (indicated in the figure) are formed during the reactions. The
reaction times are indicated and the controls (unreacted oligonucleotides with buffer, black
asterisks) are shown as the top traces.

101

Figure 4.5. HPLC analysis (C18) of platinated DNA products. The adduct profiles following
reactions of 5′-d(TTATT)-3′ with monoaquated cisPt (A), AlaPt (B), OrnPt (C), and ArgPt (D) are
given. Multilple product peaks (indicated in the figure) are formed during the reactions. The
reaction times are indicated and the controls (unreacted oligonucleotides with buffer, black
asterisks) are shown as the top traces. Some minor peaks with short retention time were also
formed in OrnPt and ArgPt reactions.
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Figure 4.6. Reaction rates of AlaPt, OrnPt, and ArgPt with RNA and DNA oligonucleotides.
Kinetic traces of reactions of monoaquated cisPt, AlaPt, OrnPt, or ArgPt with RNA and DNA
oligonucleotides showing the fraction of unreacted oligonucleotide diminishing over time. 5′UUAUU-3′ is represented by a solid line and 5′-d(TTATT)-3′ is represented by a dashed line.
Similarly, AAPt compounds (and cisPt) react and form products with DNA oligos (Fig. 4.5).
The number of products and their retention time in relation to free oligonucleotides are similar to
reactions with RNA oligonucleotides. AlaPt reacts with 5′-d(TTATT)-3′ to form one main product,
which has a longer retention time than the free DNA oligo (Fig. 4.5B). Monoaquated OrnPt reacts
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with 5′-d(TTATT)-3′ to form three major products, which have longer retention times than the free
DNA oligo on the C18 column (Fig. 4.5C). Monoaquated ArgPt also reacts with 5′-d(TTATT)-3′ to
form three major products that have longer retention times than the unreacted DNA oligo (Fig.
4.5D).
The k values were used to compare the reactivities of cisPt and each AAPt compound
with the oligonucleotides. Similar to the nucleoside level analysis, the peak areas of the
oligonucleotides at each time point can be integrated quantitatively, plotted, and fitted to an
exponential decay equation (Eq. 4.1) to extract the pseudo-first-order rate constants (k values).
The HPLC peak areas of the unreacted oligonucleotides (5′-UUAUU-3′ or 5′-d(TTATT)-3′) were
monitored and observed to decrease at different rates depending on the identity of the platinum
compound (monoaquated cisPt, AlaPt, OrnPt, or ArgPt) (Fig. 4.6). The k values for each AAPt
analogue with the oligonucleotides are summarized in Table 4.3 and shown graphically in Fig.
4.7.

Table 4.3. Pseudo-first-order rate constants, k (x10-4 s-1)a

cisPt

5′-d(TTATT)-3′

5′-UUAUU-3′

3.2 ± 0.1

5.0 ± 0.1

7.9 ± 0.1

7.5 ± 1.2

8.0 ± 0.5

17.7 ± 2.1

b

AlaPt

b

OrnPt
ArgPt

b

b

8.7 ± 0.2
7.4 ± 0.8
triplicate runs in 25 mM Na2HPO4/NaH2PO4 buffer (pH 7) at 37 °C;
b
monoaquated compounds

a
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Figure 4.7. Comparison of reactivity of platinum-based compounds with oligonucleotides.
The rate constants (k) for reaction of monoaquated cisPt, AlaPt, OrnPt, and ArgPt with DNA
oligonucleotides and RNA oligonucleotides are shown.
A comparison of the k values for cisPt with the chosen RNA (5.0 × 10-4 s-1) and DNA (3.2
× 10-4 s-1) oligonucleotides indicates that cisPt is moderately selective in its reactivity with the two
nucleic

acids

(less

than

two-fold

difference)

under

low

salt

conditions

(25

mM

Na2HPO4/NaH2PO4). The k values for reaction kinetics of cisPt with the chosen sequences are in
the same range as other reported literature values and previous work in our lab, with variation
that is consistent with the preferred targets of cisPt and salt conditions (Tables 4.2 and 4.3) [155156, 49]. Based on the k values, cisPt reactivity with 5′-UUAUU-3′ or 5′-d(TTATT)-3′ is relatively
lower compared to its reactivity with constructs that have Guo/dGuo residues. This is not
surprising due to the preference of cisPt for Guo residues [33, 38, 101, 41]. Compared to the three
AAPt compounds, cisPt has the lowest k values when reacting with 5′-UUAUU-3′ and 5′d(TTATT)-3′ because of the lack of its preferred Guo/dGuo target in the sequences (Table 4.3).
The range of k values for the reactions of AAPt compounds with oligos are as shown in
Fig. 4.7. The AAPt compounds are generally more reactive than cisPt with the chosen DNA/RNA
constructs, with k values that are two- to six-fold higher than those of cisPt. This difference was

105
also observed when the compounds react with nucleosides (Section 4.3.1). Monoaquated AlaPt
has similar reactivity with both DNA and RNA oligonucleotides (7.9 × 10-4 s-1 and 7.5 × 10-4 s-1,
respectively) (Table 4.3 and Fig. 4.7). Monoaquated OrnPt exhibits a two-fold preference for RNA
over DNA with k values of 17.7 × 10-4 s-1 and 8.0 × 10-4 s-1, respectively (Table 4.3 and Fig. 4.7)
demonstrating its preference for the ribose moiety. The functional group at the 2′ position (e.g., H
or OH) of the nucleic acid appears to influence the OrnPt reactivity. The k values of monoaquated
ArgPt with DNA and RNA oligonucleotides are similar (8.7 × 10-4 s-1 and 7.4 × 10-4 s-1,
respectively).
There is generally higher reactivity between AAPt compounds with RNA/DNA
oligonucleotides than with free nucleosides, as exhibited by the increased k values in the
oligonucleotide level reactions (Tables 4.1 and 4.3). The oligonucleotide local environment
enhances reactivity of the AAPt compounds, likely due to factors such as negatively charged
phosphate groups that attract the positively charged side chains of OrnPt and ArgPt. The
backbone phosphate group of the oligonucleotides could also provide hydrogen-bond acceptors
that stabilize interactions with the AAPt compounds. AlaPt exhibits discrimination between Ado
and dAdo at the nucleoside level (Table 4.1) likely because its reactivity is more strongly
influenced by the functional group at the 2′ position (e.g., H or OH). This influence is minimized
at the oligonucleotide level where the phosphate backbone may have a larger influence on
reactivity. Similar reactivity is observed for AlaPt with 5′-UUAUU-3′ and 5′-d(TTATT)-3′
oligonucleotides. In contrast, OrnPt does not discriminate between Ado and dAdo nucleosides,
but has a two-fold higher reactivity with 5′-UUAUU-3′ than with 5′-d(TTATT)-3′. This result implies
that the presence of a backbone phosphate group, along with other factors (e.g., the functional
group at the 2′ position), plays a role in either diminishing or amplifying the selectivity of AAPt
compounds, depending on their side chain identity.
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4.4 Conclusions
CisPt preferentially coordinates with dGuo residues, which is correlated with its anticancer
activity [33, 38, 101]. Finding platinum-based compounds that preferentially platinate alternative
targets has been an attractive goal, but has yielded little success to date. In this thesis work,
platinum-based compounds AlaPt, OrnPt, and ArgPt have been shown to exhibit kinetic
preferences for Ado/dAdo residues. These monoaquated AAPt compounds exhibit altered
reactivity and different nucleoside preferences compared to monoaquated cisPt. OrnPt exhibits a
greater than five-fold increase in reactivity with Ado/dAdo nucleosides over Guo/dGuo, and AlaPt
has over nine-fold higher selectivity for dAdo over all other purines. The AAPt compounds exhibit
unique differences in their reactivity by having altered preferences with non-canonical targets of
cisPt. These differences suggest that the mode of amino acid coordination (e.g., N vs. O) plays a
role in modulating the rate of reactivity. While cisPt only has only (N,N) type of binding, the amino
acid complexes can have (N,O) or (N,N) coordination.
The AAPt compounds have generally an increased reactivity with oligonucleotides
compared to nucleosides. The local environment flanking the target residues in a DNA or RNA
oligonucleotide, such as phosphate groups with associated cations, likely enhances the binding
kinetics of cisPt and AAPt. The negatively charged phosphate groups can interact favorably with
positively charged AAPt compounds or provide hydrogen bond acceptors that stabilize the
interactions of AAPt compounds with their targets. OrnPt has a two-fold higher preference for
RNA oligonucleotides over DNA, demonstrating that certain features of platinum-based
compounds could modulate selective targeting of one nucleic acid over another. This preference
could also be important in the development of compounds that target either DNA or RNA with
high selectivity.
HPLC fitted with a C18 column has been used previously to monitor kinetic reactions of
platinum-based compounds with their targets and to extract rate constants [138, 157]. In this
thesis chapter, HPLC fitted with a C18 column was also used for kinetic studies of AAPt with their
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nucleic acid targets. The rate constants were extracted after plotting the ratio of diminishing
reactants as a function of time. Although the formation of individual AAPt-nucleoside or AAPtoligonucleotide products could also be monitored, the identification of their rate of formation was
challenging since one adduct could be converted to another type of adduct during the course of
reaction (e.g. a monofunctional adduct converting into a bifunctional adduct). In the future, this
method could be modified to include an internal standard so as to ascertain and correct for
variability between injections. There are other alternative methods such as NMR spectroscopy
and mass spectrometry that could also be used to monitor kinetic reactions and extract rate
constants [32, 34, 149, 158]. These methods could be used to confirm the reaction kinetics and
selectivity of AAPt compounds with their targets.
The AAPt compounds studied here have altered selectivity compared to cisPt and are
therefore candidates for an alternative pathway of cytotoxicity that could involve non-canonical
targets such as dAdo residues of DNA as well as Ado residues of RNA. Since platination of
biomolecules such as proteins are often overlooked [30, 61-62], AAPt compounds may also have
reactivity that extends beyond the current scope of targets.
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CHAPTER 5
IMPACT OF AMINO ACID-LINKED PLATINUM(II) COMPOUNDS ON GLYCOSIDIC BOND
STABILITY OF ADDUCTSǂ
ǂ

Adapted from Kimutai B, He CC, Roberts A, Jones ML, Bao X, Jiang J, Yang Z, Rodgers MT,

Chow CS (2019) J Biol Inorg Chem 24:985-997

5.1 Abstract
Destabilization of glycosidic bonds accelerate depurination and formation of abasic sites
in nucleic acids, which could ultimately contribute to cell cytotoxicity. Unstable glycosidic bonds
can be caused by a change in chemical composition of the nucleoside due to modifications.
Platination of deoxyguanosine (dGuo) residues by cisplatin (cisPt) has been reported to have no
destabilizing effect on the adduct glycosidic bonds. However, changes in stabilization may occur
in non-canonical target residues that are modified by other platinum-based analogues. Amino
acid-linked platinum(II) (AAPt) compounds of alanine, ornithine, and arginine (AlaPt, OrnPt, and
ArgPt, respectively) have unique reactivities that result in altered preferences for adenosine (Ado)
or deoxyadenosine (dAdo) residues. The compounds predominantly form monofunctional
adducts by reacting at the N1, N3, or N7 positions of purine nucleobases. Features of the AAPt
compounds that impact glycosidic bond stability of Ado residues were explored in this chapter.
The glycosidic bond cleavage of the adducts was investigated using energy-resolved collisioninduced dissociation (ER-CID) tandem mass spectrometry and survival yield analysis (in
collaboration with Dr. M.T. Rodgers’ lab). Our results indicate that glycosidic bond cleavage is
activated differentially for AlaPt-Ado and OrnPt-Ado isomers. Formation of unique adducts at noncanonical residues and subsequent destabilization of the glycosidic bonds are important features
that could circumvent cisPt-based drug resistance.
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5.2 Introduction
Modification of nucleic acid residues may have unique influences on the chemical
properties of nucleosides such as bond strengths. Alkylation or protonation of DNA residues have
previously been reported to weaken the glycosidic bonds and accelerate the process of
depurination [115-118]. Hydrolytic instability of purine glycosidic bonds may impact nucleoside
integrity, particularly under varying pH and ionic strength conditions and modification states [116,
119-121]. Stability of the glycosidic bonds is important for maintaining the integrity of nucleic acids
and crucial for cell viability [159-160]. Previous experiments with N-glycosydases showed that
hydrolytic cleavage of particular Ado glycosidic bonds in rRNA is toxic, as it causes inactivation
of the ribosome [159].
In a previous theoretical study, evaluation of the effects of cisPt modification indicated that
platination at N7 does not impact stability of the dGuo glycosidic bond [26]. However, platination
of nucleic acids by other cisPt analogues may have an impact on glycosidic bond strengths. To
the best of our knowledge, the influence of platination on the glycosidic bonds of dAdo or Ado
adducts has not been investigated, likely because cisPt and other platinum-based compounds
coordinate preferentially with dGuo (or Guo) residues. AAPt compounds, including AlaPt, OrnPt,
and ArgPt, have reactivity preferences for Ado and dAdo residues (discussed in Chapters 3 and
4). A previous report from our lab also showed that OrnPt has the ability to modify Ado residues
in folded RNA [106]. We therefore sought to evaluate the relative glycosidic bond strengths of
these non-canonical structures.
Structural and chemical features of platinum-based compounds could determine the
extent of glycosidic bond stability once coordination with a nucleotide occurs. For AAPt
compounds, the type of side chain and the backbone atoms may affect stability of the adduct.
Glycosidic bond strength may also be affected differentially depending on the position of the
nucleobase at which the AAPt compounds platinate. The reactions of monoaquated AAPt
compounds with Ado result in formation of multiple monofunctional adduct isomers. These
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constitutional isomers vary at the sites at which platination occurs, including N1, N3, or N7
positions (Fig. 5.1). Understanding the features that promote glycosidic bond destabilization in
nucleic acids is important for development of analogues that trigger unique cytotoxic responses
not exhibited by cisPt [55, 29, 154]. Possible destabilization that activates cleavage of the
glycosidic bonds in AAPt-Ado adducts could also be exploited as a therapeutic pathway against
cisPt resistant cancer cells. This is also potentially useful in understanding features of platinumbased drug candidates that have improved cellular activities and effectiveness in cancer cells.

Figure 5.1 Structure of monofunctional AAPt-Ado adduct. The AAPt compounds (AlaPt,
OrnPt, or ArgPt) can coordinate at the N1, N3, or N7 position of nucleobase forming constitutional
isomers. The glycosidic bond of the adduct is shown.
In this collaborative project, I first carried out the synthesis of AAPt compounds followed
by reactions with Ado nucleosides as described in Chapter 2. Using HPLC fitted with a C18
column, I isolated products from each individual reaction so as to obtain enough samples for NMR
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spectroscopy characterization and subsequent tandem mass spectrometry analysis. Energyresolved collision-induced dissociation (ER-CID) tandem mass spectrometry and survival yield
analysis was carried out by Dr. C. C. He in Dr. M. T. Rodgers’ lab.
ER-CID tandem mass spectrometry and survival yield analysis have been used previously
to investigate glycosidic bond stabilities [116, 122-125]. In this thesis work, the techniques were
also applied to investigate the impact of AAPt coordination on relative glycosidic bond strengths.
In ER-CID tandem mass spectrometry, isolated HPLC fractions containing the nucleosideplatinum adducts are first ionized in the ESI source. The nucleoside-platinum precursor ions are
mass selected and guided into the ion trap where cleavage of adduct ions is activated using ERCID. This step is followed by mass analysis and detection of the resultant fragments (Fig. 5.2).
Survival yield analysis is a method that monitors the fragmentation patterns of ions as a function
of excitation voltage [142]. The setup of ER-CID experiments and survival yield analysis was
described in Section 2.4.12.

Figure 5.2. Schematic representation of the ER-CID experiment. HPLC
isolated adduct fractions are ionized in the ESI source. Precursor ions are mass
selected in MS1 and guided into the ion trap where they are fragmented by ERCID. Fragments are then mass analyzed in MS2 followed by detection.
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5.3 Results and discussion
5.3.1 Non-canonical AAPt-Ado adduct isomers and their differential fragmentation patterns
The reactions of Ado with the monoaquated AAPt compounds result in the formation of
more than one product as discussed in Chapter 3. These products were separated by HPLC
using a C18 column (Chapter 3, Fig. 3.3B). Characterization of the HPLC isolated products using
mass spectrometry and NMR spectroscopy were discussed in Section 3.3.1.
The fragmentation pattern of these adducts and the stability of their glycosidic bonds can
be affected differentially depending on the type of amino acid ligand linked to the platinum center
of the AAPt compound. Furthermore, isomers can also exhibit differences in stability dictated by
the site of platination (N1, N3, or N7). Cleavage of AAPt-AdoN1/N3 and AAPt-AdoN7 isomers was
activated through CID and composition of the fragments was determined by using tandem mass
spectrometry in which several fragmentation products (both charged and neutral) could be
formed, depending on the bond stability (Fig. 5.3).

Figure 5.3. Activation of AAPt-Ado adduct towards cleavage. Activation by CID of the
precursor ion results in cleavage of different bonds including the glycosidic bond. Charged and
neutral fragments are formed, depending on which functional groups are lost.
Despite having different platination sites, the N1/N3 and N7 adducts of AlaPt-Ado produce
comparable fragmentation patterns with a major fragment (m/z: 454.036 Da) formed by loss of
the ribose sugar (132.042 Da) (Fig. 5.4). The loss occurs via glycosidic bond cleavage following
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proton transfer of H2' to the nucleobase [120]. Minor neutral losses of HCl, H2O, and [Pt(Ala)(Cl)–
H] from AlaPt-AdoN1/N3 (m/z: 550.101, 532.091 and 268.104 Da, respectively) are also observed.
In contrast to the AlaPt-Ado adducts, fragmentation patterns of the OrnPt-Ado adducts
vary between the isomers, despite being subjected to similar fragmentation conditions (Fig. 5.5).
Two groups of fragments are observed in each CID mass spectrum. The first group contains
fragments formed by loss of neutral molecules of NH3, HCl, and (NH3 + HCl) from OrnPt-Ado (m/z:
612.080, 593.130, and 576.103 Da, respectively); the second group corresponds to fragments
involving glycosidic bond cleavage ions resulting in loss of the ribose sugar and the same neutral
losses (m/z: 497.063, 480.036, 461.085, and 444.058 Da, respectively). For OrnPt-AdoN1/N3, both
groups have approximately the same intensity, whereas for OrnPt-AdoN7, the second group of
fragments dominate. This result indicates a difference in the overall stability of the glycosidic
bonds of these two OrnPt-Ado isomers.

Figure 5.4. CID fragmentation patterns of AlaPt-Ado adducts. AlaPt-AdoN1 (or AlaPt-AdoN3)
and AlaPt-AdoN7 fragmentation patterns are shown. The spectra were obtained by Dr. C. C. He
in Dr. M. T. Rodgers’ lab.
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Figure 5.5. CID fragmentation patterns of OrnPt-Ado adducts. OrnPt-AdoN1 (or OrnPt-AdoN3)
and OrnPt-AdoN7 fragmentation patterns are given. The spectra were obtained by Dr. C. C. He in
Dr. M. T. Rodgers’ lab.
Similar to the OrnPt-Ado adducts, fragmentation patterns of the ArgPt-Ado adducts also
vary between the isomers, despite being subjected to similar fragmentation conditions (Fig. 5.6).
Two groups of fragments are also observed in each CID mass spectrum. The first group contains
fragments formed by loss of neutral molecules of H2O, HCl, and CH4N2O from ArgPt-Ado (m/z:
653.131, 635.165, and 611.110 Da, respectively); the second group corresponds to fragments
involving glycosidic bond cleavage ions resulting in loss of the ribose sugar and the same neutral
losses (m/z: 539.099, 521.088, 503.123, and 479.067 Da, respectively). For ArgPt-AdoN1/N3, both
groups have a wide range of intensities, with the loss of CH4N2O being the most intense. For
ArgPt-AdoN7, both groups have a wide range of intensities, but the loss of the sugar is more
dominant. This result indicates a difference in the overall stability of the glycosidic bonds of these
two ArgPt-Ado isomers.
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Figure 5.6. CID fragmentation patterns of ArgPt-Ado adducts. ArgPt-AdoN1 (or ArgPt-AdoN3)
and ArgPt-AdoN7 mass spectra are shown. The spectra were obtained by Dr. C. C. He in Dr. M.
T. Rodgers’ lab.

5.3.2 Differential activation of AAPt-Ado isomers towards glycosidic bond cleavage
Glycosidic bond survival yield analysis employing ER-CID tandem mass spectrometry has
been used previously to study relative stabilities of the glycosidic bonds in the context of
cationization and protonation of purine (deoxy)nucleosides [120, 124, 161-162]. In this study, we
aimed at investigating the glycosidic bond stabilities of AAPt-nucleoside adduct isomers. First, I
carried out reactions of AAPt compounds with Ado and isolated the adducts by HPLC using a
C18 column. This was followed by survival yield analysis carried out by Dr. C. C. He. Glycosidic
bond survival yield of the two AlaPt-Ado adducts (referred to as N1/N3 and N7, depending on the
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platination site) were compared in order to determine their relative glycosidic bond stabilities.
Because the adducts are isomers, they have an equal number of atoms and degrees of freedom,
and thus internal energy and dissociation lifetime effects on the fragmentation should be very
similar such that differences in the survival yield can be directly correlated to glycosidic bond
stability. The two OrnPt-Ado adducts were compared in a similar fashion.

Figure 5.7. Glycosidic bond survival yield curves of AlaPt adduct isomers. Glycosidic bond
survival yield curves of AlaPt-AdoN1/N3 in red and AlaPt-AdoN7 in blue. The spectrum was obtained
by Dr. C. C. He in Dr. M. T. Rodgers’ lab.

Fits to the survival yield curves of the AlaPt-Ado isomers produce GBC50% values for AlaPtAdoN1/N3 and AlaPt-AdoN7 of 0.099 V and 0.085 V, respectively (Fig. 5.7). Platination in both
isomers activates dissociation primarily through cleavage of the glycosidic bond with 95% and
100% of the fragmentation of AlaPt-AdoN1/N3 and AlaPt-AdoN7 occurring via glycosidic bond
cleavage, respectively, i.e., neutral losses account for 5% or less of the dissociation behavior for
both AlaPt-Ado isomers. Trends in the GBC50% values indicate that N7 platination is more
activating than N1/N3 platination.
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The GBC50% values determined for OrnPt-AdoN1/N3 and OrnPt-AdoN7 are much larger,
0.364 V and 0.351 V, respectively (Fig. 5.8). The trend in these values again indicates that N7
platination activates the glycosidic bond more effectively than N1/N3 coordination of platinum.
Furthermore, both OrnPt-Ado adducts exhibit significant competition between glycosidic bond
cleavage and neutral loss pathways. Indeed, neutral loss pathways account for 60% and 10% of
dissociation for OrnPt-AdoN1/N3 and OrnPt-AdoN7 adducts, respectively. Because AlaPt and OrnPtAdo differ in size, direct comparison of GBC50% values may be problematic, but the large shifts in
these values determined for the AlaPt-Ado vs. OrnPt-Ado adducts strongly suggest that binding
of AlaPt activates the glycosidic bond more effectively than OrnPt binding. The increased
competition with the neutral loss pathways in OrnPt-Ado compared to AlaPt-Ado adducts also
supports this conclusion.

Figure 5.8. Glycosidic bond survival yield curves of OrnPt adduct isomers. Glycosidic bond
survival yield curves of OrnPt-AdoN1/N3 in red and OrnPt-AdoN7 in blue. The spectrum was obtained
by Dr. C. C. He in Dr. M. T. Rodgers’ lab.
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The survival yield analysis of ArgPt-Ado isomers (ArgPt-AdoN1/N3 and ArgPt-AdoN7) will be
performed in the future. Because of the observed difference in CID fragmentation pattern (Fig.
5.6), they are predicted to have different behaviors in their glycosidic bond cleavage and neutral
loss pathways.
The difference in stability between the adduct isomers suggests that two factors can
influence the glycosidic bond stability, the type of amino acid ligand linked to the platinum center,
and the site at which the AAPt coordinates with the nucleoside. Platination by monoaquated AlaPt
results in adduct isomers that have relatively lower glycosidic bond stabilities than adduct isomers
formed by monoaquated OrnPt. The fact that N7 platination by AlaPt and OrnPt results in lower
adduct glycosidic bond stability compared to N1 (or N3) platination suggests that the closer the
proximity of the platination site to the ribose sugar, the greater the destabilization of the glycosidic
bond. Protonation or platination modifications on the nucleoside can accelerate the depurination
reaction by reducing the transition state energy [26]. The ligands of AlaPt or OrnPt may cause
electron-density withdrawal at the N9 position in a manner that is dependent on proximity of the
platinum atom. In the future, further tandem mass spectrometry and spectroscopic studies,
including computational analysis, will be performed in an effort to elucidate detailed mechanisms
for glycosidic bond cleavage of the N7 and N1/N3 AlaPt , OrnPt, and ArgPt adduct species, as
done previously with both standard and modified nucleosides [116, 120, 163] .
5.4 Conclusions
Enzymatic cleavage of Ado glycosidic bonds in RNA and subsequent depurination are
lethal to cells [159, 164]. Alternatively, cleavage through activation of glycosidic bonds could lead
to fragmentation of nucleic acids [115-118]. In this collaborative work with Rodgers’ laboratory,
glycosidic bond survival yield analysis was applied to determine the impact of AAPt coordination
on the relative glycosidic bond strength of an RNA-based nucleoside, Ado. When either AlaPt or
OrnPt coordinate to the N7 position of Ado, they destabilize the glycosidic bond to a greater extent
than when coordination occurs at the N1/N3 position. Overall, AlaPt almost exclusively activates
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the resulting AlaPt-Ado adduct via cleavage of the glycosidic bond. In contrast, OrnPt is less
activating of the glycosidic bonds such that fragmentation of OrnPt-Ado also involves other neutral
loss pathways. Such activation of AAPt-Ado adducts is particularly important considering that
cisPt is reported to have no destabilizing effect on the glycosidic bonds of target dGuo residues
[26]. Within a biological context, AlaPt and OrnPt could potentially exert destabilization of
glycosidic bonds in nucleic acid residues and lead to abasic sites. Formation of abasic sites,
especially in RNA, could possibly trigger apoptosis, as well as provide an alternative pathway of
cytotoxicity that circumvents cisPt resistance. The variation in the influence of AlaPt and OrnPt
on Ado also highlights the importance of structure for other classes of platinum-based drugs in
determining their preferred target residues and impact on adduct stability.
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CHAPTER 6
POTENCY AND ACCUMULATION OF AMINO ACID-LINKED PLATINUM COMPOUNDS IN
HUMAN CANCER AND NORMAL CELLS

6.1 Abstract
Although cisplatin (cisPt) is widely used for treatment of a variety of cancer types, its
therapeutic application has major drawbacks due to resistance, adverse toxicity, and reduced
accumulation. Second generation analogues including carboplatin and oxaliplatin have reduced
toxicity and resistance, but have low potency compared to cisPt. It is therefore important to
develop more ideal platinum-based compounds that balance between potency, selectivity for
cancer cells, and reduced toxicity in normal cells. Amino acid-linked platinum(II) (AAPt)
compounds including AlaPt, OrnPt, and ArgPt provide another class of metal-based compounds
with oral drug-like features that conform with Lipinski rules. At the molecular level, these
compounds have been demonstrated to have altered reactivity preferences and form noncanonical adducts compared to cisPt. The altered reactivity preference could translate to unique
activity at the cellular level that triggers different cytotoxic responses in cancer and normal cells.
In this thesis chapter, the half maximal inhibitory concentration (IC50) values of AAPt compounds
with various cancer and normal cells are reported. The values were determined using the MTT
(3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyltetrazolium bromide) assay. AlaPt, OrnPt, and ArgPt are
observed to have a wide range of potencies in the chosen cell lines. Whereas cisPt does not
exhibit selective potency with these cell lines, ArgPt exhibits selective potency in prostate cancer
cells over normal cells. The uptake and accumulation of platinum-based compounds in cancer
cells determines the extent of the cellular response that leads to apoptosis. Accumulation of the
AAPt compounds in prostate cancer and other cancer cell lines was determined using inductively
coupled plasma mass spectrometry (ICP-MS). Compared to cisPt, ArgPt has significantly higher
accumulation in prostate cancer cells. These studies are important for correlating potency and
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uptake of platinum-based compounds with other factors such as structural features of the
compound and DNA/RNA adducts.
6.2 Introduction
CisPt is a common metal-based anticancer drug used for the treatment of a variety of
cancer types [18, 11]. It has a cure rate of up to 80% in some forms of cancer such as testicular
cancer [18, 11]. However, cisplatin cancer applications have been hindered by drawbacks such
as resistance and adverse side effects such as nephrotoxicity [165-166, 71]. Resistance occurs
when cancerous cells do not undergo apoptosis within the clinically relevant drug doses. Factors
that lead to resistance include reduced drug accumulation, increased thiol levels that inactivate
cisPt, and increased DNA damage repair that removes cisPt adducts [71]. CisPt can also cause
major toxic side effects including nephrotoxicity, which occurs when cisPt accumulates in the
kidney and causes injury to renal epithelial cells, leading to undesirable death of healthy cells
[167]. To mitigate these challenges, analogues of cisPt such as carboplatin and oxaliplatin have
been developed with the goal of reducing toxicity and resistance [16]. The chemical
characteristics of carboplatin gives it an advantage over cisPt, and toxicity can be circumvented
due to its lower reactivity and adduct formation (discussed in Chapter 1, Section 1.4.3) [91].
Despite having reduced toxicity and lower cellular resistance, the activity of analogues such as
carboplatin has been hampered by lower potency. As high as 90% of administered carboplatin
does not react with the target and is excreted, meaning that a much higher dose is required in
order to achieve the same effectiveness as cisPt [16]. It is therefore desirable to develop new
platinum-based compounds that have the same or better efficacy than cisPt while being selective
for cancer cells in order to reduce the toxic side effects. The compounds should also be able to
circumvent cellular resistance so as to impart apoptosis of tumor cells even with long-term use.
The potency of platinum-based compounds can be determined using their IC50 values. An
IC50 value refers to the concentration of a compound that causes a reduction in cell viability by
50%. IC50 values of compounds can be determined by using quantitative colorimetric techniques
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such as the MTT assay (discussed in Chapter 2, Section 2.4.13) [168]. This assay is used to
quantify the number of viable cells based on the amount of metabolic activity that is detected. In
this assay, the mitochondrial NAD(P)H-dependent reductase enzymes in viable cells reduce the
MTT into the insoluble, purple compound known as formazan [169]. Formazan crystallizes on the
cell surface and is then dissolved by solvents such as dimethyl sulfoxide (DMSO) [168-169].
Absorbance measurements of the resulting solutions are taken using a spectrophotometer. The
absorbance readings are correlated with the percentage of viable cells and plotted as a function
of compound concentration [170]. The fitted dose-response curves are used to extract the IC50
values.
The MTT assay has been modified in which tetrazolium is used to determine the IC50
values of compounds in cells. The alternative reagents also include MTS (3-(4,5-dimethylthiazol
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), XTT (2,3-bis-(2-methoxy-4nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide), and WST (2-(2-methoxy-4-nitrophenyl)-3(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) [170]. These assays have been modified to
eliminate the need for washing and solvent solubilization steps because they generate watersoluble products [171]. However, the MTT assay is still preferred for investigating cell viability and
proliferation [171] because of its higher sensitivity and validated use in miniaturized highthroughput assays [171]. This technique is also preferred over alternatives such as the radioactive
isotope-based thymidine incorporation assay, which is more time consuming and expensive [171172]. Other techniques such as counting total viable cells using a hemocytometer are
cumbersome and require a large number of samples to be processed [172].
The IC50 values of FDA-approved platinum compounds varies depending on the
compound, the type of cells being treated, and the length of time of treatment [173-182]. In Table
6.1, examples of IC50 values of the FDA-approved platinum-based drugs in common cell lines are
given. Generally, the IC50 values of cisPt are lower than carboplatin [33-36]. For example, cisPt
has an IC50 value of 21 μM in a lung H1299 cell line following 72 h of treatment, whereas
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carboplatin achieves a similar value after 5 days of treatment (Table 6.1) [174, 180]. In lung cell
lines A549 and MCF7, oxaliplatin has similar or lower IC50 values than cisPt (Table 6.1) [178-179,
182]. This may be attributed to the structural characteristics of oxaliplatin, which includes its
relatively larger non-leaving ligand that triggers cell death by protruding into the major groove and
effectively blocking DNA replication and transcription (discussed in Chapter 1, Section 1.4.3)
[94, 96].
Table 6.1. IC50 (μM) values of cisPt, carboplatin, and oxaliplatin in human cancer cell lines
cell line

cisPt

carboplatin

oxaliplatin

[ref]

(time) [ref]

(time) [ref]

(time) [ref]

lung H1299

21 ± 4

19 ± 3

-

[129]

(72 h) [180]

(5 d) [174]

HeLa

2±1

5±2

12 ± 1

[132]

(72 h) [181]

(96 h) [175]

(72 h) [181]

MDA-MB-231

1.4 ± 0.2

8±1

23 ± 1

[130]

(5 h) [182]

(5 d) [182]

(72 h) [176]

A549

3±1

20 ± 1

0.9 ± 0.1

[183]

(5 d) [182]

(5 h) [182]

(72 h) [178]

MCF7

16 ± 6

4

2±1

[184]

(24 h) [179]

(48 h) [173]

(24 h) [179]

DU145

3

10 ± 1

2.1 ± 0.2

[133]

(72 h) [177]

(48 h) [174]

(72 h) [178]

tissue

lung

cervical

breast

lung

lung

prostate

The AAPt compounds could provide another class of metal-based compounds with oral
drug-like features according to Lipinski rules [126]. The Lipinski rules are a set of requirements
that predict the overall cell absorption and drug-likeness of a compound. The Lipinski criteria
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require that compounds should not violate more than one of the four rules, which include having:
1) less than 500 Da in molecular weight, 2) less than five hydrogen-bond donors, 3) less than ten
hydrogen-bond acceptors, and 4) logP values of not greater than five [185]. The structural
characteristics and molecular weights of AAPt compounds conform with the Lipinski rules (Fig.
6.1). There has been limited previous attempts to investigate the activity and potency of AAPt
compounds in cancer cell lines. The cytotoxicity of ArgPt, LysPt (lysine-linked platinum(II)), and
several LysPt-related derivatives were previously investigated in HeLa and KM-12 cell lines using
colony counting method [112, 103]. In these studies, ArgPt and LysPt exhibited promising IC50
values of 25 µM in a HeLa cell line following 24 h of treatment and further 7-10 days of cell growth
[112]. There is still a need to investigate the potency of AAPt compounds (including AlaPt and
OrnPt) in a larger variety of cancer cell lines including cisPt-resistant and cisPt-sensitive cells.
The results would provide a deeper understanding of the features of platinum-based compounds
that promote their activity, selectivity, and circumvention of resistance.

Figure 6.1. The structures of cisPt and AAPt compounds. The structures and molecular
weights of cisPt, AlaPt, OrnPt, and ArgPt are given.

The drawbacks of cisPt therapy such as resistance due to DNA repair, non-selectivity, and
toxicity limit its effectiveness, but could possibly be mitigated by compounds that form adducts at
novel targets that are not preferentially platinated by cisPt. CisPt preferentially binds with DNA
dGuo residues, which plays a role in its anticancer activity [18, 27, 40, 38]. Formation of adducts
at non-canonical sites could be important in circumventing resistance and triggering alternative
cytotoxic pathways in tumor cells. In Chapter 4, it was demonstrated that AAPt compounds
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(AlaPt, OrnPt, and ArgPt) have altered reactivity compared to cisPt. AAPt compounds have
reactivity preferences for dAdo and Ado residues of DNA and RNA [105-106]. These AAPt
compounds could become candidates that induce alternative cytotoxic pathways by involving noncanonical targets such as dAdo residues of DNA as well as Ado residues of RNA. The features
of compounds that lead to tumor cell death can be investigated at both the molecular and cellular
levels.
In this thesis chapter, the anticancer potency of AAPt compounds at the cellular level is
reported. The IC50 were determined in several human cancer cell lines by using MTT assay. The
potency of the compounds was investigated in prostate, breast, and lung cancer cell lines.
Prostate and lung cancers are the leading causes of cancer-related deaths among men in the
United States, whereas breast and lung cancers are the leading causes of cancer-related deaths
among women [186]. CisPt chemotherapy has been applied in the treatment of lung, breast, and
prostate cancer [187-189], but has been hindered by adverse toxicity, side effects, and resistance
[187-188]. Therefore, there is a need to develop other platinum-based compounds that have
better activity and selectivity than cisPt in these forms of cancer.
The accumulation of anticancer compounds inside cells is an important aspect that drives
their pharmacological impacts. Low accumulation of cisPt in cells causes DNA damage, which
potentially stimulates resistance rather than apoptosis [71]. Reduced cellular accumulation of
cisPt is caused by factors such as disruption of drug uptake or increased efflux [71]. Higher cellular
accumulation of cisPt (or other platinum-based compounds) is important for formation of a
sufficient number of DNA adducts to trigger apoptosis. Therefore, accumulation of the compounds
in cells can be correlated with their potency and IC50 values, in which higher accumulation
corresponds to higher potency (and lower IC50 values). Previously, whole cell cisPt uptake in
cisPt-sensitive and cisPt-resistant lung tumor cells was determined by using ICP-MS [190]. It was
observed that cisPt-resistant cancer cells have four-fold lower uptake of cisPt compared to the
cisPt-sensitive cells following exposure to the drug for a similar period of time [190]. The amount
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of cisPt bound to biological targets such as DNA and RNA, has been quantified in other studies
by using ICP-MS [59]. In the thesis work reported in this chapter, cellular accumulation of AAPt
compounds in comparison to cisPt in both cancer and normal cells was determined using ICPMS. The structural characteristics of AAPt compounds could be important for efficient cellular
uptake and accumulation. The positively charged ligand side chains of ArgPt and OrnPt could
promote cell penetration due to electrostatic interactions with the anionic plasma membrane [191].
Cancer cells have a net negative charge on the surface on their cell membranes compared to
normal cells [192-194]. This can be attributed to high levels of lactate anions secreted by cancer
cells that minimize the presence of cations on the cell surface and promote a net negative charge
[195]. This behavior is unique to cancer cells, which have an active metabolism that causes
glycolysis to form high amounts of lactate anions compared to normal cells [196]. Furthermore,
cancer cells have upregulation of negatively charged sulfated proteoglycans on the cell surface
that further contribute to the negative charge [197-198]. Favorable interactions with the negative
cell surface prior to uptake could favor selective targeting of cancer cells.
6.3 Results and discussion
6.3.1 Potency of AAPt compounds in human cancer and normal cells
The potency of AAPt compounds in prostate (DU145), lung (H1299), breast (MDA-MB453 and MDA-MB-231), and cervical (Hela) cancer cell lines was investigated by using the MTT
assay. The activities of platinum-based compounds in prostate normal (RWPE-1) and prostate
cancer (DU145) cell lines were also determined so as to understand their selective potency. The
MTT assay, as described in Section 2.4.13, was used to investigate the viability of cells following
treatment with the AAPt compounds and cisPt. The percentage of viable cells as a function of
increasing concentration of platinum-based compounds was plotted and used to extract the IC50
values.
The DU145 cell line was treated with the AAPt compounds (and cisPt) for 72 h. The doseresponse curves show that the percentage of viable cells decreases with an increase in the
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concentration of platinum-based compound (Fig. 6.2). The degree in which the number of viable
cells decreases depends on the identity of the platinum compound (cisPt, AlaPt, OrnPt, and
ArgPt). These results suggest that the different structural forms of the platinum-based compounds
have different uptake levels and/or trigger different cytotoxic responses in the cells.

Figure 6.2. Dose-response curves of AAPt compounds (and cisPt) in prostate cancer
(DU145) cell line. The MTT assay was used to determine the percentage of viable cells as a
function of increasing concentration of platinum-based compound. The type of cancer cell line
and platinum-based compound used are indicated in the plots. All cells were treated for 72 h.
Cells have varied responses to the different compounds used in the assay. GraphPad PRISM
software was used for curve fitting using the model equation Y=100/(1+(XhillSlope)/(IC50hillSlope)), in
which hillslope is -1. IC50 values were extracted from the plots. Each plot is from at least two
biological replicates.
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From the dose-response curves, the AAPt concentrations that resulted in 50% reduction
of viable cells (IC50 values) were extracted. The IC50 value of cisPt was compared to those of
AAPt compounds (Table 6.2). Cispt has an IC50 value of 4 µM in prostate cancer cells following
the 72 h treatment. This value is consistent with a reported IC50 value of 3 µM following treatment
of the same cell line with cisPt over 72 h [177]. AlaPt has an IC50 value of 75 µM in the DU145
cell line, which is 19-fold higher than cisPt value (Table 6.2). This result shows that in this cell
line, AlaPt is less potent (or has lower uptake) and its chemical structure does not elicit cytotoxic
responses comparable to cisPt. OrnPt has an IC50 value of 46 µM in the DU145 cell line which is
11-fold higher than cisPt (Table 6.2). This result shows that OrnPt is also less potent in prostate
cancer cells compared to cisPt.
Table 6.2. Comparison of potency of AAPt compounds, cisPt, and carboplatin in DU145 cell line
Compounds (ref)
cell line (ref)
IC50 value (μM)ǂ

ǂ

cisPt

DU145 [133]

4±1

AlaPt

DU145 [133]

75 ± 13

OrnPt

DU145 [133]

46 ± 12

ArgPt

DU145 [133]

12 ± 2

carboplatin [174]

DU145 [133]

10 ± 1

error is from at least two biological replicates

ArgPt has an IC50 value of 12 µM in the DU145 cell line (Table 6.2). This value is threefold higher than that of cisPt, showing only a moderately lower potency. Although the low IC 50
value of cisPt may translate to high potency, the high activity may also cause toxicity to rapidly
dividing cells and other side effects [165-166, 71] and hence, a three-fold lower activity of ArgPt
could be more ideal in cancer targeting. Carboplatin is reported to have an IC50 value of 10 µM in
DU145 [174], which is similar to that of ArgPt in the same cell line (Table 6.2). Therefore, ArgPt
and the clinically used carboplatin have the same potency in prostate cancer cells, but are
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potentially less toxic than cisPt in normal cell lines. The lower potency of carboplatin is
advantageous in circumventing the adverse toxicity usually caused by high dosages of platinum
compounds [91]. For ArgPt, having an IC50 value that is comparable to carboplatin could be
important in balancing selective potency in cancer cells and toxicity in normal cells. ArgPt and
carboplatin may have structural features that promote both potency and reduced toxicity.
Because of the potency of ArgPt in prostate cancer cells, its activity in a prostate normal
(RWPE-1) cell line was also investigated and compared to cisPt. In RWPE-1, cisPt has an IC50
value of 4 µM after a 72 h treatment (Fig. 6.3 and Table 6.3). This low micromolar value is similar
to its IC50 value in the DU145 cancer cell line, meaning that cisPt is highly potent and not selective
for cancer over normal prostate cells. This result was expected because cisPt is known to be nonselective and toxic to normal cells [199-200].

Figure 6.3. Dose-response curves of cisPt and ArgPt in normal prostate (RWPE-1) cell
lines. An MTT assay was used to determine the percentage of viable cells as a function of
increasing concentration of platinum-based compound. The type of cancer cell line and platinumbased compound used are indicated in the plots. The cell lines were treated for 72 h. Cells have
varied responses to the different compounds used in the assay. GraphPad PRISM software was
used for curve fitting using the model equation Y=100/(1+(XhillSlope)/(IC50hillSlope)), in which hillslope
is -1. IC50 values were extracted from the plots. Each plot is from at least two biological replicates.
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Table 6.3. Comparison of IC50 (μM) values of cisPt and ArgPt in normal and cancer cell lines
tissue
cell line (ref)
disease
cisPtǂ
ArgPtǂ
prostate DU145 [133]

carcinoma

4±1

12 ± 2

prostate RWPE-1 [134]

normal

4±1

69 ± 5

fold change in 1
IC50 values
ǂ
error is from at least two biological replicates

6

ArgPt has a low IC50 value of 12 µM in prostate cancer cells and a moderately high IC50
value of 69 µM in prostate normal cells (Fig. 6.3 and Table 6.3). The six-fold difference in the IC50
values of ArgPt in prostate cancer and normal cells shows that ArgPt is moderately selective for
the cancer cells. The selective potency of ArgPt in the cancer cell line compared to normal cells
could be due to its ligand side chains. Cancer cells have been reported to have a higher net
negative charge on their cell surface compared to normal cells [192-194] and also upregulation
of negatively charged sulfated proteoglycans on the cell surface [197-198]. The negative surface
and sulfated sugars may enable favorable electrostatic interactions with the positive guanidinium
side chains [201, 195] leading to attraction of ArgPt towards cancer cells and promoting uptake
by the same cells.
Although OrnPt has a positive side chain, its four-fold lower potency could be related to
its different amine side chain (compared to guanidinium). The positively charged amine may not
possess favorable interactions with cancer cells compared to the guanidinium in ArgPt. This
difference is observed in various cell penetrating peptides (CPP), in which the arginine moiety
stimulates higher cellular uptake compared to lysine (which has similar amine moiety as ornithine)
[202, 201, 203]. An example is where arginine-enriched peptides stimulates more cellular
internalization through endocytosis than lysine-enriched peptides [202]. Efficient uptake of both
arginine- and lysine-rich peptides is also attributed to their interactions with cell surface
proteoglycans, however, absence of proteoglycans does not limit internalization of arginine-rich

131
peptides meaning that the arginine moiety modulates cell penetration through several pathways
that may not be available for the lysine moiety [201]. Furthermore, as mentioned in Section 2.4.2,
it is possible that OrnPt may exist with an (N, N) type of structure. The (N, O) and (N, N) type of
structures could elicit different cytotoxic responses in cells. Therefore, among the three AAPt
compounds investigated, ArgPt has higher potency in cancer cells over normal cells, a feature
that could be advantageous over cisPt.

Figure 6.4. Dose-response curves of cisPt and ArgPt in breast cancer cell lines. An MTT
assay was used to determine the percentage of viable cells as a function of increasing
concentration of platinum-based compound. The type of cancer cell line and platinum-based
compound used are indicated in the plots. All cells were treated for 48 h except MDA-MB-453
which was treated for 64 h. GraphPad PRISM software was used for curve fitting using the model
equation Y=100/(1+(XhillSlope)/(IC50hillSlope)), in which hillslope is -1. IC50 values were extracted from
the plots. Each plot is from at least two biological replicates.
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As mentioned before, breast and lung cancer are the leading causes of cancer-related
deaths among women in the United States [186]. Because of the promising results of ArgPt with
prostate cancer cell lines, its potency in breast (Fig. 6.4 and Table 6.4) and lung (Fig. 6.5 and
Table 6.4) cancer cell lines was also investigated in comparison to cisPt using the MTT assay.
The potency of the compounds in a cervical cancer cell line (HeLa) was also determined (Figs.
6.4 and 6.5). The dose-response curves of all cell lines tested show that the percentage of viable
cells is diminished with an increase in the concentration of platinum compounds depending on
the type of cell line and identity of the platinum compound. ArgPt has an IC50 value of 35 µM in
the breast cancer cell line MDA-MB-453 and 73 µM in breast cancer cell line MDA-MB-231 (Table
6.4). The response to ArgPt treatment is therefore different in the two breast cancer cell lines
under investigation, with a two-fold higher potency in MDA-MB-453 cells compared to MDA-MB231 cells. ArgPt has an IC50 value of 73 µM in the H1299 cell line and 78 µM in the HeLa cell line.
The IC50 values in all four cell lines indicate that ArgPt has only moderate activity in these cell
lines. Compared to cisPt, ArgPt has significantly less potency in the same cell lines (Table 6.4).
To confirm that the cellular potent activity is only from the complexes of amino acids linked with a
platinum center and not the free amino acids, future experiments will involve the use of respective
amino acids as controls.
Table 6.4. IC50 (μM) values ArgPt in comparison with cisPt
tissue
cell line (ref)
treatment time

cisPtǂ

ArgPtǂ

breast

MDA-MB-231 [130]

48 h

17 ± 4

73 ± 10

breast

MDA-MB-453 [128]

64 h

10 ± 1

35 ± 3

lung

H1299 [129]

48 h

25 ± 2

73 ± 5

cervical

HeLa [132]

48 h

23 ± 2

78 ± 9

ǂ

error is from at least two biological replicates
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Figure 6.5. Dose-response curves of ArgPt and cisPt in cervical and lung cancer cell lines.
MTT assays were used to determine the percentage of viable cells as a function of increasing
concentration of platinum-based compound. GraphPad PRISM software was used for curve fitting
using the model equation Y=100/(1+(XhillSlope)/(IC50hillSlope)), in which hillslope is -1. IC50 values were
extracted from the plots. Each plot is from at least two biological replicates.

6.3.2 Quantification of platinum abundance in cells
In this thesis work, the cellular accumulation of AAPt compounds and cisPt in DU145 and
RWPE-1 cell lines was determined. Because of the selective potency of ArgPt in prostate cancer
cells compared to normal cells, it was of interest in this thesis work to determine the possible
difference in uptake and accumulation of the compound in both cell types. Cells were treated with
either AAPt or cisPt compounds and their cellular platinum concentration determined
quantitatively by using ICP-MS (Chapter 2, Section 2.4.14). The ICP-MS has four tune modes
from which quantification can be carried out. Quantification was done in the high energy helium

134
(HEHe) tune mode because the internal standard signal was stable and the R value of calibration
was closest to 1. The calibration curves from the four tune modes are shown in the Appendix
(Figs. 1A-4A). As shown in Table 6.5, accumulation of the platinum-based compounds varies
depending on the cell line and the identity of compound. To confirm the consistency of the
quantification, the samples were diluted 2X and 10X, followed by measurements on the ICP-MS
and correction of dilution factors (Table 6.6). Readings for respective samples were consistent
with each other with a low error percentage ranging from 0.1 to 7.8%.

Table 6.5. Accumulation of platinum compounds in prostate cancer and normal cells
disease
cell line
Pt compound amount (nmol/106 cells)
normal

RWPE-1

cisPt

0.9 ± 0.3

carcinoma

DU145

cisPt

15 ± 8

normal

RWPE-1

OrnPt

0.9 ± 0.2

carcinoma

DU145

OrnPt

28 ± 11

normal

RWPE-1

ArgPt

3.2 ± 0.1

carcinoma

DU145

ArgPt

96 ± 16

Table 6.6. ICP-MS analysis of diluted samples of cells treated with platinum-based compounds
2X
10X
percentage
original
dilution
dilution average
error
normal/cisPt

0.9

0.9

0.9

0.9

<0.1

cancer/cisPt

15

16

16

16

1.9

normal/OrnPt

0.9

1.1

1.1

1.0

<0.1

cancer/OrnPt

28

30

28

29

2.4

normal/ArgPt

3.2

4.2

4.1

3.8

7.8

cancer/ArgPt

96

114

111

107

5.2
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CisPt has an accumulation of 15.3 nmol per million cancer cells, which is 17-fold higher
than its accumulation in normal cells (Table 6.5 and Fig. 6.6). OrnPt has an accumulation of 28
nmol per million cancer cells, which is thirty-fold higher than its accumulation in normal cells.
ArgPt has an accumulation of 96 nmol per million cancer cells, which also represents a 30-fold
higher accumulation than in normal prostate cells. Therefore, OrnPt and ArgPt exhibit higher fold
changes in their accumulation in cancer cells over normal cells compared to cisPt. The
considerably higher accumulation in cancer cells than normal cells could be important in triggering
selective potency. The 30-fold higher ArgPt accumulation in cancer cells translated to a six-fold
selective potency in the same cells compared to normal cells (Tables 6.2 and 6.3). The presence
of a positively charged guanidinium on the side chain of ArgPt may be important for its penetration
and potency in cells. It has been reported that positively charged residues including arginine
promote cell penetration due to strong electrostatic interactions with anionic plasma membranes
[204] and through their interactions with the negative sulfated proteoglycans [201-202]. Cancer
cells have a higher net negative surfaces on their cell membranes [192-194] and upregulated
levels of proteoglycans [197-198], which would likely interact favorably with the positive ArgPt
side chains. Therefore, it is plausible that ArgPt has favorable interactions with the surfaces of
cancer cells and transit through the cell membrane followed by interactions with the negatively
charged nucleic acids inside cells. Although OrnPt also has a positive amine on its ligand side
chain, it has a four-fold lower potency and three-fold lower accumulation than ArgPt in DU145 cell
line. This is likely because the guanidinium moiety of arginine is more efficient in promoting cell
internalization compared to the amine moiety of ornithine (or lysine) [201-202]. This also means
that other properties of ArgPt in addition to its positively charged guanidinium on the side chain
could play a role in mediating potency and accumulation.
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Figure 6.6. Accumulation of platinum-based compounds in prostate normal (blue, DU145 cell
line) and cancer (red, RWPE-1) cell lines. Error is calculated fom three repeats.

While cellular uptake of the AAPt compounds (and cisPt) is crucial in adduct formation
and triggering cell death, other factors associated with the cells could also play a role in mediating
the extent of potency once uptake occurs. The difference in potency of ArgPt in all the cell lines
investigated in this thesis work could be explained by their p53 status. It is suggested that
antitumor agents including cisPt induce apoptosis through involvement of the tumor suppressor
p53 protein [205-206]. Cell lines with downregulated or mutated p53 proteins are less
chemosensitive to cisPt

[205-206]. The p53 status and cisPt sensitivity in the cell lines

investigated in this thesis work are consistent. If ArgPt induces apoptosis through involvement of
p53 proteins in a manner similar to cisPt, then cells with this tumor suppressor would be more
chemosensitive to ArgPt. Breast cancer cell line MDA-MB-453 has full length p53 [207] while its
related MDA-MB-231 has mutated p53 proteins [208]. The response to ArgPt by these two cell
lines are consistent with their p53 status in which MDA-MB-453 is two-fold more sensitive to ArgPt
than the MDA-MB-231 cell line. H1299 and HeLa cell lines are p53 null [209-210] and this may
explain why ArgPt has relatively low potency in these cell lines. The DU145 cell line also
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expresses p53 [211], and this could also contribute to the observed high sensitivity to ArgPt as
indicated by the low IC50 value.
6.4 Conclusions
At the cellular level, ArgPt exhibits increased potency and accumulation compared to cisPt.
While cisPt is potent in both cancer and normal prostate cells, ArgPt is selective in potency
towards prostate cancer cells compared to normal cells. ArgPt also has higher accumulation in
prostate cancer cells, which correlates with its lower IC50 value and higher potency. ArgPt is
observed to have a 30-fold higher accumulation in prostate cancer cells than normal cells, which
translates into a six-fold selective potency in cancer cells. Structural characteristics of AAPt
compounds could enable the compounds to have unique cell penetration properties and potency
compared to cisPt. The positively charged guanidinium on side chain of ArgPt could promote cell
penetration due to electrostatic interaction with anionic plasma membrane. Unique features of
cancer cells including the higher net negative charge on the surface of cell membranes or the
presence of negatively charged sulfated proteoglycans could also recruit ArgPt towards cancer
cells and promote selective uptake of the compounds. Although, OrnPt is also observed to have
higher accumulation in prostate cancer cells than normal cells, its potency in prostate cancer cells
is relatively low compared to ArgPt. The possible existence of OrnPt adducts with an (N, N) type
of structure of metal complex could explain this difference, especially if the (N, N) type of
structures do not have favorable interactions with cells compared to (N, O) type of structures.
Future directions will involve using respective free amino acids during MTT assays as controls
so as to ascertain if the complex of platinum center together with the amino acid ligand induce
the potent activity of AAPt compound as opposed to free amino acid alone. Furthermore,
competition studies of cellular uptake of free amino acids and AAPt compounds could be carried
out by incubating cells with the compounds prior to ICP-MS quantification of platinum
accumulation. These studies may give further information on possible cell receptors or
transporters that could be aiding the uptake of AAPt compounds.
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Inherent cellular features including the status of tumor suppressors such as p53, could also
modulate the extent of potency in a given cancer cell line. Cell lines with low p53 abundance or
mutated p53 have lower sensitivity towards not only cisPt but also OrnPt and ArgPt. This tumor
suppressor may play a role in mediating the cytotoxic pathway of ArgPt and OrnPt in a manner
similar to cisPt, but this has to be tested with further experimentation. The high accumulation of
AAPt compounds in cancer cells combined with selective potency and non-canonical targets
(reported in previous chapters) could enable the compounds to have a robust and unique
cytotoxic pathway that circumvents challenges hindering cisPt application.
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CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTIONS
7.1 Overall conclusions
Cisplatin (cisPt) was approved over 40 years ago for anticancer therapy and has since
been used for treatment of several forms of cancer [9, 11]. CisPt preferentially form adducts with
deoxyguanosine (dGuo) residues, which alters the DNA structure and inhibits biological
processes such as replication and transcription [11, 38]. The adducts trigger other cellular
responses, including cell cycle arrest, DNA repair, and apoptosis [1]. The clinical use of cisPt has
been limited by cellular resistance and adverse side effects such as nephrotoxicity [69-71]. These
drawbacks have provided the inspiration to explore other modified cisPt ligands and research
their structure-activity relationships. The parent cisPt has two ammine and two chlorido ligands
that modulate its various chemical properties ranging from reaction kinetics to preferred biological
targets of the compound [16-18].
The ligands of second generation cisPt analogues possess unique biochemical effects
that have played a role in improving their therapeutic activities. In carboplatin for example, the
chelate ring in cyclobutanedicarboxylate stabilizes the leaving ligand and slows the aquation rate
[91-92]. This in turn slows the rate of adduct formation with DNA, which ultimately reduces the
reactivity and toxicity of the compound compared to cisPt at high dosage [91, 34]. The non-leaving
1,2-diamminocylohexane ligand in oxaliplatin protrudes into the major groove of DNA where it
effectively blocks the replication machinery from bypassing the adduct [94, 96]. This is important
in circumventing a form of resistance that occurs in cancer cells where the replication machinery
is able to read through cisPt adducts. Although the second-generation antitumor platinum-based
drugs have advantages over cisPt in terms of reduced toxic side effects and the ability to
circumvent resistance, they are limited by their low efficacy [16]. The compounds also require
combination therapy with other anticancer agents in order to be fully effective [95].
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There is still a need to develop platinum-based compounds that can balance high potency,
reduced resistance, and low toxicity in cells. Since cisPt and second-generation platinum drugs
are known to target dGuo residues of DNA, platinum-based compounds that have alternative
target residues or biomolecules such as RNA could trigger unique biochemical events compared
to cisPt. However, there has been limited success in finding platinum-based compounds that
preferentially platinate alternative non-cisPt targets. Previous work in our lab showed that amino
acid-linked platinum(II) (AAPt) compounds coordinate with RNA residues [106]. The work in this
thesis focused on synthesis of AAPt compounds and characterization of the non-canonical
adducts that form with adenosine (Ado) residues. The reaction kinetics, impact on glycosidic bond
stability, potency, and accumulation of AAPt compounds in cancer cells were also investigated.
AAPt compounds are generated by attaching amino acids to a platinum metal center [106,
103-105]. In Chapter 2, the synthesis and characterization of three AAPt compounds (AlaPt,
OrnPt, and ArgPt) were described. The structural characterization of the compounds
demonstrated that the respective amino acid is chelated with the Pt(II) center through the
backbone nitrogen and oxygen atoms giving a five-membered ring ((N,O) type of structure) [104105]. Even though the (N,N) type structure in OrnPt was not observed in the X-ray crystal
structure, it was not ruled out since crystallization conditions may have favored only the (N,O)
type structure [107].
CisPt predominantly targets the N7 position of Guo residues and results in formation of
bifunctional and monofunctional types of adducts. Compared to cisPt, the AAPt compounds have
a wider range of reactivities and targets because of the diversity of the side chain functional
groups together with the contribution of backbone atom metal coordination. AAPt compounds
form adducts with non-cisPt targets including Ado/dAdo residues of RNA and DNA. In Chapter
3, the non-canonical adducts formed by AAPt compounds (AlaPt, OrnPt, and ArgPt) were
characterized. The adducts formed are monofunctional isomeric adducts that vary at the
platination sites. The compounds coordinate specifically at the N1/N3 and N7 positions of the Ado
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nucleobases. In this thesis, mass spectrometry and 1D-NMR spectroscopy methods were used
to identify the types of adducts formed. However, these methods give limited information on the
structural orientations of the adducts which are modulated by factors such as steric hindrance
and hydrogen-bonding properties. The 1H-NMR spectroscopy is also limited in differentiating
between N1 and N3 platination sites because of their similar proximity to H2 proton. Future
studies could employ X-ray crystallography or 2D-NMR spectroscopy to differentiate between N1
and N3 platination.
Kinetic studies in Chapter 4 indicate that monoaquated AlaPt, OrnPt, and ArgPt have
altered reactivity and different target preferences compared to cisPt [105]. AlaPt has nine to 20fold higher selectivity for dAdo over all other purines. OrnPt exhibits a four to six-fold increased
reactivity with Ado/dAdo nucleosides over Guo/dGuo, whereas ArgPt has four- to five-fold higher
reactivity with dAdo/dAdo than with Guo/dGuo. Since cisPt only has the (N,N) type of structure
while the amino acid complexes can have (N,O) type of structures, the altered reactivity
preferences suggest that the mode of amino acid coordination together with the ligand side chain
play a role in modulating the nucleoside preferences and rates of reactivity. Furthermore, the
selectivity of cisPt for dGuo is attributed to formation of a hydrogen bond between the cisPt
ammine ligand and the 6-oxo group of Guo during transition state [27]. In contrast, the preferences
of AlaPt, OrnPt, and ArgPt could be due to hydrogen-bonding interactions with Ado/dAdo
functional groups. The trans adduct structures of AAPt-Ado are stabilized because of hydrogen
bonding between the 6-amine of Ado and carboxylate ligand of the AAPt compound. The lower
reactivities of the selected AAPt compounds with Guo/dGuo are likely lower due to the lack of
such an interaction. HPLC fitted with a C18 column was used to monitor the rate of diminishing
reactants prior to extracting the rate constants. It was challenging to monitor rate of formation of
individual products since there is possible conversion from one type of adduct to another with
different retention time. There are other methods available such as NMR spectroscopy and mass
spectrometry that have been used previously to investigate the reaction kinetics of platinum-
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based compounds [32, 34, 149, 158] and could also be used to confirm the reactivities and
preferences of AAPt compounds with their nucleic acid targets.
The reaction kinetics of AAPt compounds (and cisPt) with 5′-UUAUU-3′ and 5′-TTATT-3′
oligonucleotides were also studied in which monofunctional and doubly platinated adducts were
observed. The reactivities of the compounds with these oligonucleotides generally increased
compared to reactions with nucleosides, as exhibited by the increased k values. The local
environment flanking the target residues in DNA or RNA oligonucleotide, such as the phosphodiester backbone, likely enhances reactivity with AAPt compounds. The negatively charged
phosphate groups could interact with the positive ligands of the AAPt compounds (OrnPt and
ArgPt). The functional groups of the backbone could also hydrogen bond with functional groups
of AAPt, which would stabilize the coordination of the compounds with their targets. OrnPt was
also observed to have a two-fold higher preference for the RNA oligonucleotide than the
corresponding DNA, which means that its structural features could be important in development
of nucleic acid-selective platinum-based compounds. To further understand the impact of local
environment on the reactivities of AAPt compounds, other oligonucleotides aside from 5′-UUAUU3′ and 5′-TTATT-3′, could also be used in reaction kinetics. Oligonucleotides with varied lengths,
different sequences flanking target sites, or changing positions of Ado residues would provide
further understanding on how target positions in relation to flanking sequences or oligonucleotide
length could affect the reactivities of AAPt compounds.
Platination of nucleosides could influence the stability of nucleic acids as reported in
Chapter 5. Collision induced dissociation (CID) and glycosidic bond survival yield analysis were
applied to determine the impact of platination on the relative glycosidic bond strength of noncanonical AAPt-Ado adducts. When either AlaPt, OrnPt, or ArgPt coordinate to the N7 position of
Ado, they destabilize the glycosidic bonds to a greater extent than when they coordinate at the
N1 or N3 positions. Depending on the proximity of the platinum atom, the ligands of the selected
AAPt compounds could cause electron-density withdrawal at the N9 position leading to
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destabilization of the glycosidic bonds. Overall, AlaPt-Ado adducts are observed to predominantly
fragment via cleavage of the glycosidic bond. In contrast, fragmentation of OrnPt-Ado involves
cleavage of the glycosidic bonds and other neutral loss pathways. Activation of glycosidic bond
cleavage is particularly unique to the selected AAPt compounds considering that cisPt is reported
to have no destabilizing effect on the glycosidic bonds of target dGuo residues [26].
Destabilization of glycosidic bonds could be biologically relevant considering that AAPt
compounds could exert formation of abasic sites in nucleic acids. Irreparable abasic sites,
especially in RNA, could trigger apoptosis and provide an alternative cytotoxic pathway that averts
cisPt resistance.
To explore features of ligands that improve activity and selectivity of platinum-based
compounds, the potency and accumulation of AAPt compounds was investigated in Chapter 6.
The MTT assay was used to investigate cellular potency, whereas ICP-MS was used to assess
accumulation of AAPt compounds in comparison with cisPt. While cisPt is potent in both cancer
and normal prostate cells, ArgPt selectively accumulates and is more potent in prostate cancer
cells. ArgPt has a 30-fold higher accumulation and a six-fold selective potency in cancer cells
compared to normal cells. The unique uptake and potency of ArgPt compared to cisPt could be
attributed to its ligands. The positively charged guanidinium ligand side chain in ArgPt likely has
favorable electrostatic interactions with plasma membranes, which could recruit the compound
and enhance cell penetration. Unique features of cancer cells such as the net negative charge on
the surface of cell membranes and presence of higher levels of negative sulfated glycoproteins
[193, 195, 194, 201, 197-198] could also recruit ArgPt towards cancer cells and promote selective
uptake of the compound. Other factors that modulate the extent of chemosensitivity in cancer
cells include their tumor suppressor p53 status. Cell lines with downregulated or mutated p53 are
less sensitive towards cisPt treatment [209, 206]. This tumor suppressor may also play a role in
chemosensitivity of cancer cells towards AAPt compounds, but this has to be confirmed with
further experiments.

144
Overall, the different attributes of the selected AAPt compounds (AlaPt, OrnPt, and ArgPt)
investigated in this thesis work are important in development of cisPt analogues that have
improved anticancer activity. These aspects, which include unique platination sites, formation of
non-canonical adducts, reaction kinetics, selective potency, and high accumulation in cancer
cells, could enable platinum-based compounds to have robust and unique antitumor activities that
avert chemoresistance and adverse toxicity. To ascertain if the complex of platinum center
together with the amino acid ligand induce the potent activity of AAPt compound as opposed to
free amino acid alone, MTT assays could be carried out using respective free amino acids as
controls. Studying competitive cellular uptake and accumulation of free amino acids and AAPt
compounds may give further information on the mode of uptake or possible transporters that could
be aiding the cell penetration of AAPt compounds.
7.2 Future directions
7.2.1 Impact of platinum adducts on hydrolytic cleavage of RNA oligonucleotides
The impact of platination on cleavage of glycosidic bonds of nucleoside adducts was
investigated using glycosidic bond survival yield analysis as described in Chapter 5. It would be
of interest to follow up on these experiments by investigating the rates of depurination of
oligonucleotides using HPLC or UV analysis. The presence of alkylated or non-canonical bases
in nucleic acids may promote cleavage of the glycosidic bonds [212-213], and modifications could
promote hydrolysis of glycosidic bonds leading to damage of DNA through depurination [213].
Modification of DNA/RNA oligonucleotides by AAPt compounds may also promote hydrolysis of
glycosidic bonds. The impact of platination on hydrolysis and damage of DNA/RNA
oligonucleotides could be investigated by platinating nucleic acids with AAPt compounds (and
cisPt) under physiological conditions and monitoring depurination kinetics using HPLC/UV
analysis. The resulting depurination products could be characterized by using mass spectrometry.
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7.2.2 Quantification of AAPt compounds bound to cellular DNA and RNA
In Chapter 6, the whole cell abundance of AAPt compounds in comparison with cisPt was
described. It would also be of interest to quantify the number of adducts formed by platinumbased compounds with cellular biological targets so as to understand their distribution,
localization, and preferred targets. Platinum metals bound to RNA versus DNA need to be
quantified and compared to understand the preferred nucleic acid target of the compounds. These
studies would involve treating cells with platinum-based compounds followed by isolation of DNA
and RNA. Because of the elemental quantification capability and robust detection limit of ICP-MS,
it could be employed to quantify the platinum-based compounds bound to the respective nucleic
acids.
7.2.3 Downstream effects of AAPt platination of mRNA
Since platination by AAPt compounds occurs preferentially with Ado/dAdo sites of nucleic
acids as described in Chapters 3 and 4, their cellular activities could lead to inhibition of unique
downstream protein functions that are dependent on Ado/dAdo-rich sites. Cancerous cells have
an upregulation of mRNA polyadenylation [214-215], which could provide an important selective
target over normal cells. The mRNA has been reported to be platinated by cisPt [55] and could
also be one of the biological targets of AAPt compounds. The poly(Ado) tail of mRNA would
provide an Ado-rich region for which the selected AAPt compounds (AlaPt, OrnPt, and ArgPt)
could platinate preferentially. Since mRNA associates with a number of proteins such as
poly(Ado) binding protein (PABP), which are crucial in facilitating nuclear export and translation
processes [216], it would be of interest to understand the impact of platination on such RNAprotein interactions and their downstream effects. Such in vitro experiments could be analyzed
using gel electrophoresis and mass spectrometric analysis.
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APPENDIX A
PROTOCOL FOR HUMAN CANCER AND NORMAL CELL CULTURE
This information describes the protocol for maintaining both cancer and normal cell lines used in
Chapter 6.
General
Cell culturing was carried out in an aseptic laminar flow hood to ensure protection from
contaminants. The hood was cleaned with 70% ethanol before and after every use. Before
introducing items such as media into the hood, their container surfaces were sterilized with 70%
ethanol. Autoclaved tubes/tips and sterile cell plates/dishes were used in all experiments. For
cancer cells, Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), penicillin (5 units/mL), and streptomycin (0.1 mg/mL) was used. For normal cells,
keratinocyte serum free medium (K-SFM) supplemented with human recombinant epidermal
growth factor 1-53 (EGF 1-53), bovine pituitary extract (BPE), penicillin (5 units/mL), and
streptomycin (0.1 mg/mL) was used. The cell culture incubator was always kept at 37 °C and 5%
CO2. All the cell lines used in this thesis work are monolayer cell cultures that attach to the bottom
of plate/dish when they are viable and are only suspended when treated with trypsin or if they are
dead.
Recovery of cryopreserved cells
Cells are usually cryopreserved in liquid nitrogen in a cryovial with DMSO/media solution.
Their recovery should ensure minimal cell death and removal of DMSO from cell solution before
cell growth is reestablished. The cryovial with cells was removed from the liquid nitrogen and
quickly placed in 37 °C waterbath. After one minute of agitating, the vial was sterilized with 70%
ethanol before opening the cap. The cell solution was transferred into a centrifuge tube with an
additional 1 mL of appropriate media and centrifuged at 1000 rpm for 4 min at 25 °C. The
supernatant was removed, mixed with another 1 mL of media to resuspend the cells, and
centrifuged again. The supernatant was removed again, and the cell pellet resuspended with 1
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mL media before transferring all contents into a cell culture dish (60 x 15 mm) with an additional
3 mL of media. The seeded dish was stored in the incubator to allow the cells to attach to the
plate and grow.
Some cells usually die due to stress conditions of storage and therefore the cell growth of
new culture is recovered by seeding the dishes with a high density of cells. The dishes should be
checked periodically under microscope to ensure cell growth, confluency, and availability of
media. Fresh media can be added after 3-5 days.
Trypsinizing and passaging monolayer cells
When cells reach over 80% confluency, they were passaged (split) into secondary dishes
as described below.
Cancer cells
To split the cell culture, the media was first removed from the dish. The cell dish was
washed with 2 mL of PBS. Trypsin-EDTA (0.25%, 0.5 mL) was added into the dish and incubated
for 2-5 min at 37 °C to detach the cells from surface of dish. Fresh media (2.5 mL) was added to
the dish to inactivate the trypsin. Equal volume of cell suspension were distributed into secondary
dishes. More media was added into the secondary plates for a total volume of 8 mL in each 100
x 20 mm secondary dish (or 3 mL if using 60 x 15 mm dishes). The cells were then stored in the
incubator until they were used for experiments or until they reached over 80% confluency (where
they were split again into tertiary dishes).
Normal cells
The normal cells are treated differently from cancer cells because their media do not
contain FBS to deactivate the trypsin. The media was first removed from the confluent cell culture
dish and washed with 2 mL of PBS. Trypsin (0.05%, 0.5 mL) was added and incubated for 2-5
min at 37 °C to suspend the cells. To the dish, 0.5 mL of 10% FBS is added, agitated, and
transferred into a centrifuge tube. The tube was centrifuged at 1000 rpm for 4 min at 25 °C
followed by removal of supernatant. The cell pellet was resuspended with 3 mL of appropriate
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media. Equal volume of cell suspension were distributed into secondary dishes. More media was
added into the secondary plates for a total volume of 8 mL in each 100 x 20 mm secondary dish
(or 3 mL if using 60 x 15 mm dishes). The cells were then stored in the incubator until they were
used for experiments or until they reached over 80% confluency (where they were split again into
tertiary dishes).
Storage of cells for future experiments
Cancer cells
The cells were resuspended with 0.5 mL trypsin (0.25%). Appropriate media (1.5 mL) was
added to the suspension and mixed. The contents were transferred into a centrifuge tube and
centrifuged at 1000 rpm for 4 min at 25 °C. The supernatant was removed and 1 mL of appropriate
fresh media was added to the tube. Another 1 mL of DMSO was also added into the tube and
mixed. The contents were transferred into sterile cryovial, capped and placed in -80 °C overnight.
The cryovials were then placed in liquid nitrogen freezer for long term storage.
Normal cells
The cells were resuspended with 0.5 mL trypsin (0.05%). After the cells were dispersed,
0.5 mL of 10% FBS was added into the dish and mixed. The contents were transferred into a
centrifuge tube and centrifuged at 1000 rpm for 4 min at 25 °C. The supernatant was removed
and 1 mL of appropriate fresh media was added to the tube. Another 1 mL of DMSO was also
added into the tube and mixed. The contents were transferred into sterile cryovial, capped and
placed in -80 °C overnight. The cryovials were then placed in liquid nitrogen freezer for long term
storage.
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ICP-MS CALIBRATION AND INTERNAL STANDARDS
The ICP-MS was calibrated in four different tune modes using 195Pt and two internal
standards (209Bi and 115In). The calibration graph with R value closest to 1 and stable internal
standards was selected for quantification of samples (Fig. 1A-4A).

Figure 1A. ICP-MS Calibration graph with no gas tune mode. The calibration graph together
with measurements of internal standards (Bi-209 and In-115) in the same mode are given. DL is
detection limit and BEC is background equivalent concentrations.

150

Figure 2A. ICP-MS calibration graph in helium tune mode. The calibration graph together with
measurements of internal standards (Bi-209 and In-115) in the same mode are given. DL is
detection limit and BEC is background equivalent concentrations.
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Figure 3A. ICP-MS calibration graph in high energy helium (HEHe) tune mode. The
calibration graph together with measurements of internal standards (Bi-209 and In-115) in the
same mode are given. DL is detection limit and BEC is background equivalent concentrations.
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Figure 4A. ICP-MS calibration graph in hydrogen tune mode. The calibration graph together
with measurements of internal standards (Bi-209 and In-115) in the same mode are given. DL is
detection limit and BEC is background equivalent concentrations.
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Although cisplatin (cisPt) has been used for several years in cancer therapy, its application
has faced challenges of adverse toxicity, lack of selectivity, and cellular resistance. Several
second-generation cisPt analogues have been synthesized, but only a few have been approved
worldwide for anticancer usage. The approved analogues, which include carboplatin, oxaliplatin,
and nedaplatin, have advantages in averting adverse toxicity and resistance in their antitumor
application. However, compared to the parent cisPt, these analogues have low potency and
usually require to be administered with other compounds in order to be effective. There is still a
need to develop alternative platinum-based compounds with balanced potency, selectivity for
cancer cells, and reduced side effects.
CisPt is known to target deoxyguanosine (dGuo) residues of DNA and coordinate at their
N7 positions. New analogues could be developed to selectively coordinate with alternative targets
and form non-canonical adducts that could potentially be important in avoiding resistance and
lack of selectivity. Efforts to find compounds that coordinate with alternative sites of DNA or RNA
have had limited success. Previous work in our lab showed that positively charged amino acidlinked platinum(II) (AAPt) compounds have altered reactivity compared to cisPt when reacting
with folded RNA. In this thesis, AAPt compounds of alanine, ornithine, and arginine (AlaPt, OrnPt,
and ArgPt, respectively) were synthesized. The structures of these AAPt compounds consist of
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one chelating amino acid and two chlorido ligands that coordinate with the platinum center to form
a five-membered ring. The objectives of this thesis were to characterize the non-canonical
adducts formed by AAPt compounds, investigate their reaction kinetics with nucleic acids, study
their impact on glycosidic bond stability, and investigate their cellular potency and accumulation.
AlaPt, OrnPt, or ArgPt react with Ado nucleosides to form multiple products that were
isolated from HPLC and further characterized using mass spectrometry and NMR spectroscopy.
The compounds coordinate with Ado to predominantly form isomeric monofunctional adducts that
vary at their platination sites (N1, N3, or N7). The compounds also react with oligonucleotide
sequences 5′-d(TTATT)-3′ and 5′-UUAUU-3′ in which monofunctional and doubly platinated
adducts are observed. Kinetic reactions of AAPt compounds with purine nucleosides indicate that
AlaPt, OrnPt and ArgPt have reactivity preferences for Ado/dAdo residues over Guo/dGuo
residues. These AAPt compounds have between five- to nine-fold higher reactivity with Ado/dAdo
nucleosides than with Guo/dGuo. The reactivity of these compounds with DNA/RNA
oligonucleotides is enhanced compared to their reactivity with nucleosides. This preference is
likely because the negatively charged backbone phosphate groups could interact favorably with
the AAPt compounds or provide hydrogen-bond acceptors that stabilize the interactions of AAPt
with the oligonucleotides.
Changes in the chemical composition of a molecule affect its stability. Modification of
nucleoside residues due to coordination with platinum-based compounds could also impact their
adduct bond stabilities. The fragmentation and stability of glycosidic bonds were investigated
using collision induced dissociation (CID) and glycosidic bond survival yield analysis. It was
observed that platination by AlaPt and OrnPt at the N7 position destabilizes the glycosidic bonds
more than platination at the N1 or N3 positions. Comparatively, AlaPt activates fragmentation of
the adducts predominantly through glycosidic bond cleavage, while OrnPt activates fragmentation
through glycosidic bond cleavage and significant neutral losses.
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The cellular potency of AAPt compounds in human cancer and normal cells was
investigated using MTT assays. The potent activity of these compounds was observed in several
cell lines including prostate cancer cell line (DU145). While cisPt exhibits potency in both prostate
cancer and normal cell lines, ArgPt is more selective with a six-fold higher potency in prostate
cancer cells over normal cells. The uptake and accumulation of platinum-based compounds could
contribute to the selective potency of platinum-based compounds. Therefore, the accumulation of
the compounds was investigated in prostate normal and cancer cells using inductively coupled
plasma mass spectrometry (ICP-MS). ArgPt exhibits a thirty-fold higher accumulation in cancer
cells compared to normal cells, which likely translates to its observed selective potency.
The work in this thesis could be important in providing important structural and chemical
information that can be applied in the development of newer platinum-based drugs that have
improved anticancer activities. Characteristics that enable formation of non-canonical adducts
and altered reactivity preferences could be important in circumventing cellular resistance.
Features that promote selective potency and increased uptake by cancer cells are also crucial in
reducing toxic side effects.

168

AUTOBIOGRAPHICAL STATEMENT
BETT KIMUTAI
ADVISOR: Dr. Christine S. Chow
THESIS TITLE: NON-CANONICAL TARGETS, REACTION KINETICS, AND CELLULAR
POTENCY OF AMINO ACID-LINKED PLATINUM(II) COMPOUNDS
EDUCATION:
•

PhD; Biological Chemistry, 2019, Wayne State University, Detroit, MI, USA

•

B.S; Biochemistry, 2012, Fairleigh Dickinson University, Teaneck, NJ, USA

PUBLICATIONS
1. Kimutai B, He CC, Roberts A, Jones ML, Bao X, Jiang J, Yang Z, Rodgers MT,
Chow CS, Amino acid-linked platinum(II) compounds: non-canonical nucleoside
preferences and influence on glycosidic bond stabilities (2019) J Biol Inorg Chem
24:985-997
2. He CC, Kimutai B, Bao X, Hamlow L, Zhu Y, Strobehn SF, Gao J, Berden G,
Oomens J, Chow CS, Rodgers MT, Evaluation of hybrid theoretical approaches
for structural determination of a glycine-linked cisplatin derivative via infrared
multiple photon dissociation (IRMPD) action spectroscopy (2015) J Phys Chem A
119:10980-10987

